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SUMMARY 
 
Mycobacterium ulcerans, causing the devastating skin disease Buruli ulcer (BU), has 
evolved from the fish pathogen M. marinum. By the acquisition of a virulence plasmid 
(pMUM) a progenitor of M. ulcerans has gained the unique property of producing a 
polyketide-derived macrolide toxin termed mycolactone. The toxin is responsible for 
the characteristic chronic ulcerative pathology of BU. Adoption of pMUM was 
probably the key event in the evolution of M. ulcerans, constituting a population 
bottleneck that led to the development of a new species with a highly clonal 
population structure. Subsequent reductive evolution is indicative for the adaptation 
to more stable environmental niches and led to the emergence of three M. ulcerans 
lineages considered as different ecotypes. M. ulcerans lineage 3, responsible for BU 
infections in Africa and Australia, is characterized by extremely low levels of genetic 
diversity. This genetic monomorphism has long hindered molecular epidemiological 
studies aiming at the identification of transmission pathways and environmental 
sources of M. ulcerans. 
Our whole genome sequence comparison of Ghanaian M. ulcerans strains 
representing three previously identified variable number of tandem repeat (VNTR) 
types in Ghana, enabled the identification of single nucleotide polymorphisms (SNPs). 
Real-time PCR-based SNP typing assays at the detected SNP loci facilitated 
medium-throughput analyses of a comprehensive collection of Ghanaian M. ulcerans 
isolates. Typing results of M. ulcerans strains isolated between 1999 and 2007 from 
patients residing in the BU endemic Densu River Basin and another BU endemic 
area in the Amansie West district of Ghana demonstrated the presence of two 
different clonal complexes in the two regions. Local clustering of certain haplotypes 
within the Densu River Basin revealed that M. ulcerans is very focally transmitted, 
which excludes some of the currently discussed modes of transmission. Our recently 
developed temperature-switch PCR-based typing strategy is used by a reference 
laboratory in Ghana to monitor the spatio-temporal distribution and further spread of 
the detected M. ulcerans variants in that region.  
M. ulcerans infection foci are commonly connected with close proximity to human-
disturbed aquatic environments. While BU in Ghana is highly associated with 
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residence along the lower part of the Densu River, where the construction of an 
impoundment has led to the formation of a lake and wetlands surrounding this area, 
no infections have so far been reported from villages located further upstream. 
However, results of our sero-epidemiology studies indicated that healthy inhabitants 
of communities both downstream (BU endemic) and upstream (BU non-endemic) of 
the Densu River are equally exposed to M. ulcerans. About one third of healthy 
individuals from both areas showed specific humoral responses against the M. 
ulcerans 18KDa small heat shock protein. Moreover, environmental samples 
collected in the BU endemic and non-endemic communities showed no significant 
difference in PCR positivity targeting M. ulcerans sequences.  
Elusive transmission pathways and reservoirs of M. ulcerans combined with the lack 
of a vaccine against BU complicate the prevention of this disease. Since the current 
strategy to control BU relies on early case detection and rapid treatment, the 
identification of alternative drugs is of high importance. Therefore a compound 
screening platform for M. ulcerans was developed within the framework of this thesis 
and is currently used to screen compound libraries for new scaffolds which may 
eventually have the potential to replace rifampicin. 
Taken together, the spatio-temporal patterns of M. ulcerans haplotypes in the Densu 
River Valley as well as the observed clustering of BU cases in certain communities 
along the Densu River indicate that the emergence of M. ulcerans infection foci 
cannot be solely explained by an interaction between M. ulcerans and the 
environment. We hypothesize that BU patients with ulcerative lesions containing vast 
loads of mycobacteria may play an active role in the dissemination of M. ulcerans in 
the environment. This would have major implications for strategies to better control 
the disease and remains to be investigated further.  
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ZUSAMMENFASSUNG 
 
Mycobacterium ulcerans, der Erreger der gravierenden Hauterkrankung Buruli-Ulkus 
(BU), hat sich aus dem Fischpathogen M. marinum entwickelt. Durch den Erwerb 
eines Virulenzplasmids (pMUM) hat ein M. ulcerans-Vorfahre die einzigartige 
Fähigkeit erlangt, ein Makrolid-Toxin namens Mycolakton zu produzieren, das für die 
BU-typische chronisch-ulzerative Pathologie verantwortlich ist. Die Aufnahme von 
pMUM war vermutlich das Schlüsselereignis für die Entstehung des Erregers und 
führte durch diesen genetischen „Flaschenhalseffekt“ zu der Entwicklung einer neuen 
Spezies mit hochklonaler Populationsstruktur. Die darauf folgende reduktive 
Evolution deutet auf die Anpassung an eine stabilere ökologische Nische hin und 
führte zu der Entwicklung von drei M. ulcerans Abstammungslinien, die verschiedene 
Ökotypen darstellen. Da die M. ulcerans Abstammungslinie 3, die BU Infektionen in 
Afrika und Australien hervorruft, nur minimale genetische Diversität aufweist, war die 
Erforschung der Herkunft und Übertragungswege von M. ulcerans durch 
Feintypisierung von Isolaten lange Zeit unmöglich.  
Vergleiche der Genomsequenzen von Vertretern der drei in Ghana vorhandenen M. 
ulcerans VNTR (Variable Number of Tandem Repeat) Varianten ermöglichte die 
Identifizierung von Einzelnukleotid-Polymorphismen (single nucleotide 
polymorphisms, SNPs). Mit Hilfe der identifizierten SNP-Positionen wurden Real-
Time PCR-basierende Assays entwickelt, mit denen M. ulcerans Isolate aus Ghana 
typisiert werden konnten. Die Typisierung von M. ulcerans Stämmen, die zwischen 
1999 und 2007 von Patienten aus dem BU endemischen Densu Flussgebiet und 
einer anderen endemischen Region im Amansie West Bezirk isoliert wurden, hat 
gezeigt, dass in den beiden Regionen zwei unterschiedliche klonale M. ulcerans 
Komplexe vorherrschen. Da auch innerhalb des Densu Flussgebietes die 
Verbreitung der meisten M. ulcerans Varianten nur auf ein bestimmtes Teilgebiet 
begrenzt war, können einige der derzeit diskutierten Übertragungswege des 
offensichtlich sehr fokal übertragenen Erregers ausgeschlossen werden. 
M. ulcerans Infektionsbrennpunkte sind im Allgemeinen mit aquatischen 
Umgebungen assoziiert, die durch den Menschen verändert worden sind. So tritt BU 
in Ghana vorwiegend entlang des unteren Densu Flussbereichs auf, in dem durch 
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den Bau eines Staudamms ein See mit umliegenden Feuchtgebieten entstanden ist, 
während aus Dörfern im oberen Flussbereich noch keine Krankheitsfälle gemeldet 
wurden. Unsere sero-epidemiologischen Studien haben gezeigt, dass dennoch 
sowohl Bewohner aus Gemeinden flussabwärts (BU endemisch) als auch weiter 
flussaufwärts (nicht BU endemisch) gleichermassen mit M. ulcerans in Kontakt 
kommen. Bei etwa einem Drittel der gesunden Studienteilnehmer aus beiden 
Flussgebieten konnten spezifische Antikörper gegen das so genannte „18KDa small 
heat shock protein“ von M. ulcerans nachgewiesen werden.  
Da Herkunft und Übertragungswege von M. ulcerans unklar sind und bis heute kein 
Impfstoff verfügbar ist, wird BU weniger durch Prävention, als vielmehr mit der 
Behandlung von Patienten in möglichst frühen Krankheitsstadien bekämpft. Daher ist 
die Suche nach alternativen Chemotherapeutika essentiell. Wir haben im Rahmen 
dieser Arbeit eine Screening-Plattform für M. ulcerans entwickelt, die nunmehr dazu 
verwendet wird, ausgewählte Wirkstoffbibliotheken auf neue Substanzen zu 
durchsuchen, die im besten Fall das Potential haben Rifampicin zu ersetzen.  
Zusammengefasst, weisen sowohl die räumlich-zeitliche Verbreitung von M. ulcerans 
Varianten im Densu Flussgebiet als auch das fokale Auftreten von BU in bestimmten 
Gemeinden entlang des Flusses darauf hin, dass die Entstehung von M. ulcerans 
Infektionsbrennpunkten nicht nur auf eine Wechselwirkung zwischen M. ulcerans und 
der Umwelt zurückzuführen ist. Basierend auf unseren Beobachtungen vermuten wir, 
dass BU Patienten mit bakteriell hoch belasteten ulzerierenden Läsionen eine 
wichtige Rolle bei der Verbreitung des Erregers in der Umwelt spielen. Dies könnte 
bedeutende Konsequenzen für die Vorgehensweise bei der Bekämpfung von BU 
haben und liefert einen wichtigen Ausgangspunkt für zukünftige Forschung. 
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Mycobacterium ulcerans (M. ulcerans) causes the chronic and destructive skin 
disease Buruli ulcer (BU). Until today, cases have been reported from more than 30 
countries world-wide with the highest incidence rates in Western Africa, where BU 
constitutes a substantial public health problem. In spite of considerable advances 
during the past few years in understanding this enigmatic disease, important aspects 
such as environmental reservoirs and transmission pathways have yet to be explored. 
The following sections summarize the current understanding of BU and its causative 
agent as well as unresolved research issues in this field. 
 
History and geographical distribution of Buruli ulcer 
Chronic skin ulcers consistent with M. ulcerans infection were first described in 1897 
by Sir Albert Cook, a British physician working at the Mengo Hospital in Kampala, 
Uganda. In 1935, cases of unusual skin ulcers were reported in patients from the 
Bairnsdale district in Australia [1]. However, the first detailed characterization of BU 
patients living in an area around Bairnsdale was provided in 1948 by MacCallum and 
his colleagues, who were the first to isolate the etiologic agent of the disease, a 
mycobacterium henceforth designated as M. ulcerans [2]. The first large numbers of 
cases were recorded in the Buruli County (Nakasongola District) in Uganda during 
the 1960s, giving rise to the official designation Buruli ulcer for this disease [3]. In the 
following decade M. ulcerans infection foci were predominantly reported in a number 
of West and Central African countries such as Congo [4], Ghana [5], Uganda [6] and 
Nigeria [7]. Since then new BU infection foci were discovered in Togo [8] and Angola 
[9] and strong increases in the incidence rates were recorded in several West African 
countries including Benin [10], Ivory Coast [11], Ghana [12] and Cameroon [13]. In 
1998, the World Health Organization established the global Buruli ulcer initiative in 
order to raise awareness about the hitherto neglected disease and to coordinate 
global BU control and research efforts [14]. Health workers and researchers from 
various countries have subsequently shared experiences and information regarding 
transmission, pathogenesis, molecular biology and treatment [15]. 
Until today BU has been reported from 32 tropical and subtropical countries in Africa 
(Angola, Benin, Burkina Faso, Cameroon, Congo, Ivory Coast, Democratic Republic 
of the Congo (former Zaire), Equatorial Guinea, Gabon, Ghana, Guinea, Kenya, 
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Liberia, Malawi, Nigeria, Sierra Leone, Sudan, Togo Uganda), Latin America (Brazil, 
French Guiana, Mexico, Peru, Suriname), South-East Asia (China, Indonesia, Japan, 
Malaysia, Sri Lanka) and the Western Pacific (Australia, Kiribati, Papua New Guinea) 
[16].  
 
 
Figure 1: A global map representing countries that have reported cases of Buruli ulcer disease as of 
2010. Data source: World Health Organization. Map production: Control of Neglected Tropical 
Diseases. 
 
Accurate estimations of BU case numbers and burden of the disease is very difficult 
due to the characteristic focal distribution of BU within endemic countries affecting 
predominantly remote areas of Western Africa with limited access to the formal 
health sector, where comprehensive reporting systems are lacking. In 2010, the 
highest incidence rates were reported from Ivory Coast (2533 cases), Ghana (1048 
cases), Benin (572 cases) and Cameroon (287 cases) (Figure 1) [17]. However, 
there is evidence of vast under-reporting [18].  
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Clinical presentation of Buruli ulcer 
BU is a chronic, necrotizing infection of the subcutaneous adipose tissue. Most 
commonly it starts as a painless, mobile swelling in the subcutaneous tissue referred 
to as nodule (Figure 1A), which may eventually break down to form a slowly 
progressing ulcer with characteristic undermined edges. Other pre-ulcerative 
manifestations include papules (Figure 2B), which are predominantly observed in 
Australian BU patients as well as oedema (Figure 2C) and plaques (Figure 2D), often 
causing large ulcerations (Figure 2E) [19,20]. Untreated infection may lead to 
extensive tissue destruction followed by contractures and deformities (Figure 2F) due 
to uncontrolled self-healing processes.  
WHO has defined lesions with a cross-sectional diameter of less than 5 cm as 
category I (small), 5-15 cm as category II (moderate), and more than 15 cm, lesions 
at crucial sites (eye, breast, and genitalia), or multiple lesions as category III 
(advanced) lesions. For various reasons, including the indolent nature of BU, lack of 
systemic symptoms, stigmatization, association with witchcraft and limited access to 
medical care, patients in rural regions of Africa tend to seek treatment at the formal 
health sector late and often present with large ulcers [20].  
The percentage of BU patients with osteomyelitis was reported to be 13% in a study 
including 1611 BU patients from Benin [21]. Secondary infection of BU lesions occurs 
with Staphylococcus aureus and Pseudomonas aeruginosa being the most 
prominent causes (Yeboah-Manu et al., submitted). 
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Figure 2: Non-ulcerative and ulcerative forms of Buruli ulcer, Complications: A: Nodule; B: Papule; C: 
Edema; D: Plaque; E: ulcer; F: Patients with disabilities. Source: WHO 
 
Approximately 80% of the ulcers occur on the limbs, most commonly involving the 
lower extremities [22]. All age groups are affected by the disease with a nearly equal 
gender distribution, but children under the age of 15 make up at least 50% of all 
cases in Africa [23]. 
 
Environmental reservoirs and transmission of Mycobacterium ulcerans 
The epidemiology of BU is still poorly understood; however, M. ulcerans infection foci 
are typically associated with proximity to stagnant and slow-flowing water bodies 
(Figure 3) and often connected to human-disturbed aquatic environments. While it is 
known that other mycobacteria such as M. leprae and M. tuberculosis are transmitted 
A 
C D 
B 
E F 
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by person-to-person contact, it is commonly assumed that infection with M. ulcerans 
takes place through trauma of the skin [24] or insect bites via an environmental 
reservoir in the ecosystem [22]. 
 
     
Figure 3: Typical Buruli ulcer riverine endemic sites in the Densu River Basin of Ghana (2010). 
 
Definite environmental reservoirs and transmission pathways have yet to be 
elucidated, since cultivation of the extremely slow growing M. ulcerans from possible 
environmental sources contaminated with faster growing mycobacterial species and 
other microorganisms is more than a challenge. Only one pure culture of M. ulcerans 
could ever be obtained from an environmental source, more precisely from an 
aquatic water bug collected in Benin [25]. Hence, environmental studies are largely 
based on the detection of M. ulcerans genomic DNA sequences. One of the DNA 
targets, the insertion sequence (IS) element 2404 has been detected by PCR in 
various environmental samples including water [26], aquatic insects [27] and plants 
[28], snails [29], and small fish [30]. However, the presence of this IS element in 
other environmental mycobacteria has been reported. Since 2007 confirmatory real-
time PCR assays targeting not only IS2404 but also another IS element (IS2606) and 
a sequence encoding the ketoreductase B domain of the mycolactone polyketide 
synthase genes are available to complement the specificity of the IS2404 PCR. 
Analysis of the three targets facilitated the detection of M. ulcerans DNA in soil, 
sediment, and mosquito extracts from a BU endemic area in Australia [31]. However, 
since PCR is not able to prove for the presence of viable bacteria, results are difficult 
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to interpret. A recent study in South-Eastern Australia has implicated tree-dwelling 
native possums as a possible animal reservoir [32] and mosquitoes as potential 
vectors [33,34] of M. ulcerans in BU endemic settings of Victoria. A similar potential 
animal reservoir could not be identified in BU endemic regions of Africa so far. 
However, there are strong indications, that spread of M. ulcerans from chronic, 
ulcerated lesions to insect vectors or another currently unknown environmental 
reservoir and subsequent infection of individuals living in the same settlements 
should be considered.  
 
Evolution and diversity of Mycobacterium ulcerans 
M. ulcerans is closely related to and has a common ancestor with the fish pathogen 
Mycobacterium marinum (M. marinum) [35]. Based on a universal molecular clock 
rate [36] it was estimated that M. ulcerans has diverged from M. marinum around a 
million years ago by the acquisition of a plasmid (pMUM001) encoding enzymes 
required for the production of the toxin mycolactone [35,37]. The exact species 
definition of M. ulcerans is currently complicated by the identification of other closely 
related mycolactone producing mycobacteria (MPM), which have so far not been 
associated with BU [38–41]. Though given distinct species names such as M. 
shinshuense, M. marinum, M. pseudoshottsii and M. liflandii, genetic analyses 
suggest that all MPM are derived from a common ancestor and are genetically 
coherent [42]. Hence, it has recently been proposed that all MPM should be renamed 
M. ulcerans [42,43].  
After the acquisition of pMUM and insertion sequence (IS) elements 2404 and 2606, 
M. ulcerans diverged into at least two principal lineages by reductive evolution 
including extensive gene loss predicted to be associated with adaptation to a new 
niche environment. M. ulcerans strains from Asia, South America and Mexico as well 
as fish and frog isolates belong to the ancestral lineage, whereas the classical 
lineage includes clinical isolates from Africa, Australia and South East Asia [44]. 
Whole genome comparison of 35 M. ulcerans, MPM and M. marinum strains 
suggests a further subdivision of ancestral strains into lineage 1 including human 
isolates from South America as well as fish and frog isolates with world-wide origin 
and lineage 2 consisting of clinical M. ulcerans isolates from Japan. In this study the 
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classical lineage - defined as lineage 3 - was largely represented by human and 
other animal isolates from Africa and Australia. It was suggested that “each of the M. 
ulcerans lineages probably represents different ecotypes, reflecting adaptation to 
related but distinct niche environments” and should be considered as M. ulcerans 
ecovars [42]. Deletion or inactivation of genes required for pigment biosynthesis, 
anaerobiosis, and intracellular growth suggests that the environment M. ulcerans is 
adapting to might be dark (especially lineage 3 isolates, which have lost UV-
protecting pigment genes), aerobic and possibly extracellular [42,45].  
M. ulcerans lineages are generally characterized by limited genetic diversity, which is 
typically found in bacterial populations that have recently gone through an 
evolutionary bottleneck such as the acquisition of a plasmid [46]. Further loss of gene 
function and chromosomal rearrangements among the closely related and highly 
clonal Australian and African isolates suggests that lineage 3 has passed through a 
second evolutionary bottleneck [42]. Extremely low levels of genetic diversity have 
been identified among West African M. ulcerans strains [47–50], indicating a 
relatively recent dispersal of one M. ulcerans clone throughout this region. Little is 
known about the evolution and geographical expansion of M. ulcerans in West Africa 
largely due to the lack of genetic typing methods with sufficient resolution to 
differentiate between closely related strains. In this PhD thesis the development and 
application of genetic fine-typing tools and the analysis of clinical M. ulcerans isolates 
from various African countries, in particular from Ghana, are described in chapters 2-
4. The genome, evolution and diversity of M. ulcerans is reviewed in chapter 5 of this 
thesis.  
 
Pathology and the role of mycolactone 
The pathology of BU is determined by unique characteristics of M. ulcerans. While 
the low optimum growth temperature of 28-32 °C renders the skin a favorable site for 
infection and slowly progressing lesions can be attributed to the extremely long 
generation time of M. ulcerans (about 72 hours on routine mycobacteriological 
media), the production of mycolactone provokes extensive tissue necrosis [51]. 
Connor and Lunn have already suggested in 1965 that “M. ulcerans elaborates a 
diffusible toxic substance that causes tissue necrosis” after a histopathologic analysis 
Chapter 1. Introduction 
Inauguraldissertation 
15 
of a pre-ulcerative tissue specimen showing acid-fast bacilli in the center of a necrotic 
zone in the subcutaneous fat virtually devoid of inflammatory cells [52]. But it is only 
since 1999 that a polyketide-derived macrolide referred to as mycolactone can be 
definitely associated with the virulence of M. ulcerans infection [53]. Today, the 
classic histological features of BU lesions, namely the necrosis around clumps of 
extracellular acid-fast bacilli and the defective inflammatory response are explained 
by the cytotoxic and immunosuppressive properties of mycolactone [54]. While there 
is evidence for a transient intracellular stage of M. ulcerans during the establishment 
of infection, the release of mycolactone appears to be responsible for the killing of 
host cells and infiltrating leukocytes in advanced stages of the infection [55]. 
Mycolactone is present in cutaneous lesions but can also be detected in lymphoid 
tissues and serum [54,56]. It has been shown that M. ulcerans produces an 
extracellular matrix containing mycolactone but also other proteins and lipids that 
may play a role in the virulence of M. ulcerans [57]. 
Polyketides are produced by various organisms, but mycolactones are the first 
discovered macrolides in mycobacterial species and the first identified polyketide 
virulence determinants of a bacterial human pathogen [58]. Hence, the ability to 
produce mycolactone is restricted to M. ulcerans and other closely related MPM. So 
far, five structural variants (mycolactones A/B, C, D, E and F) have been identified 
among a worldwide collection of M. ulcerans and other MPM strains [59]. The genetic 
basis for mycolactone production is discussed in chapter 5 of this thesis.  
 
Diagnosis of Buruli ulcer 
Initial diagnosis of BU by experienced clinicians or health workers in endemic regions 
can be confirmed in the laboratory by four different methods including direct smear 
examination (Figure 4A), PCR (Figure 4B), histopathology (Figure 4C) and culture of 
M. ulcerans (Figure 4D) [20]. 
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Figure 4: Laboratory techniques to confirm clinical BU diagnosis. A: direct smear examination 
(Yeboah-Manu, 2006); B: Agarose gel showing M. ulcerans insertion sequence 2404 PCR bands for 
positive samples (7-10 and 13); C: Histopathological characteristics associated with untreated BU 
lesions [60]; D: Culture of M. ulcerans on Löwenstein-Jensen medium. 
 
While direct smear examination of swab specimens taken from undermined edges of 
the ulcers by Ziehl-Neelsen (ZN) stain is the simplest and most accessible diagnostic 
technique, the sensitivity of this method may be as low as 40%. The three remaining 
methods are largely confined to central reference laboratories. BU can be definitively 
diagnosed by M. ulcerans culture, but primary isolation may take 8 to 12 weeks. M. 
ulcerans recovery rates vary between laboratories but can be as high as 75% for 
tissue specimens [61], 41% for fine-needle-aspirates (FNA) and 43% for swab 
samples [62]. Culture, histopathology and PCR require good laboratory infrastructure 
and highly qualified personnel. PCR targeting IS2404 is currently the gold standard 
for BU diagnosis in reference laboratories approaching 100% specificity. The 
A B 
C D 
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sensitivity is dependent on the PCR technique, but may approximate 100% (85% for 
FNA samples [63]) relative to the other diagnostic techniques [31,64]. Due to 
potential problems with amplicon contamination, strict quality control is required.  
Diagnosis in many rural health facilities of endemic African regions is still mainly 
based on clinical findings. Since differential diagnosis of pre-ulcerative and ulcerative 
BU includes some important diseases like phagedenic ulcer and cutaneous 
tuberculosis, there is an urgent need for a specific, fast, cheap and simple point-of-
care diagnostic test for BU, which can directly be applied at peripheral health centers 
and hospitals. 
 
Treatment of Buruli ulcer and prospects for a vaccine 
The only treatment option for BU has long been wide surgical excision of the necrotic 
tissue followed by skin grafting and, if available, rehabilitative physiotherapy [20]. In 
response to a pilot study evaluating the efficacy of rifampicin and streptomycin on 
early BU lesions [65], the WHO released provisional guidelines in 2004 advising a 
combination chemotherapy of oral rifampicin and intramuscular streptomycin 
administered daily for eight weeks [66]. Routine implementation of this regimen has 
greatly improved healing and reduced the frequency of relapses to less than 2% 
[67,68]. However, streptomycin is administered by daily injections and is potentially 
nephrotoxic and ototoxic [69]. Although rifampicin is currently the key drug for the 
treatment of BU, it has to be combined with another antibiotic to increase its effect 
and to avoid the development of resistance, which has been described after 
rifampicin monotherapy in a BU mouse model [70]. While pilot studies on fully oral 
chemotherapy using a combination of rifampicin and clarithromycin yielded promising 
results [71,72], identification of new compounds active against M. ulcerans that could 
replace rifampicin is crucial.  
In chapter 7 of this PhD thesis the development of an Alamar Blue-based assay to 
analyze compounds for their activity against M. ulcerans growth is described. 
Screening of a set of azole compounds led to the identification of a low-molecular 
weight compound with good activity against M. ulcerans. The developed screening 
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platform is currently used in our laboratory to analyze further compounds for their 
activity against M. ulcerans.  
Taking advantage of the temperature sensitivity of M. ulcerans, the application of 
heat in the form of phase change material as a treatment option has been tested in a 
proof-of-principle study for a limited number of BU patients [73]. A larger 
thermotherapy study is currently ongoing. 
Patients in remote areas of Africa with limited or no access to adequate health 
facilities often seek traditional treatment including magico-religious rites as well as 
application of herbal preparations or other natural substances, which have no proven 
efficacy and bear a high risk of secondary infection of the wounds [15,74]. Although 
prompt and appropriate treatment of BU can minimize irreversible physical disabilities 
and treatment costs, patients in developing countries often seek adequate medical 
treatment only at late disease stages [74]. The obvious preference for traditional 
healing in remote African areas has a variety of reasons including, financial 
difficulties as well as problems associated with the duration of hospital admission 
(often more than 3 month per patient) and social stigma connected with the 
mysterious nature of the disease [74–76].  
Until today, there is no specific vaccine against M. ulcerans and it remains 
controversial, whether BCG vaccination has a short-lasting protective effect [77]. 
However, it was reported that BCG vaccination at birth leads to protection against BU 
osteomyelitis in children and adults [21]. A major protective antigen of the BCG 
vaccine is the Ag85 complex, whose homologues are present in many mycobacteria. 
It was argued that a vaccine based on M. ulcerans antigens could offer a more 
specific and effective protection than BCG. Hence, the protective efficacies of two 
DNA vaccines encoding Ag85A from BCG and from M. ulcerans were compared in a 
M. ulcerans mouse model. Species-specificity was reflected in a higher protective 
efficacy of the M. ulcerans vaccine [78]. Hence, possible vaccine strategies proposed 
include adjuvanted subunit based protein vaccines or an attenuated, live vaccine 
based on M. ulcerans [18]. Even though mycolactone would represent a suitable 
target for the development of a toxoid-based vaccine, the polyketide itself is not 
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immunogenic and until now it was not possible to develop a protein conjugate that 
elicits high titers of potentially neutralizing mycolactone-specific antibodies [79]. 
 
Immune response to M. ulcerans 
Antigenic cross-reactivity between M. ulcerans, M. tuberculosis, M. bovis and various 
environmental mycobacteria complicates investigations on M. ulcerans-specific 
immune responses. One suitable serological marker for exposure of individuals living 
in BU endemic areas to M. ulcerans was identified as the immunodominant 18 kDa 
small heat shock protein (shsp), which has no homologues in M. tuberculosis and M. 
bovis [80]. In the largest sero-epidemiological study ever conducted for BU, we have 
determined anti-18 kDa shsp IgG titers in sera collected from healthy inhabitants of 
the BU endemic Densu River Valley of Ghana. The study, which is described in 
chapter 6 of this thesis, showed that a considerable proportion (about 32%) of 
exposed, but healthy individuals develop specific humoral responses against a M. 
ulcerans antigen, indicating that infection with M. ulcerans may lead only in a small 
proportion of exposed individuals to active BU. These results together with the 
observation that BU can heal spontaneously suggests the existence of protective 
immunity [81], even though the underlying protective mechanisms are largely 
unknown.  
Apart from humoral immune responses, the control of M. ulcerans infection may be 
primarily dependent on adaptive cell-mediated immunity. Delayed-type 
hypersensitivity response to an extract of M. ulcerans (burulin) on skin testing was 
observed rarely in patients with early disease, but frequently in patients with healed 
or active disease [82], indicating a degree of T-cell sensitization. Despite evidence of 
Th1-mediated protective immunity it is not known to what extent BU patients can 
mount a M. ulcerans-specific Th1 response, since M. ulcerans infection has been 
widely associated with the suppression of local and systemic immune responses 
[81,83]. The production of interferon gamma (IFN-γ), which is preferentially secreted 
by Th1 cells, was shown to be reduced during active BU [83]. However, the 
suppression of systemic immune responses remains controversial. To give one 
example, Hong et al. have reported that mycolactone has immunosuppressive effects 
at the systemic level, since it is able to diffuse beyond the site of M. ulcerans 
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infection [54]. On the contrary, a recent study in a mouse model indicated that 
infection with M. ulcerans may lead to local and regional suppression of the immune 
response rather than induction of systemic immunosuppression [81]. In this vein, the 
lack of inflammatory responses in necrotic areas of BU lesions might be explained by 
mycolactone-induced apoptosis and necrosis of the inflammatory infiltrate [84].  
After chemotherapy the local immunosuppression is reversed and leads to an active 
inflammatory process with leukocyte infiltrates cumulating in the development of 
ectopic lymphoid structures indicative for healing processes [60]. Some of the 
patients develop immune-mediated clinical deteriorations termed “paradoxical 
reactions” during the course of antibiotic treatment [85]. Recently, it has been 
reported that in some cases secondary M. ulcerans infection foci developing several 
months after successful treatment of the initial lesion may be resolved by the immune 
system [86].  
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Objectives 
Efforts to identify transmission pathways and environmental sources of M. ulcerans 
have long been hampered by the lack of typing methods with sufficient resolution for 
micro-epidemiological studies. In this PhD thesis we anticipate the identification of 
useful SNP markers for the fine-typing of M. ulcerans strains from Ghana by the 
following strategy: 
- Whole genome sequence comparison of M. ulcerans strains from Ghana in 
order to detect a comprehensive set of SNP markers. 
- Development of genotyping assays based on real-time PCR as well as 
conventional PCR at the identified SNP positions. 
- SNP typing of M. ulcerans strains from a BU endemic region in the Densu 
River Valley by the established SNP assays to be able to differentiate between 
M. ulcerans haplotypes and to monitor their circulation in this region.  
A major mystery of BU is its focal distribution within endemic countries. In Ghana BU 
is highly endemic in communities along the lower part of the Densu River, while no 
cases have so far been reported from villages located further upstream. Until today it 
is not known, whether differences in BU prevalence can be attributed to a difference 
in the exposure to M. ulcerans or other currently unknown factors. It is unclear as well 
what proportion of a population in BU endemic and non-endemic communities is 
actually exposed to M. ulcerans. Our approach to gain better insight into the 
epidemiology of M. ulcerans in the Densu River Valley is: 
- The determination of humoral responses against the M. ulcerans 18KDa small 
heat shock protein in blood sera collected from healthy inhabitants of BU 
endemic and non-endemic communities along the Densu River. 
The identification of alternative drugs for BU, suitable for application at peripheral 
health centers in developing countries is one of the major research goals for BU. 
Therefore another aim of this PhD thesis is: 
- The development of a drug screening platform to analyze compound libraries 
for new scaffolds with M. ulcerans growth inhibitory activity.  
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ABSTRACT 
 
Mycobacterium ulcerans is the causative agent of Buruli ulcer, the third most 
common mycobacterial disease after tuberculosis and leprosy. It is an emerging 
infectious disease that afflicts mainly children and youths in West Africa. Little is 
known about the evolution and transmission mode of M. ulcerans, partially due to the 
lack of known genetic polymorphisms among isolates, limiting the application of 
genetic epidemiology. To systematically profile single nucleotide polymorphisms 
(SNPs), we sequenced the genomes of three M. ulcerans strains using 454 and 
Solexa technologies. Comparison with the reference genome of the Ghanaian 
classical lineage isolate Agy99 revealed 26,564 SNPs in a Japanese strain 
representing the ancestral lineage. Only 173 SNPs were found when comparing 
Agy99 with two other Ghanaian isolates, which belong to the two other types 
previously distinguished in Ghana by variable number tandem repeat typing. We 
further analyzed a collection of Ghanaian strains using the SNPs discovered. With 68 
SNP loci, we were able to differentiate 54 strains into 13 distinct SNP haplotypes. 
The average SNP nucleotide diversity was low (average 0.06–0.09 across 68 SNP 
loci), and 96% of the SNP locus pairs were in complete linkage disequilibrium. We 
estimated that the divergence of the M. ulcerans Ghanaian clade from the Japanese 
strain occurred 394 to 529 thousand years ago. The Ghanaian subtypes diverged 
about 1000 to 3000 years ago, or even much more recently, because we found 
evidence that they evolved significantly faster than average. Our results offer 
significant insight into the evolution of M. ulcerans and provide a comprehensive 
report on genetic diversity within a highly clonal M. ulcerans population from a Buruli 
ulcer endemic region, which can facilitate further epidemiological studies of this 
pathogen through the development of high-resolution tools. 
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AUTHOR SUMMARY 
 
Mycobacterium ulcerans is the causative agent of Buruli ulcer (BU), a necrotizing skin 
disease and the third most common mycobacterial disease after tuberculosis and 
leprosy. It is an emerging infectious disease that afflicts mainly children and youths in 
West Africa. The disease is also found in tropical and subtropical regions of Asia, the 
Western Pacific, and Latin America. Limited knowledge of this neglected tropical 
disease is partially due to the lack of known genetic polymorphisms among isolates, 
which hinder the study of transmission, epidemiology, and evolution of M. ulcerans. 
Our aim is to systematically profile genetic diversity among M. ulcerans isolates by 
sequencing and comparing the genomes of selected strains. We identified single 
nucleotide polymorphisms (SNPs) within a highly clonal M. ulcerans population from 
a Buruli ulcer endemic region. Based on the SNPs discovered, we developed SNP 
typing assays and were able to differentiate a collection of M. ulcerans isolates from 
this Buruli ulcer endemic region into 13 SNP haplotypes. Our results lay the ground 
for developing a highly discriminatory and cost-effective tool to study M. ulcerans 
evolution and epidemiology at a population level. 
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INTRODUCTION 
 
Mycobacterium ulcerans causes Buruli ulcer (BU), a necrotizing skin disease and the 
third most common mycobacterial disease, after tuberculosis and leprosy [1]. In the 
past decade the incidence of BU has increased dramatically in West African 
countries, but the disease is also found in tropical and subtropical regions of Asia, the 
Western Pacific, and Latin America [2]. Due to the focal distribution of the disease 
and the fact that it affects mainly poor rural communities, BU belongs to the 
neglected tropical diseases. Limited knowledge about the disease is partially caused 
by the lack of molecular fine-typing methods, which hinder the study of transmission, 
epidemiology, and evolution of the clonal pathogen. 
Genetic analyses suggested that M. ulcerans diverged from the fish pathogen M. 
marinum between 470,000 and 1,200,000 years ago by acquiring the virulence 
plasmid pMUM001 [3],[4]. Whole genome comparison of M. marinum strain M and M. 
ulcerans strain Agy99 revealed that the two strains share >98% nucleotide sequence 
identity, although extensive DNA insertions and deletions have been observed [4]. 
Our recent comparative genomic hybridization study found extensive large sequence 
polymorphisms (LSPs) among M. ulcerans clinical isolates of diverse geographic 
origins. Two distinct M. ulcerans lineages have been defined: the ancestral lineage of 
strains from Asia, South America and Mexico, which are genetically closer to the 
progenitor M. marinum, and the classical lineage of strains from Africa, Australia and 
South East Asia [5],[6]. 
Although continental types of M. ulcerans strains have been well established, 
differentiation between isolates within a geographic region, such as strains from 
African countries, has remained a challenge [7],[8]. Different genotyping methods 
have been applied to M. ulcerans, including IS2426 polymerase chain reaction (PCR) 
[9],[10], amplified fragment length polymorphism (AFLP) [11], IS2404 restriction 
fragment length polymorphism (RFLP) [12],[13], multi-locus sequence typing (MLST) 
[3],[14],[15], variable-number tandem repeat (VNTR) typing [7],[8],[16],[17] and 
IS2404-Mtb2 PCR [18]. Among these, AFLP [11] and recently established VNTR 
typing methods [7],[8] were the only techniques that have provided some resolution 
among clinical strains of M. ulcerans from Africa, confirming that genotypic diversity 
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attributable to insertions, deletions, and duplications of variable DNA fragments 
exists among African strains. However, protein coding genes in M. ulcerans African 
populations harbor extremely low levels of polymorphisms. No single nucleotide 
polymorphisms (SNPs) were detected in a multi locus sequence typing of a few 
chromosomal and plasmid genes [3],[14],[15]. 
To systematically and comprehensively study the genetic diversity and the evolution 
of M. ulcerans strains, a genome wide profiling is needed. The complete genome 
sequence of M. ulcerans Agy99 consists of a circular chromosome of 5632 Kb and a 
plasmid pMUM001 of 174 Kb [4], which can be used as the reference for 
comparative genome analysis. The ongoing revolution in massively parallel 
sequencing technology [19],[20], such as the availability of Roche 454 Life Sciences 
Genome Sequencer FLX [21], Applied Biosystems SOLiD System, and Illumina 
Solexa Genome Analyzer [22], has made it possible to sequence large numbers of 
bacterial strains within days [23]. Next generation sequencing platforms have been 
used for genome wide profiling of novel genetic variations in many different 
organisms, including viruses [24], bacteria [25],[26],[27], plants [28],[29], worms [30] 
and humans [31],[32]. Here we report the sequencing of the genomes of three 
selected M. ulcerans strains using pyrosequencing (Roche 454 Life Science) and 
Solexa (Illumina) sequencing by synthesis technologies. Based on these sequences 
we identified SNPs, which we used to estimate evolutionary times for the emergence 
of M. ulcerans. We also developed SNP typing assays as high-resolution genotyping 
methods for M. ulcerans. Genetic fingerprinting of bacterial isolates will be a valuable 
tool for distinguishing relapses from new infections, tracing infection chains, and 
identifying environmental reservoirs. Molecular epidemiological analyses based on 
SNP typing may finally contribute to better disease control by identifying preventable 
risks for infection. 
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RESULTS 
 
Selection of M. ulcerans strains for genome sequencing 
With the aim to comprehensively investigate genome diversity of M. ulcerans strains 
from an individual geographical region, we selected two Ghanaian patient isolates 
from different residential districts and sequenced their genomes with 454 and Solexa 
technologies, respectively (Table 1). These two strains were isolated from the same 
African country as the fully sequenced reference strain Agy99 [4]. Whereas Agy99 
was isolated in 1999 from a BU patient, the two selected Ghanaian patient isolates 
NM20/02 and NM31/04 were isolated after an apparent process of replacement of 
VNTR types in Ghana [7] in the years 2002 and 2004, respectively. Agy99, NM31/04 
and NM20/02 represent the three VNTR types (Table 1) previously identified in 
Ghana [7]. While the Ghanaian strains belong to the classical lineage, we also 
included a Japanese patient isolate, ITM Japan8756 (denoted as Jp8756 from here 
on in the paper), as a representative of the ancestral lineage in our analysis. Its 
genome was sequenced with the Solexa Genome Analyzer. Selected genomic 
regions of this strain were also sequenced with a NimbleGen comparative genome 
sequencing (CGS) microarray and the results were compared. 
 
Single nucleotide polymorphisms in M. ulcerans strains 
We sequenced three M. ulcerans strains with single end reads generated by two 
different next–generation sequencing platforms. For NM20/02, we obtained 424,494 
GS FLX reads (Roche 454) with an average length of 213 bases. For NM31/04 and 
Jp8756, we obtained 2.5 and 2.7 million 35-bp Solexa reads, respectively (Table 2). 
To identify SNPs, we mapped the reads to the reference genome, including both the 
Agy99 chromosome and the plasmid pMUM001. 
We used the 454 software gsMapper for GS FLX reads and MAQ [33] for Solexa 
reads. The MAQ places Solexa reads mapped to multiple locations randomly, while 
gsMapper excludes reads mapped to repeated regions, such as insertion sequences 
(IS)2404 and IS2606, which are present in high copy numbers in the M. ulcerans 
genome [4]. Therefore, the Agy99 chromosome was better covered by Solexa reads 
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than by GS FLX reads. 94% of the Agy99 chromosome was mapped with NM20/02 
GS FLX reads, 99.99% with NM31/04 Solexa reads, 94.47% with Jp8756 Solexa 
reads. The average depth was 14 to 15 fold. We identified 135 chromosomal SNPs in 
NM20/02, 83 SNPs in NM31/04, and 26,564 SNPs in Jp8756 (Table S1).  
The coverage for pMUM001 varied a lot from strain to strain. 33% of the pMUM001 
was mapped with NM20/02 reads, 100% with NM31/04 reads, and 20% with Jp8756 
reads. The average depth ranged from 63 for NM31/04 reads to 17 for Jp8756 reads 
(Table 2). Because the low coverage of the plasmid in NM20/02 could be an artifact 
from the gsMapper, which excluded reads mapped to non-unique regions, we 
mapped NM20/02 reads to pMUM001 using another software, MOSAIK 
(http://bioinformatics.bc.edu/marthlab/Mosaik), which allowed us to compare mapping 
results with non-uniquely mapped reads included or excluded. When all mapped 
reads were assembled regardless of their uniqueness, the full length of pMUM001 
was well covered (Figure S1 A), suggesting the presence of a pMUM001-like plasmid 
in NM20/02. When only uniquely mapped reads were recorded, pMUM001 was 
partially covered (Figure S1 B). Reads mapped to regions such as those encoding 
Type I modular polyketide synthase genes, transposase genes, IS elements (IS2606 
and IS2404) were excluded due to their non-uniqueness. Although mapping analysis 
using MOSAIK confirmed that the lack of pMUM001 coverage in NM20/02 was a 
data analysis artifact, the lack of pMUM001 in Jp8756 was confirmed. MAQ didn't 
exclude non-uniquely mapped reads and was able to map the full length of 
pMUM001 with NM31/04 reads, which were analyzed exactly the same way as 
Jp8756 reads. Mapping using MOSAIK not only confirmed the lack of pMUM001 
coverage by Jp8756 reads (Figure S1 E), but also revealed that the depth of 
pMUM001 regions covered by uniquely mapped Jp8756 reads were very low, which 
ranged from one read to four reads (Figure S1 F), while the depth of pMUM001 
regions covered by uniquely mapped reads ranged from 10 to 50 in NM20/02 and 
NM31/04 (Figure S1 B and D). Most likely the under-representation of plasmid DNA 
in the total DNA sample is due to either complete or partial loss of plasmid 
sequences, which is frequently found in M. ulcerans strains that have been cultured 
over extended periods of time. Previous plasmid sequences analyses have found 
that plasmids in Japanese and African M. ulcerans strains are highly conserved in 
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size and sequence [15],[34]. However, a recent study found different strains of M. 
ulcerans were capable of producing structurally distinct mycolactones, which could 
be due to presence of sequence variations in pMUM001[35]. Our study suggests that 
the plasmids from all three African strains are highly similar. We only found one 
intergenic SNP and one synonymous SNP shared by NM31/04 and NM20/02 
plasmids. The two non- synonymous SNPs found in the NM20/02 plasmid were 
within IS2606 genes. In Jp8756 we identified one intergenic SNPs in the plasmid 
regions with sufficient coverage (Table S1). To elucidate how the sequence 
variations affect mycolacton production, future experiments in the lab will be needed 
to enrich and analyze the plasmids in each test strain, together with characterization 
of mycolacton production. 
Before next generation sequencing technologies became widely available, we have 
sequenced Jp8756 using comparative genome sequencing microarrays covering 
selected regions of the Agy99 chromosome and pMUM001. A total of 1,618 SNPs 
were identified in the selected 1.2 Mb chromosomal protein coding regions. 1,389 
(86%) of these SNPs were confirmed by Solexa sequencing (Table S2). On both 
mutation mapping arrays and re-sequencing arrays, probes targeting pMUM001 
showed very low signals (Figure S2), as compared to probes targeting the Agy99 
chromosome, which also confirmed the lack of plasmid DNA in the Jp8756 DNA 
sample. 
In total 26,669 SNPs were identified by comparing the Jp8756 to the Agy99 
chromosome; 18,510 in 3,597 protein coding genes, and 8,159 in 1,768 different 
intergenic regions (Table S1). 99.35% of the SNPs were found only in the Japanese 
strain (Figure 1). In comparison to Agy99, the average number of SNPs ranged from 
1 per 210 bp in Jp8756 to 1 per 68 Kb in NM31/04. While the Japanese strain 
Jp8756 and the Ghanaian strain Agy99 share 99.53% nucleotide sequence identity, 
the average percentage of polymorphic nucleotide sites between Ghanaian strains is 
only 0.0015% (NM31/04 vs. Agy99) and 0.0024 (NM20/02 vs. Agy99), respectively. 
These results are consistent with previous findings that strains of the ancestral 
lineage are genetically distant to the classical lineage strains [6]. There are 103 
SNPs specific to the Ghanaian strains with an average of 0.0018% of polymorphic 
nucleotide site differences from the Agy99 genome (Figure 1). 
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We classified identified SNPs into five different categories: strain specific SNPs, 
transversions, synonymous SNPs (sSNPs), non-synonymous SNPs (non-sSNPs), 
and intergenic SNPs. Figure 2 shows the total numbers of SNPs and the percentage 
of different categories of SNPs found in each strain. Overall, only 34 SNPs were 
found parsimoniously informative (PI), common to at least two strains or “non-strain-
specific.” The numbers of “strain-specific” SNPs varied from 33 (40% of 83 SNPs) in 
NM31/04 to 26,496 (99.7% of 26564 SNPs) in Jp8756. In all three strains the 
percentage of intergenic SNPs was around 40%, indicating a similar distribution of 
point mutations in coding and non-coding regions. Interestingly, the majority of 
coding region SNPs (63%) found in Jp8756 was synonymous, while in the two 
Ghanaian strains the majority was non-synonymous. About 100 non-synonymous 
SNPs found in strain Jp8756, but none of the non-synonymous SNPs found in the 
two Ghanaian strains caused premature stop codons. While the accumulation of 
pseudogenes seems to play an important role in both the divergence of M. ulcerans 
from M. marinum and the emergence of M. ulcerans continental types [4], our 
observation suggests that there is no further formation of pseudogenes within the 
studied Ghanaian strains. The percentage of SNP transition ranged between 65% 
and 68%, suggesting a substitution bias in favor of nucleotide substitution within the 
purine or pyrimidine group. 
We did not try to identify insertions or deletions (indels) of any size. First of all, single-
base/small indels were difficult to identify based on 454 data due to higher indel error 
rate observed in pyrosequencing [36]. Secondly, identification of single-base/small 
indels using short reads, such as solexa or SOLiD data, requires paired-end data [33], 
which were not provided in our study. Without paired-end data, discovery of single-
base/small indels using short reads requires gapped alignments of millions of short 
reads, which is computational challenged. Most currently available short read 
mapping tools supports only non-gapped alignments. Gapped alignment tools such 
as BLAST is not feasible for mapping short reads in a reasonable time scale and not 
guaranteed to give the right answer [37]. Last but not least, identification of large 
indels with high confidence also requires paired-end data. This is because missing 
regions can be explained by other factors, such as insufficient sequencing coverage, 
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differences in mapping algorithms when dealing with reads mapped to repeated 
regions, and so on. 
 
Genes potentially under selections 
Among the 94 protein coding genes containing SNPs found in the Ghanaian strains, 
most genes harbored only one SNP (Figure 3). Only three genes contained two 
SNPs: MUL_2118 (hypothetical protein), MUL_3524 (diphosphomevalonate 
decarboxylase) and MUL_3716 (nucleoside diphosphate kinase). When considering 
all strains, 3,597 genes harbored SNPs, most of which contained one to five SNPs 
(Figure 3), but much higher numbers of SNPs per gene were also observed. For 
example, the peptide synthetase Nrp gene MUL_2638 contained 59 SNPs, the 
Pks12 gene MUL_2266 harbored 55 SNPs, and the fatty acid synthase Fas gene 
MUL_3818 had 30 SNPs. However, all three genes were over 9 Kb in length, which 
may account for the high number of SNPs. We did find 70 genes with a SNP density 
higher than 1 per 80 bp, which was one standard deviation higher than the average 
SNP density (Table 3). More than 50% of these consisted of genes encoding 
hypothetical proteins. Others included genes associated with antigenic proteins (i.e. 
esxE, esxF, mpt64), lipoproteins (i.e. dsbF, lppN, lpqV), PE/PE-PGRS family proteins 
(MUL_4359, MUL_0355), membrane proteins (mmr) and transcription regulators 
(MUL_2645, MUL_0993). The high number of SNPs may represent evidence for 
selection pressure on these genes. We thus calculated values of synonymous 
differences per synonymous site (pS) and nonsynonymous differences per 
nonsynonymous site (pN) across all SNP harboring loci. The average pN−pS value 
was −0.00276±0.0073 (P<0.001, pS = 0.0073±0.0063, pN = 0.0046±0.0033), 
suggesting that on average the frequency of synonymous mutation was significantly 
higher than the non-synonymous mutation frequency; i.e. there was no evidence for 
diversifying selection. Among the 70 genes found earlier with high SNP density, five 
genes (esxE, mmr, MUL_0355, as well as the hypothetical protein genes MUL_0161 
and MUL_2106) showed significantly high pN−pS values (above the mean + 3× 
standard deviations) and might be under diversifying selection, while six genes (glbO, 
mcmA2b, MUL_1435, MUL_2645, MUL_4312 and MUL_4846) showed significantly 
low pN−pS values (less than the mean−3× standard deviations), which might be under 
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negative selection (Table 3). Meanwhile, we found 32 genes with average SNP 
density but significant low pN−pS values, including genes related to transcription and 
translation (whiB4, trxC, trpG, MUL_0058, MUL_2937, MUL_4776) and another 
ESAT-6 family protein gene, esxR (Table 3). 
There has been growing evidence suggesting that some of the ESAT-6 family 
proteins are involved in the interplay between host and pathogen via either antigenic 
variation or antigenic drift [38]. ESAT-6 protein encoding genes (esxA esxB) are 
deleted in M. ulcerans strains of the classical lineage [4],[39], which could contribute 
to antigen variation and enable the pathogen to escape the immune defense of the 
host. The Agy99 genome contains 12 genes encoding ESAT-6 like proteins [4]. This 
may represent a genomic basis for antigenic variation. The duplicated genes might 
encode antigenically different proteins with the same function. The differential 
expression of individual genes could enable them to substitute for each other 
functionally but escape from host immune recognition. The high number of SNPs and 
significantly high/low pN−pS values we observed here on ESAT-6 family protein 
genes such as exsE, esxF, esxR, and another secreted antigenic protein gene mpt64, 
may be the result of selective pressure imposed by the immune system of the host. 
Mutations that lead to replacement of amino acids within the immunodominant 
epitopes have been proposed as a mechanism producing antigenic drift [40]. 
However, it remains to be investigated whether the esx genes are expressed, if their 
expression is controlled and coordinated, and if the mutations identified here lead to 
antigenic drift. 
We further examined whether certain functional classes of genes were under positive 
selection by comparing pN−pS values according to the Clusters of Orthologous Group 
(COG) classification. We found no significant overrepresentation of any functional 
class in gene group with positive pN−pS values (under diversifying selection), except 
the “Function unknown” class (p value <0.05). Five functional classes showed 
overrepresentation of genes with negative pN−pS values, indicating possible 
selections against amino acid changes, including functional classes J (translation, 
ribosomal structure and biogenesis), O (posttranslational modification, protein 
turnover, chaperones), F (nucleotide transport and metabolism), H (coenzyme 
transport and metabolism) and V (defense mechanisms). 
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Phylogeny and estimation of the divergence time of M. ulcerans strains 
To evaluate the phylogenetic relatedness of the M. ulcerans strains sequenced in this 
study, we first analyzed the 34 PI SNP sites using the compatibility matrix program 
[41] to detect the effects of recombination on sequence divergence among the genes 
harboring these SNPs (Figure 4). In the square matrix, each white square 
corresponds to two compatible nucleotide sites, at which all nucleotide changes can 
be inferred to have occurred only once in a phylogeny. Black squares represent 
incompatible sites, where nucleotide changes are inferred to have occurred multiple 
times either due to recombination or repeated mutation. We found the 34 PI SNPs 
formed three groups: SNPs shared by the two Ghanaian test strains (at genomic 
locations of 1289632, 2366378, 2631719, 3621904, 3670882, 3692657), SNPs 
shared by NM31/04 and Jp8756 (at genomic locations of 119244, 3594811, 4144236, 
4144237) and the rest of the SNPs shared by NM20/02 and Jp8756. The SNPs were 
compatible within each group but not across groups. The overall compatibility score 
of all 34 PI SNP sites was 0.5294, which measures the extent of the sites consistent 
with one phylogeny. The neighbor similarity score of the matrix was 0.6506, which 
was not significantly higher than scores of 1000 random matrices produced by 
shuffling the order of sites (mean score 0.6168, P = 0.30), suggesting that 
recombination among these regions has been rare. 
We then used the split decomposition method to detect possible conflicting 
phylogenetic signals (Bandelt and Dress 1992). NeighborNet Network analysis of the 
34 PI SNP sites revealed two parallel paths indicative of the presence of 
phylogenetic incompatibilities in the divergence of M. ulcerans strains, which could 
arise from recurrent mutation or recombination in the genomes. However, one 
parallel path showed much lower bootstrap support value (65.5%) than the other 
parallel path (100%). The paths with high bootstrap support values (over 99.5%) 
showed a tree-like network (Figure 5), suggesting that a bifurcating tree is an 
appropriate model for constructing strain phylogeny. Therefore, we constructed a 
minimum evolution tree of M. ulcerans strains rooted with M. marinum M to estimate 
the divergence time (Figure 6). We first compared the 3,597 SNP harboring M. 
ulcerans genes with the M. marinum M genome and identified 3,059 genes that have 
homologous genes in M. marinum M [42]. We then generated concatenated allelic 
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sequences of the 3,059 genes for the three test strains and two reference strains (a 
combined total of 1,032,790 codons in 3,113 kb of coding sequences per strain), 
based on which a minimum evolution tree of M. ulcerans strains was constructed. 
Estimated divergence time based on comparison of numbers of synonymous 
substitutions per nucleotide site (dS) in the 1,032,790 allelic codons are shown in 
Table 4. The calculations were based on the estimated rate of synonymous 
substitution in bacteria of 5.8×10−9 to 7.8×10−9 substitution per site per year [43]. Our 
results suggest that Agy99 and M. marinum M diverged from a common ancestor 
about 1.13 to 1.52 million years ago, which confirms the recent divergence of M. 
ulcerans from its M. marinum progenitor, and seems more precise than the earlier 
estimation of between 1.2 and 4.7 million years [3]. The African classical lineage 
strain Agy99 and the Japanese ancestral lineage strain Jp8756 diverged about 394 
to 529 thousand years ago (Table 4). Although the ancestral lineage was found 
genetically closer to the progenitor M. marinum in regions of difference (RD) 
composition [6], the SNP data suggested the Japanese strain was closer to the 
Ghanaian strains than to M. marinum. The discrepancy between the SNP phylogeny 
and the RD phylogeny could indicate that regions of M. ulcerans genomes harboring 
these genetic variations have diversified through different mechanisms at variable 
rates. The discrepancy could also be due to the small number of strains analyzed in 
our study. Among Ghanaian M. ulcerans strains the divergence times is less than 
3,000 years. However, there are uncertainties in our phylogenetic estimates because 
of rate heterogeneity. The two-cluster test in LINTREE showed that all the interior 
nodes within the Ghanaian clade evolved at a uniform rate, while the Japanese strain 
evolved at a significantly different rate (CP = 99.96%). The branch-length test further 
indicated that the Japanese strain evolved significantly slower than average, and that 
all three Ghanaian strains evolved significantly faster than average. Thus, the 
divergence time of three Ghanaian strains is likely to be shorter than estimated here. 
 
Genetic diversity among Ghanaian clinical isolates 
We are developing hairpin primer SNP assays [44] based on the 173 SNP loci 
discovered through pairwise comparisons of the three M. ulcerans Ghanaian strains 
and are analyzing our collection of Ghanaian M. ulcerans isolates at these loci. At the 
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current stage it is possible to resolve the nucleotides at 68 SNP loci in 54 Ghanaian 
strains with 13 distinct SNP haplotypes identified (including the three reference 
strains). Previously only 3 haplotypes were found in this strain collection by VNTR 
typing, which was the best resolution achieved [7]. The nucleotide diversity ranged 
from 0.05 to 0.40 across the 23 sSNP and 31 intergenic SNP loci with an average 
diversity of 0.09 (Figure 7). Across the 14 non-sSNP, the average nucleotide diversity 
was 0.06. This level of nucleotide diversity means that two isolates selected at 
random from this collection will differ at a SNP locus in 6–9% of the cases. The 
alleles at the sSNP loci were highly nonrandom in their haplotype distribution. This 
statistical association can be seen in the distribution of the linkage disequilibrium 
coefficient (D) for 1,176 pairwise comparisons of alleles at 54 sSNP and intergenic 
SNP loci (Figure 8). A total of 751 (64%) of these comparisons were significant by a 
chi-squared test, and 600 (51%) were significant using a highly conservative 
Bonferroni correction for multiple tests [45]. The standardized coefficient of linkage 
disequilibrium (D′) was strongly U-shaped with 96% of the locus pairs in complete 
linkage disequilibrium. This observation indicates that there are at most three out of 
the four possible haplotypes for most locus pairs. It also suggests that recurrent 
mutation and recombination events have played only a minor role in generating 
haplotype diversity. Detailed epidemiological analysis of the typing results is out of 
the scope of this paper and will be summarized elsewhere (manuscript in 
preparation). 
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DISCUSSION 
 
In this study we have sequenced genomes of two Ghanaian and one Japanese M. 
ulcerans disease isolates by using two different massively parallel sequencing 
platforms. By comparison of genome sequences of these strains with the genome of 
the Ghanaian reference strain Agy99, we have identified over a hundred SNPs within 
Ghanaian strains and about 26,000 SNPs in the Japanese strain. The SNPs 
identified among Ghanaian strains for the first time allow to resolve the population 
structure and evolutionary relationship of an intra-continental population of M. 
ulcerans. The SNP data confirmed the recent divergence of M. ulcerans and M. 
marinum from a common ancestor and refined the estimated time of emergence to 
about 1.3 million years. We also estimated that the classical M. ulcerans lineage 
(represented by the Ghanaian strains) diverged from the ancestral lineage 
(represented by the Japanese strain) about 400,000 years ago, which is about the 
time when the modern human species, Homo sapiens, evolved (~250,000 to 400,000 
years). However, we need to point out two limiting factors of our current estimates. 
First is the limited number of strains analyzed. Future studies should include many 
more strains from different countries and continents representing branches of the two 
lineages to improve the phylogenetic resolution and accuracy of the dating. Second 
is that our dating was based on the estimated rate of synonymous substitution in 
bacteria of 5.8×10−9 to 7.8×10−9 substitution per site per year, which was not the 
most appropriate clock rate for calculating the age of genetically monomorphic 
pathogens [46]. However, till now studies trying to establish the ideal molecular clock 
calibrated against a fossil record have not yielded much usable new information [46]. 
The clock rate we used has been used to date other monomorphic pathogens such 
as M. ulcerans [3], M. tuberculosis [43],[47] and Escherichia coli [48], and our 
estimated age of M. ulcerans is thus still informative and comparable to these 
previous estimations. 
The SNP analysis suggested that the Japanese strain was closer to the Ghanaian 
strains than to M. marinum, which is contradictory to the previous finding based on 
RD composition, where the ancestral lineage was found genetically closer to the 
progenitor M. marinum [6]. The discrepancy might suggest that regions of M. 
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ulcerans genomes harboring these genetic variations have diversified through 
different mechanisms at variable rates. However, more strains within the ancestral 
lineage should be analyzed before firm conclusions can be drawn. Among Ghanaian 
strains the divergence time was less than 3000 years. Two-cluster and branch-length 
tests in this study revealed that the Ghanaian strains evolved significantly faster than 
average, thus the actual divergence time within Ghana could be much shorter than 
our current estimate. M. ulcerans was first isolated in 1948 [49], but large ulcers 
almost certainly caused by M. ulcerans have been already described by Sir Albert 
Cook in 1897. Since the late 1980s the number of reported cases has increased 
dramatically in West Africa [50],[51],[52],[53] and in Australia [54]. Increased disease 
incidence has been primarily attributed to factors such as environmental changes, 
increased exposure of the affected populations, and improved surveillance. VNTR 
typing results gave indications for the emergence and spreading of new genetic 
variants of M. ulcerans within Ghana [7]. More in-depth phylogenetic and functional 
analyses are needed to test if mechanisms such as virulence evolution and host 
adaptation of M. ulcerans play a role in the increasing incidence of BU. 
Genome comparison of M. ulcerans Agy99 and M. marinum M revealed that M. 
ulcerans underwent reductive evolution with genomic signatures such as proliferation 
of ISE, accumulation of pseudogenes, chromosomal rearrangements, genome 
downsizing, and acquisition of foreign genes by acquisition of plasmids or 
bacteriophages [4]. Microarray based comparative genomic hybridization with a 
worldwide set of M. ulcerans isolates identified genomic regions of difference and 
demonstrated that the two major M. ulcerans lineages can be distinguished based on 
the location and size of genomic deletions [5],[6]. Due to the lack of paired-end 
sequencing data, we did not carry out systematic analysis on chromosomal deletions 
and rearrangements. But when we tried to close sequencing gaps using the Agy99 
chromosome as the reference, there were more successful gap closure reactions in 
Ghanaian strains than in the Japanese strain. Failed gap closure attempts in 
Ghanaian strains were mostly around IS elements, while this was not the case for the 
Japanese strain (data not shown). These results suggest a high frequency of large 
chromosomal rearrangement events in the Japanese strain compared to the African 
classical lineage strains. In the two Ghanaian strain, NM31/04 and NM20/02, the 
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plasmid was fully covered by sequence reads and almost identical to pMUM001 in 
Agy99, while the plasmid in the Japanese strain was only partially covered with low 
depth. Altogether these observations suggest a more stabilized genome and a less 
important role of reductive evolution within M. ulcerans Ghanaian strains. 
SNP analysis revealed no further pseudogene formation within the Ghanaian strains, 
and the Ghanaian strains were found to evolve significantly faster than average. 
While the majority of coding region SNPs found in Jp8756 was synonymous, the 
majority found in the two Ghanaian strains was non-synonymous. Further functional 
analysis of genes containing these non-sSNPs would help to elucidate if they could 
lead to “pathoadaptive” niche expansion, or provide a selective advantage in both 
sporadic infection and epidemic spread, which have been found in other bacterial 
pathogens [55],[56] and suggested for M. ulcerans [39],[57]. 
The low genetic diversity and high linkage disequilibrium within Ghanaian isolates 
supports the hypothesis that the M. ulcerans population spread over the African 
continent has gone through a severe bottleneck during adaptation to a possibly host-
specific environment and has not yet accumulated much sequence diversity [15]. 
SNP typing of Ghanaian isolates was consistent with VNTR typing [7], but allowed to 
further differentiate between isolates coming from the same BU endemic focus. 
Closely related, but distinct clonal complexes including strains with minor variation 
seem to dominate in different BU endemic areas. Diversity of these local clonal 
complexes is indicative for ongoing microevolution. 
Although there has been impressive recent progress in studying the transmission of 
BU, the precise environmental reservoirs and mode(s) of transmission are not fully 
understood [58],[59]. High-throughput genotyping platforms, such as Hairpin primer 
real time PCR assays [44], BeadArray [60] and OpenArray [61] will make genome 
wide SNP typing a highly discriminatory and cost-effective tool to study M. ulcerans 
evolution and epidemiology at a population scale. More in-depth phylogenetic and 
phenotypic analyses of a large number of disease isolates and environmental strains 
(once becoming available) is expected to shed more light into transmission and 
virulence evolution of M. ulcerans after its divergence from M. marinum. The study 
will also help to identify SNPs associated with host specificity and geographical 
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origins. However, the current set of SNP markers were obtained by comparing 
genomes of three very closely related Ghanaian strains and one very distant 
Japanese strain. Future genome sequencing of more representative strains from 
diverse locations around the world will be necessary to identify additional SNP 
markers to delineate the origin and spread of M. ulcerans at both local and global 
level. 
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MATERIALS AND METHODS 
 
Bacterial strains and genomic DNA isolation 
The three M. ulcerans strains sequenced with various sequencing platforms are 
listed in Table 1. Strain Jp8756 (ATCC 33728) from Japan was provided by 
Francoise Portaels (Institute of Tropical Medicine, Antwerp, Belgium). Isolation and 
characterization of strains NM31/04 and NM20/02 from Ghana has been described 
elsewhere [7],[8],[62],[63]. We used the complete Agy99 genome sequence 
(chromosome, NC_008611, and the plasmid pMUM001, NC_005916) as the 
reference sequences. Genomic DNA was isolated as described [64]. 
 
Pyrosequencing of M. ulcerans NM20/02 
We sequenced the genome of M. ulcerans NM20/02 using the Roche 454 Life 
Sciences Genome Sequencer FLX following the manufacturer's instructions (Roche 
454 Life Science, Branford, CT, USA). The shotgun library was prepared with 5 µg 
genomic DNA using the “Standard DNA Library Preparation Kit” (04852265001, 
Roche). Nebulized, purified, and adaptors attached single strand DNA fragments 
were clonally amplified using the “Emulsion PCR Kit I” (04852290001, Roche). 
Sequencing on the GS FLX was performed using the “Standard LR70 Sequencing 
Kit” (04932315001, Roche). Images were processed using the “Genome Sequencer 
FLX Data Processing Pipeline 1.1.02.15”. A total of 424,494 reads with average 
length of 213 bases were obtained. 
We mapped 454 reads to the reference sequence using gsMapper (v1.1.02.15, 
Roche) to make SNP calls. To identify high confidence SNPs, we filtered 
substitutions reported by gsMapper using two rules: (1) supported by at least three 
non-duplicated reads, with at least one aligned in the forward direction and at least 
one aligned in the reverse direction. (2) Requirement for at least five conserved 
bases on both sides of the SNPs. We randomly selected 37 SNPs distributed across 
the genome for PCR and capillary sequencing. 29 SNPs were validated, three were 
miscalled due to sequencing errors in the Agy99 genome, and five failed due to 
unspecific PCR reactions (Table S3). After manual inspection, we found that each of 
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the five SNPs was supported by all the reads (7 to 16) uniquely mapped to the region, 
thus was likely to be a true SNP. Unspecific PCR reactions might be due to the 
presence of genes paralogous to genes harboring or flanking the SNPs. 
 
Solexa sequencing of M. ulcerans NM31/04 and Jp8756 
We sequenced the genomes of M. ulcerans NM31/04 and Jp8756 with the Illumina 
Genome Analyzer according to the manufacturer's instructions (Illumina, San Diego, 
CA, USA). The DNA Colony/Cluster Template Library was prepared using the 
Illumina “Genomic DNA Sample Prep Kit” (Illumina). Briefly, 5 µg of genomic DNA 
was broken into fragments of approximately 100 bp by nebulization. After end 
repairing and adaptor ligation, the samples were gel-purified to recover fragments of 
150–250 bp, which were PCR amplified for 15 cycles. For quality control, an aliquot 
of the library was cloned into a TOPO plasmid. Six clones from each bacterial strain 
were picked and subjected to capillary sequencing. The DNA Colony/Cluster 
Template Library was then used for flow-cell preparation using the “Standard Cluster 
Generation Kit” (Illumina). Sequencing on the Illumina Genome Analyzer was 
performed using “Genomic DNA sequencing primer V2” for 36 cycles. At the end of 
the run, images were processed using the “Solexa Data Analysis Pipeline 0.2.2.6”. A 
total of 2.538 and 2.651 million reads of 35 bases in length were obtained for 
NM31/04 and Jp8756, respectively. 
We mapped Solexa reads to the reference sequences using MAQ v0.6.3, which is 
particularly developed for building mapping assemblies from Illumina Solexa reads. 
For each read, un-gapped alignment against the reference was performed; all hits 
with up to 2 mismatches in the first 24 bp were found. Each read was placed to the 
position where the sum of quality values of the mismatched nucleotides is minimum 
[33]. For detection of high confidence SNPs, we first filtered the SNP calls reported 
by MAQ based on two rules: (1) supported by more than three non-duplicated reads; 
(2) covered by at least one read with a mapping quality higher than 40. We then 
randomly selected 84 SNPs called in NM31/04 or Jp8756 for PCR and capillary 
sequencing to determine the cutoff value of the consensus quality. We found that the 
consensus quality equal or higher than 40 excluded most false positive SNP calls 
and that the false positive rate was about 1% (Figure S3). 
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NimbleGen comparative genome sequencing (CGS) of selective regions in M. 
ulcerans Jp8756 
Before next-generation sequencing became widely available, NimbleGen CGS was 
the cost effective tool for the comparative analysis of microbial genomes to identify 
SNPs, insertions, or deletions with high speed and accuracy [65]. We first used a 
mutation mapping array tiling the reference genome to locate potential mutation 
harboring sites. Then a high density re-sequencing array tiling the putative sites was 
produced to identify the mutations [66]. The method has been applied successfully to 
survey the entire or partial genomes of several bacteria [48],[67],[68], including M. 
tuberculosis [69]. 
For CGS analysis of M. ulcerans Jp8756, we selected 1,265 of the 4,160 protein 
coding genes across the chromosome of Agy99 (1,210,734 bp out of 5,805,761 bp, 
20%) and 51 of the 81 protein coding genes on the plasmid pMUM001 (135,612 bp 
out of 174,155 bp, 78%) (Table S2). These genes include drug resistance genes, 
known antigens, genes with housekeeping roles, and genes of hypothetical proteins. 
To avoid cross hybridization and ambiguous SNP calls, we excluded protein coding 
genes with paralogs in the M. ulcerans genome. Highly conserved genes between M. 
ulcerans and its ancestor M. marinum were also excluded. Mutation mapping and re-
sequencing probes were designed for selected gene using the ArrayScribe software, 
synthesized using the Maskless Array Synthesis (MAS) technology [70],[71], and 
printed in a random layout. Genomic DNA samples from Jp8756 and the reference 
Agy99 were hybridized to the arrays separately following the NimbleGen protocol. 
Data were analyzed using NimbleScan software (NimbleGen). A list of 1,619 
identified SNPs is provided in Table S2. 
 
SNP validation 
We used Sanger sequencing of PCR products to validate a selected subset of SNPs. 
Primer sequences used for PCR and sequencing are provided in Table S3. PCR 
products were purified using the NucleoSpin Extract II Kit (Clontech Laboratories, 
Mountain View, CA). 
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SNP typing 
We are developing hairpin primer (HP) assays [44] for SNPs discovered through 
pairwise comparisons of the three M. ulcerans Ghanaian strains (Agy99, NM20/02, 
and NM31/04) and analyzing our collection of clinical isolates from Ghana [7]. All HP 
assays were tested on the three reference strains to confirm the presence of each 
allele and to verify the performance of the SNP assays. Assays on the clinical DNA 
samples were considered reliable only if the cycle thresholds generated in the paired 
wells differed by three or more cycles. At the reported stage, it was possible to assign 
alleles to 68 SNP loci in 54 Ghanaian isolates (including the reference strains) using 
this approach. 
 
Phylogenetic analysis 
To identify putative regions of recombination or gene conversion, we used the 
Reticulate program and constructed a compatibility matrix [41]. We also used the 
SplitsTree program to detect conflicting phylogenetic information and determine if a 
bifurcating tree is an appropriate model to construct strain phylogeny [72]. A 
minimum evolution tree rooted with M. marinum was constructed by using the MEGA 
[73] software based on the numbers of synonymous substitutions per nucleotide site 
in concatenated SNP harboring protein coding genes in all strains. The numbers of 
synonymous substitutions per synonymous site were calculated from the 
concatenated nucleotide sequences using the modified Nei-Gojobori Jukes Cantor 
method. The Complete deletion method was used for handling alignment gaps. 
Because rate heterogeneity may have contributed to uncertainty in phylogeny 
estimates, we applied the two-cluster and branch-length tests in LINTREE [74] to 
identify significant rate heterogeneity in the phylogeny. The two cluster test was used 
to test the molecular clock hypothesis for the two lineages above each interior node 
of a tree and the branch-length test was used to examine the deviation of each root-
to-tip branch length relative to the average length [74]. To generate the concatenated 
sequences, we first determined homologous genes in the M. marinum M genome [42] 
for each of the 3,597 protein coding gene harboring SNPs by standalone BLAST 
search [75]. Using the threshold of 90% nucleotide sequence identity over a 
minimum alignment length of 90% of both query and hit genes, 3,059 homologous 
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genes were identified. Protein sequences of the homologous genes were aligned 
using the CLUSTALW program [76]. Homologous genes were then aligned using the 
EMBOSS [77] Tranalign program so that the corresponding amino acid sequence 
alignment was imposed on the DNA sequence alignment. Allelic genes in M. 
ulcerans strains and homologous genes in M. marinum M with alignment gaps were 
then concatenated. 
 
Accession numbers 
The sequencing reads of the NM20/02, NM31/04 and Jp8756 genomes have been 
deposited in the NCBI Short Read Archive database under the accession number 
SRA008258. 
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TABLES 
 
Table 1. Mycobacterium ulcerans strains sequenced in this study. 
 
 
Table 2. Summary of next generation sequencing results. 
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Table 3. Genes potentially under selection ordered by SNP density. 
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Table 4. Estimation of time of divergence between M. ulcerans Agy99 and other 
M. ulcerans and M. marinum strains. 
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FIGURES 
Figure 1. Venn diagram of single nucleotide polymorphisms in M. ulcerans 
strains. 
 
 
 
Figure 2. Summary of single nucleotide polymorphisms in M. ulcerans strains. 
The number in parentheses represents the total number of SNPs in each sequenced 
strain. The color bars show the distributions of different SNP categories in each strain. 
NM20/02 (135) NM31/04 (83) 
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26496 
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Figure 3. Distribution of number of SNPs per gene. 
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Figure 4. Compatibility matrix of parsimony informative SNPs. The genome 
positions are numbered to the left of the matrix. Black squares indicate incompatible 
sites, where nucleotide changes are inferred to have occurred multiple times either 
due to recombination or repeated mutation. White squares represent compatible sites, 
at which all nucleotide changes can be inferred to have occurred only once in a 
phylogeny. 
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Figure 5. NeighborNet network of the M. ulcerans strains based on the 
parsimony informative SNPs. Bootstrap values shown close to branches are based 
on 1000 bootstrap replicates. 
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Figure 6. Minimum evolution tree based on 1,032,790 allelic codons of the M. 
ulcerans and M. marinum strains. The scale shows the divergence time frame and 
the number of synonymous substitutions per nucleotide site. The rate of synonymous 
substitution used for time calibration was 5.8×10−9 substitution per site per year. 
 
 
 
Figure 7. Nucleotide diversity among SNPs identified through genome 
comparison of three Ghanaian strains, for which complete SNP data have been 
collected in 54 Ghanaian M. ulcerans strains. 
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Figure 8. Linkage disequilibrium among study loci. A). The distribution of the 
linkage disequilibrium coefficient (D) for 1,176 pairwise comparisons of alleles at 54 
sSNP and intergenic SNP loci. A total of 751 (64%) of these comparisons are 
significant by a chi-squared test, and600 (51%) remained significant using a 
Bonferroni correction for multiple tests. B). The distribution of the standardized 
coefficient of linkage disequilibrium (D'). Ninety-six percent of the locus pairs are in 
complete linkage disequilibrium. 
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ABSTRACT 
 
Buruli ulcer (BU) is an emerging necrotizing disease of the skin and subcutaneous 
tissue caused by Mycobacterium ulcerans. While proximity to stagnant or slow 
flowing water bodies is a risk factor for acquiring BU, the epidemiology and mode of 
M. ulcerans transmission is poorly understood. Here we have used high-throughput 
DNA sequencing and comparisons of the genomes of seven M. ulcerans isolates that 
appeared monomorphic by existing typing methods. We identified a limited number of 
single nucleotide polymorphisms (SNPs) and developed a real-time PCR SNP typing 
method based on these differences. We then investigated clinical isolates of M. 
ulcerans on which we had detailed information concerning patient location and time 
of diagnosis. Within the Densu river basin of Ghana we observed dominance of one 
clonal complex and local clustering of some of the variants belonging to this complex. 
These results reveal focal transmission and demonstrate, that micro-epidemiological 
analyses by SNP typing has great potential to help us understand how M. ulcerans is 
transmitted.  
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AUTHOR SUMMARY 
 
Mycobacterium ulcerans causes a destructive skin disease known as Buruli ulcer 
(BU), which has been reported from more than 30 tropical or subtropical countries, 
with the highest prevalence in Western Africa. Due to the striking genetic 
monomorphism of African M. ulcerans populations, conventional genetic 
fingerprinting methods have largely failed to differentiate isolates coming from the 
same BU endemic area. Here we report a highly discriminatory fingerprinting method 
for M. ulcerans using a single nucleotide polymorphism-based genetic fine-typing 
technique. This method has enabled us for the first time to identify different M. 
ulcerans haplotypes within a BU endemic area. Linking the origins of M. ulcerans 
strains with the patients` residences unveiled the clustering of unique M. ulcerans 
haplotypes within the Densu river basin of Ghana. Results show, that haplotypes do 
not spread within a short time over the entire BU endemic region, but rather form 
independent focal transmission clusters. 
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INTRODUCTION 
 
Infection with Mycobacterium ulcerans causes a chronic, necrotizing disease of the 
skin and the subcutaneous adipose tissue commonly known as Buruli ulcer [1]. This 
serious infectious disease remains a major health problem in many parts of the world, 
but in particular, in Western and Central Africa [2]. In spite of considerable research 
efforts made during the past few years transmission and environmental reservoirs of 
M. ulcerans are still incompletely characterized [1]. Endemic foci are usually linked to 
wetlands and riverine areas, which has lead to the assumption that M. ulcerans is an 
environmental mycobacterium and that micro-traumata of the skin may initiate 
infection [3]. However, isolation of the slow growing M. ulcerans from an 
environmental source has been achieved only once so far, from an aquatic insect [4]. 
PCR screening of environmental samples for the presence of IS2404 has implicated 
insects such as biting aquatic hemiptera and mosquitoes in the transmission of M. 
ulcerans [5-7], but their positivity for M. ulcerans DNA in polymerase chain reaction 
(PCR) tests may be only an indicator for the presence of M. ulcerans or other 
genetically closely related mycobacteria in the environment. Although BU is known to 
develop in all age groups with a nearly equal gender distribution, children 15 years of 
age or younger make up at least 50% of all cases in Africa [8]. Occasional clustering 
of cases within families may reflect a common source of infection or increased 
genetic susceptibility to infection rather than human-to-human transmission. 
Seroepidemiological studies have indicated that infection with M. ulcerans may lead 
to disease only in a minority of exposed individuals [9]. 
Many genetic fingerprinting methods have been applied for M. ulcerans, including 
IS2404, IS2606 and IS2426 PCR [10,11], amplified fragment length polymorphism 
analysis (AFLP) [12], IS2404 restriction fragment length polymorphism analysis 
(RFLP) [13,14], multi-locus sequence typing (MLST) [15-17], variable-number tandem 
repeat analysis (VNTR) [18-21], IS2404-Mtb2 PCR [22], and large sequence 
polymorphisms [23]. Among these, AFLP [12] and VNTR typing [19,21] were the only 
methods to reveal any genetic diversity among African strains. 
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MLST, which has now been developed for more than 50 microbial taxa [24], revealed 
extremely low levels of polymorphisms in several protein coding genes of African M. 
ulcerans strains [16,17]. Analyses of the population structure of bacterial pathogens 
such as M. tuberculosis [25], Yersinia pestis [26] or Salmonella enterica Typhi [27] 
have shown that single nucleotide polymorphism (SNP) typing is the most suitable 
fine-typing method for genetically monomorphic species [24]. This prompted us to 
develop a SNP typing method for M. ulcerans strains from a BU endemic area of 
Ghana. We selected two Ghanaian patient isolates representing two different 
Ghanaian VNTR types [19] for genome re-sequencing and compared obtained 
sequences with the published genome sequence of the reference strain Agy99 [28]. 
Whole genome comparison between these three strains detected 173 SNPs in total 
[29], which were used for the establishment of amplification refractory mutation 
system (ARMS) real-time PCRs using hairpin-shaped primers [30]. Typing of 74 
strains isolated from patients living in the BU endemic Densu river basin at 65 SNP 
loci revealed the presence of five haplotypes in addition to the Agy99 reference 
haplotype. Sequencing of 4 additional strains chosen on the basis of detected 
haplotypes enabled further differentiation of isolates. Location of the homes of 
patients from whom the strains were isolated facilitated a phylogeographic analysis of 
haplotype distribution.  
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MATERIALS AND METHODS 
 
Ethics statement  
In the present study, M. ulcerans isolates were obtained from BU diagnostic samples. 
Data were analyzed anonymously and bacterial isolates delinked from the patients 
from whom they originated. Ethical approval to use the diagnostic specimens for 
immunological and microbiological research was obtained from the ethical review 
board of the Noguchi Memorial Institute for Medical Research, University of Ghana, 
Legon, Ghana. Written informed consent was provided by all patients for standard 
surgical treatment and anaesthesia. In addition the ethical review board requested 
written informed consent for taking blood samples for immunological research on a 
special consent form, but not for potential later investigations of bacterial isolates 
generated during standard diagnostic procedures.  
 
Mycobacterial strains and genomic DNA extraction 
A total of 74 M. ulcerans patient isolates from a BU endemic area located in the Ga 
West, Ga East and Akuapim South Districts were included in the SNP typing analysis. 
Patients were aged 2 - 75 years, while 71% of the patients were younger than 15 
years. In addition, M. ulcerans patient isolates from the Ashanti Region (Amansie 
West District) of Ghana and from other West-African countries (Ivory Coast, Togo, 
Benin, Democratic Republic of Congo and Angola) were enclosed for further SNP 
typing analyses (Table 1). The complete Agy99 genome sequence published in 2007 
[28] and re-sequenced genomes of isolates NM20/02, NM31/04 [29], NM14/01, 
NM43/02, NM49/02 and NM54/02 were used as reference sequences. The genomes 
of strains NM14/01, NM43/02, NM49/02 and NM54/02 were analyzed at Monash 
University using an Illumina GAIIx Genome Analyzer. A 100x coverage per genome 
was obtained on average. The Short Read Mapping Package (SHRiMP) software 
was used for aligning the genomic reads against the target Agy99 genome. For SNP 
identification the Nesoni software was used. Genomic DNA was isolated by cell wall 
disruption and phenol-chloroform extraction as described previously [31].  
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SNP typing 
Real-time PCR hairpin primer (HP) assays [30] were used to detect SNPs in the 74 
Ghanaian M. ulcerans strains. Real-time PCR was performed using Power SYBR 
green 1x PCR Master Mix (Applied Biosystems), 5 ng genomic DNA and 0.3 µM 
forward and reverse primers each in a total volume of 25 µl. Reactions were carried 
out in a Step One Plus Real-time PCR system (Applied Biosystems) with a 96-well 
block. Thermal conditions were as follows and as described previously [30]: stage 1, 
95°C for 10 min, 70°C for 30 s; stage 2, 72°C for 30 s, 95°C for 20 s, 69°C for 30 s, 
lowering one degree in the last step for every cycle during 10 cycles; stage 3, 72°C 
for 30 s, 95°C for 20 s, and 60°C for 30 s, repeated 40 times; Melt curve stage, 95°C 
for 15 s, 60°C for 1 min, 95°C for 15 s. Data were collected in the last step of stage 3 
and after the Melt curve stage for analysis with the Step One Software version 2.0 
(Applied Biosystems). SNPs were detected by ARMS assays and for each assay two 
PCRs with two sets of PCR primers were performed in parallel. Each PCR reaction 
contains SNP-specific primers, which are designed to be either fully complementary 
to the DNA template or mismatched at the 3`end nucleotide. As reactions with totally 
complementary primers have a more rapid developing fluorescence curve and an 
earlier cycle-threshold, differences between the two reactions allow the detection of 
SNPs. 
The hairpin-shaped primers were designed as described previously [30]. In the first 
step linear primers were designed with Primer3 [32] to produce short amplicons (30 
to 90 bp) and to anneal between 60 and 65°C. A tail was added to the 5' end of the 
SNP-detecting primer in order to produce a stem with the 3' end of the primer. The 
stem was designed with mfold software 
(http://www.bioinfo.rpi.edu/applications/mfold/old/dna/) to have a melting temperature 
of 67 to 70°C with a free energy of between -0.5 and -2.0. Primers are provided in 
Table S1.  
 
Validation of SNP typing assays 
Assays were validated on the published genome Agy99 as well as the reference 
strains NM20/02, NM31/04, NM14/01, NM43/02, NM49/02 and NM54/02 to confirm 
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the presence of each allele and to verify the performance of SNP assays. Assays 
with genomic DNA samples from clinical isolates were considered reliable only if the 
cycle thresholds generated in the paired wells differed by three or more cycles and if 
the melting curves of paired wells were coherent. ARMS assays with low 
discriminatory power were not included into the standard set of 65 SNP typing 
assays. Sanger DNA sequencing of PCR products was used to validate a selected 
subset of SNPs. Primers used for PCR and sequencing were designed using Primer3 
[32] software. PCR was performed using FirePol 10x buffer and 0.5 µl FirePolTaq-
Polymerase (Solis BioDyne), 5 ng genomic DNA, 0.72 µM forward and reverse 
primers each, 2mM MgCl2 and 0.4 mM dNTPs (Sigma) in a total volume of 25 µl. 
PCR reactions were carried out in a Gene Amp PCR System 9700 PCR machine 
(Applied Biosystems). Thermal conditions for PCR amplification of M. ulcerans 
genomic DNA were as follows: initial denaturation step, 94°C for 5 min; 32 cycles: 
94°C for 30 s (denaturation), 60°C for 30 s (annealing), 72°C for 1 min (elongation); 
final extension step, 72°C for 10 min. PCR products were analyzed on 1% agarose 
gels. PCR products were purified using the Nucleo Spin Extract II Kit (Macherey-
Nagel). Sequencing of purified PCR products was done by Macrogen (World 
Meridian Venture Center, Seoul/Korea). Sequencing was conducted by the Sanger 
method using BigDyeTM terminator cycling conditions using the Automatic Sequencer 
3730xl (Applied Biosystems).  
Several random SNP loci were validated by Sanger sequencing in order to verify the 
ARMS approach for a differentiation of M. ulcerans isolates. Additionally, validation of 
pivotal SNPs loci revealing different haplotypes within the endemic area around the 
Ga District as well as differences between Amansie West District strains and isolates 
from other African countries was carried out. 100% of 36 randomly chosen SNP loci 
tested in reference strains Agy99, Nm20/02 and Nm31/04 were reconfirmed by 
Sanger sequencing. 100% of 70 significant SNP loci dividing Ga District strains into 5 
haplotypes other than Agy99 and distinguishing Amansie West District as well as 
African strains were likewise verified by Sanger sequencing. In contrast, four real-
time PCR typing results, which were validated because of unique allele occurrences 
in certain Ga District isolates diverged from reconfirmatory Sanger sequencing 
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analysis. Subsequent repetition of real-time PCRs in duplicates revised the initial 
real-time PCR analyses and confirmed Sanger sequencing results. 
 
Phylogenetic analysis 
MEGA software version 4.1 (beta) [33] was used to reconstruct the neighbor-joining 
tree based on SNP typing data (Phylogeny Test and options: Bootstrap 1000 
replicates; Gaps/Missing Data: Complete Deletion; Codon Positions: 
1st+2nd+3rd+Noncoding; Model: Nucleotide, Number of differences; Substitutions to 
include: Transitions + Transversions; Pattern among lineages: Same = 
Homogeneous; Rates among sites: Uniform rates). 
We created a map of West Africa by using the map creator tool of Epi Info version 
3.5.1 in order to illustrate detected SNP patterns in different African countries.
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RESULTS 
 
Development of ARMS SNP typing assays 
Recently we have compared 454 and Illumina genome sequencing data of M. 
ulcerans patient isolates NM20/02 and NM31/04 originating from two different BU 
endemic areas of Ghana with the published genome sequence of the Ghanaian 
strain Agy99 [29]. Based on the identification of 173 SNPs we have developed 
medium-throughput ARMS-based real-time PCR SNP assays with hairpin-shaped 
(HP) primers. Initial ARMS assays were successful for 108 of 173 detected SNP loci 
at predefined optimal conditions. We were able to discriminate alleles under a single 
standard condition at 73/108 (67.6%) SNP loci. This is close to the success rate of 
72.4% reported by Hazbon and Alland for their first round of HP-assay design [30]. 
Real-time PCR analysis revealed sequencing errors in the Agy99 reference 
sequence at eight of these loci, which were thus not suitable for further typing 
analyses. Redesign of the 100 initially failed assays and ongoing whole-genome 
sequencing of additional isolates will increase the pool of discriminatory SNP assays 
for future analyses of the population structure of African M. ulcerans. Developed SNP 
assays were used to type a collection of strains from two different BU endemic areas 
of Ghana and other African countries (Figure 1).  
 
Different clonal complexes of M. ulcerans dominate in the BU endemic regions 
of Africa 
SNP typing of three strains from the Amansie West District of Ghana including the 
sequenced Amansie West reference strain NM31/04 revealed differences at 24 of the 
65 SNP loci analyzed (37%) between these isolates (Figure 1B). In comparison to 
Agy99 differences at 29, 27 and 5 loci were found. A neighbor-joining tree analysis 
sub-grouped haplotypes from the two different BU endemic areas of Ghana into two 
clades (Figure 2). Clade 1 comprises strains isolated between 2001 and 2007 in the 
Densu river basin, which could be differentiated into 6 haplotypes (Figure 1A). All 
Amansie West District isolates are sub-grouped together with the 1999 isolate Agy99 
into clade 2 (Figure 2). 
Chapter 3. Genetic fine-typing of M. ulcerans 
Inauguraldissertation 
79 
Typing of patient isolates from other BU endemic African countries at the 65 SNP loci 
yielded 2 of 15 strains with patterns similar to haplotypes found in Ghana (Figure 1A 
and B). The only strain available from Togo had a haplotype which differed at only 
one locus from haplotype 6 found in the Densu river basin. One of the two analyzed 
strains from the Ivory Coast had a haplotype similar to the haplotypes of strains from 
the Amansie West District of Ghana. The other isolate from the Ivory Coast as well as 
all seven analyzed strains from Benin, three strains from the Democratic Republic of 
Congo (DRC) and two strains from Angola shared a distinct SNP pattern when 
compared to the Ghanaian isolates (Figure 1A and B). Thus, SNP typing results of 
clinical isolates from Ghana and isolates from other African countries revealed a 
neighbor-joining tree with 3 main branches. The strain from Togo is sub-grouped 
together with haplotypes 2-6 into clade 1, while strain 1 from the Ivory Coast is 
classed with Amansie West District isolates and Agy99 into clade 2. The other 13 
West-African strains are sub-grouped into clade 3 (Figure 2). 
 
SNP typing of M. ulcerans patient isolates from a BU endemic area of Ghana 
identifies ten haplotypes belonging to a dominating clonal complex 
Using the 65 established ARMS assays we SNP-typed 74 M. ulcerans patient 
isolates collected between 2001 and 2007 from the BU endemic Densu river basin of 
Ghana, from which the sequenced strains Agy99 and NM20/02 originated. Within this 
group of 74 strains of common geographical origin, differences at 14 of the 65 SNP 
loci tested (22%) were observed (Figure 1A). Altogether five haplotypes (designated 
haplotypes 2-6) other than the Agy99 associated haplotype 1 could be distinguished. 
Haplotypes 2 - 6 differed at 41, 43, 47, 48 and 55 of the 65 analyzed SNP loci from 
haplotype 1 (strain Agy99), respectively.  
Based on detected haplotypes we re-sequenced 4 representative strains NM14/01 
(haplotype 5), NM43/02 (haplotype 3), NM49/02 (haplotype 6) and NM54/02 
(haplotype 4) in order to further differentiate strains from the same haplotype. We 
detected new unique SNPs in NM43/02 (26 SNPs), NM54/02 (11 SNPs), NM14/01 (9 
SNPs) and NM49/02 (4 SNPs) and established 24 new assays, which enabled a 
segregation of each haplotype into two haplotypes (Figure S1). A phylogenetic tree 
for haplotypes 1-10 is shown in Figure 3. 
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Temporal and spatial distribution of haplotypes 
In contrast to the generally rarer haplotypes 2-4; 6-8 and 10, haplotypes 5 and 9 
were found within each time interval (one year) from 06/2001 to 06/2006 (data not 
shown). Haplotypes 1 and 2 were not found again in the whole strain collection. 
Possible explanations include the actual absence of these haplotypes from the 
residual clonal M. ulcerans complex in the Densu river basin as well as phylogenetic 
or sampling bias.  
For a phylogeographic analysis the homes of patients from whom the strains were 
isolated were marked in a map, depicting the distribution of haplotypes (Figure 4). 
Haplotypes 4, 6, 7, 9 and 10 appear to be unevenly distributed; i.e. they were found 
only in certain parts of the BU endemic area. Haplotype 10 was even found only 
within one small village. In contrast, the most prevalent haplotype (haplotype 5) co-
localized with all other haplotypes. Interestingly, two M. ulcerans isolates of identical 
haplotype (haplotype 4) were isolated from two patients coming from the same 
household, suggesting a common source of infection.  
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DISCUSSION 
 
Previous investigations on the genetic diversity of M. ulcerans by comparative 
genomic hybridization analysis enabled differentiation of a world-wide collection of 
strains into two main lineages and six continental haplotypes [34]. However, 
phylogeographic and transmission pathway analysis requires high-resolution fine 
typing of strains from the same BU endemic region. This has been accomplished so 
far only for a few M. ulcerans populations and at low resolution. VNTR analysis of a 
Ghanaian strain collection based on the polymorphic loci ST1 and MIRU1 revealed 
the presence of three distinct allele combinations (BD/B, C/BAA and BD/BAA) in 
Ghana. All isolates from the Buruli ulcer endemic Densu river basin tested, except for 
Agy99, displayed combination BD/B [19]. Our recent genome re-sequencing analysis 
[29] compared the two Ghanaian VNTR type reference strains NM20/02 (BD/B) and 
NM31/04 (C/BAA) to Agy99 (BD/BAA) with the goal of detecting single nucleotide 
polymorphisms suitable for development of a fine-typing method. By selection of 
isolates with the three prevalent VNTR types in Ghana we expected to capture as 
much of the genetic variation present in the Ghanaian M. ulcerans population as 
possible. Our assumption was reinforced by re-sequencing four M. ulcerans strains 
initially grouped into haplotypes 3-6. Only 16 additional SNPs could be detected by 
comparison of the four strains to reference strain Agy99, while 50 unique SNPs could 
be identified by comparing the four strains among themselves. We anticipated that 
detected SNPs will provide the first useful genetic markers for phylogeographic and 
transmission pathway analyses at least in the Densu river basin and other BU 
endemic areas of Ghana.  
We have identified 10 different haplotypes in a relatively small BU endemic area 
within the Densu river basin. Haplotypes 1-10 are descendants of a founder 
haplotype that has spread over the district; the most common haplotype 5 may 
represent this founder haplotype. Analysis of this spatial distribution of haplotypes 
indicates that emerging new haplotypes do not readily spread over the entire 
endemic area, but form focal transmission clusters. 
Our data are comparable to studies of other genetically monomorphic organisms like 
Salmonella typhi, which report multiple strain types circulating within a specific 
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location [35-37]. Comparison of typing results in strains from two geographically 
separate BU endemic areas in the Densu river basin and the Amansie West Districts 
of Ghana uncovered a total of 61 differing alleles at 65 SNP loci. Within each of the 
two endemic areas SNP variation was significantly smaller (14 and 24 differences, 
respectively) than the overall variation between the two endemic areas. These results 
indicate the dominance of two different clonal complexes in the two separate 
Ghanaian BU endemic areas. SNP typing of two strains from Ghanaian neighboring 
countries showed similar SNP patterns when compared to AW District isolates (strain 
1 from the Ivory Coast) or Ga District haplotypes (strain from Togo). Typing of 13 
strains collected in additional African countries (Benin, DRC, Angola, strain 2 from 
the Ivory Coast) revealed a completely new SNP pattern compared to all other 
isolates. On the basis of typing with the Ghanaian set of SNPs these 13 strains could 
not be distinguished among each other and were thus clustered together into a clade. 
This clustering may however represent a phylogenetic discovery bias, i.e grouping of 
actually diverse strains leading to a so called “branch collapse”. Future addition of 
SNP loci identified by genome re-sequencing of a comprehensive pan-African 
selection of M. ulcerans isolates will lead to a further subdivision and differentiation of 
African strains. Phylogenetic discovery bias is implicit to SNP typing and will continue 
to exist as long as not every single sample will be sequenced. It will become smaller 
though with every additional re-sequenced genome. SNP typing based on a wider 
range of SNPs may therefore yield evidence for genetic divergence of strains from 
Benin, DRC, and strain two from the Ivory Coast. Hence, phylogeographic analyses 
in other African BU endemic areas will require whole genome comparison of strains 
from that area to develop a local set of informative SNPs. This is supported by our 
recent identification of seven insertion sequence element-related SNP types within 
Africa [38].  
M. ulcerans has evolved from the aquatic environmental M. marinum and seems to 
have adapted to a more stable ecological niche [28]. Gain of the immunosuppressive 
toxin mycolactone is accompanied by loss of highly immunogenic proteins [39], 
suggesting an adaptation to survival in host environments that are screened by 
immunological defense mechanisms. Serological analyses have indicated that many 
individuals living in BU endemic areas are exposed to M. ulcerans, whereas relatively 
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few develop clinical disease [9]. There is no published evidence for direct person to 
person transmission of M. ulcerans. Based on numerous reports demonstrating an 
association of BU with slow flowing or stagnant water bodies, it is therefore 
commonly assumed that infection takes place through trauma of the skin or insect 
bites via an environmental reservoir in the aquatic ecosystems. Both biotic 
components, such as biofilms and aquatic invertebrate species are being considered 
as potential vectors and/or reservoirs [5,6,40-42]. Recent findings in south-eastern 
Australia have implicated mammals as environmental reservoir (Fyfe et al., submitted) 
and mosquitoes as vectors of M. ulcerans [43,44]. While large numbers of possums 
in a BU-endemic area of Australia are infected with M. ulcerans, a similar mammalian 
reservoir has not been identified in BU endemic regions of Africa. If such a reservoir 
plays a role in transmission, spread of M. ulcerans from chronic, ulcerated lesions to 
insect vectors or another currently unknown environmental reservoir should be 
considered. Subsequent infection of individuals living in the same settlements may 
be responsible for the focal transmission patterns, such as of haplotype 10, which 
was found only within one small village.  
The Densu river basin represents one of the coastal drainage systems of Ghana. Its 
water is collected in the Weija Lake, which developed after construction of a dam at 
the river’s mouth in the 1970s. If M. ulcerans bacteria would be carried freely by the 
flow of water of the Densu river and its tributaries, haplotypes present in upper parts 
of the river system should be represented in the lower parts. However, among patient 
isolates coming from the lower part of the basin close to the Weija Lake the rare 
haplotypes 4 and 7 dominated. M. ulcerans bacteria that are swept downstream in 
the river water thus do not seem to play a major role in transmission.  
Results of this retrospective pilot study indicate that future longitudinal micro-
epidemiological studies involving SNP typing of isolates may give deeper insight into 
transmission pathways and relevant reservoirs of M. ulcerans. 
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TABLES 
 
Table 1. M. ulcerans strains included in the analysis. 
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Figure 1. SNP typing analysis of African M. ulcerans isolates. A M. ulcerans 
isolates from the Densu river basin of Ghana were analyzed at 65 SNP loci (Primer 
IDs) by real-time PCRs. Base exchanges relative to the reference sequence of strain 
Agy99 were registered as 1 (grey). Allele matches with Agy99 were recorded as 0 
(white). 5 haplotypes in addition to haplotype 1 (Agy99) could be distinguished on the 
basis of 14 SNP loci. B SNP typing results of strains from a second BU endemic area 
of Ghana as well as from additional African countries carried out with the set of SNP 
assays developed by whole genome sequencing of Ghanaian isolates. AW: Amansie 
West; Ga: strains from the Densu river basin; IC: Ivory Coast; T: Togo; B: Benin; C: 
Democratic Republic of Congo; A: Angola. 
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Figure 2. Geographical distribution of African M. ulcerans clades. Map of West-
Africa, showing the distribution and SNP haplotypes of three African M. ulcerans 
clades. Clade 1: yellow; clade 2: green; clade 3: blue. AW: Amansie West; Ga: 
strains from the Densu river basin; IC: Ivory Coast; T: Togo; B: Benin; C: Democratic 
Republic of Congo; A: Angola. A neighbor-joining tree shows sub-grouping of 
detected haplotypes from the Densu river basin together with the only strain from 
Togo into clade 1, strains from AW together with strain Agy99 and strain 1 from the 
Ivory Coast into clade 2 and all other strains from additional African countries into 
clade 3 (scale: number of differences at the SNP loci tested). 
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Figure 3. Neighbor-joining tree of 75 Ghanaian M. ulcerans isolates. 75 M. 
ulcerans isolates were aligned based on their SNP type (scale: number of differences 
at the SNP loci tested). HT = haplotype. 
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Figure 4. Geographical distribution of M. ulcerans haplotypes. Map of the Densu 
river basin, showing the homes of patients from whom the strains have been isolated 
between 2001 and 2006 (colored dots). Haplotypes 2 (black), 3 (white), 4 (yellow), 6 
(purple), 7 (dark blue), 8 (light blue), 9 (dark green), 10 (light green) are unevenly 
distributed, whereas haplotype 5 (red) co-localizes with all other haplotypes. The 
background map was created using elevation data from the Shuttle Radar 
Topography Mission (SRTM). Water bodies were classified using optical data from 
Landsat ETM and radar data from TerraSAR-X. 
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ABSTRACT 
 
Mycobacterium ulcerans (M. ulcerans), the causative agent of the devastating skin 
disease Buruli ulcer (BU), is characterized by an extremely low level of genetic 
diversity. Recently, we have reported the first discrimination of closely related M. 
ulcerans variants in the BU endemic Densu River Valley of Ghana. In the study real-
time PCR-based single nucleotide polymorphism (SNP) typing at 89 predefined loci 
revealed the presence of ten M. ulcerans haplotypes circulating in the BU endemic 
region. Here we describe the development of temperature-switch PCR (TSP) assays 
that allow distinguishing these haplotypes by conventional agarose gel-based 
analysis of the PCR products. After validation of the accuracy of typing results, the 
TSP assays were successfully established in a reference laboratory in Ghana. 
Development of the cost-effective and rapid TSP-based genetic fingerprinting method 
will thus allow investigating the spread of M. ulcerans clones by regular genetic 
monitoring in BU endemic countries. 
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AUTHOR SUMMARY 
 
As the third most common mycobacterial disease after tuberculosis and leprosy, 
Buruli ulcer constitutes a considerable health problem in many parts of the world, but 
in particular in West and Central Africa. Although this emerging skin disease is 
commonly associated with proximity to aquatic habitats, the mode of transmission 
remains obscure. While the clonal population structure of Mycobacterium ulcerans 
provides a great potential to trace transmission pathways and evolutionary 
relationships, micro-epidemiological studies have long been hampered by a striking 
lack of genetic diversity among African M. ulcerans populations. Whole genome 
comparison of M. ulcerans strains isolated from patients living in the BU endemic 
Densu River Valley of Ghana led to the identification of single nucleotide 
polymorphisms between these closely related strains. The subsequent development 
of SNP typing assays enabled a differentiation of ten M. ulcerans haplotypes in the 
BU endemic region. Here we selected canonical SNP markers for a spatio-temporal 
analysis of M. ulcerans variants in the Densu River Valley of Ghana using a 
temperature-switch PCR-based approach. 
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INTRODUCTION 
 
Infection with M. ulcerans causes a chronic and necrotizing skin condition known as 
Buruli ulcer. This emerging disease occurs focally in more than 30 predominantly 
tropical countries worldwide, but mainly affects impoverished populations of West 
and Central Africa with limited access to health care services [1]. Recent findings 
suggest that M. ulcerans has diverged about a million years ago from the fish 
pathogen Mycobacterium marinum by the acquisition of a plasmid encoding the 
enzymes required for the production of mycolactone [2–4]. Mycolactone is a cytotoxic 
macrolide toxin that plays a key role in the unique pathology of BU [5], characterized 
by the formation of progressive skin ulcers. While a potential transmission model 
implicating mammals as reservoirs and mosquitoes as vectors of M. ulcerans has 
been proposed for a local BU endemic region in south-eastern Australia [6,7], 
epidemiologic information for BU endemic African settings is sparse.  
Remarkably little genetic diversity between M. ulcerans isolates from African BU 
patients has hindered molecular epidemiological studies tracing the spread of genetic 
variants of M. ulcerans. However, from a phylogenetic perspective the genetic 
monomorphism of this pathogen, which is associated with a clonal ancestry, holds a 
great potential to trace transmission pathways and evolutionary relationships. 
Several studies of other genetically highly homogeneous pathogens such as 
Mycobacterium leprae [8], Bordetella pertussis [9], Yersinia pestis [10] and Bacillus 
anthracis [11] have demonstrated the validity of genome-wide single nucleotide 
polymorphisms as markers for such phylogenetic analyses. 
In our previous work we compared genome sequences of three Ghanaian M. 
ulcerans isolates, selected on the basis of the three earlier identified variable number 
of tandem repeat (VNTR) types among 57 M. ulcerans strains from Ghana [12], in 
order to detect a comprehensive set of SNP markers for genotyping studies. The 
subsequent development of 65 real-time PCR-based typing assays for the identified 
SNP loci allowed us to differentiate 75 M. ulcerans strains from a BU endemic area in 
the Densu River Valley of Ghana into six haplotypes. Genome re-sequencing of four 
haplotype representatives followed by further SNP detection and design of 24 
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additional real-time PCR assays led to the identification of ten haplotypes (HT1-10) 
among the 75 M. ulcerans isolates (Table 1).  
Here we report the development of a simplified and cost-effective SNP typing method 
based on TSP and analysis of PCR products by conventional agarose gel 
electrophoresis. For this approach we have selected ten canonical SNP (canSNP) 
markers that facilitate a rapid differentiation of the ten described M. ulcerans 
haplotypes in the Densu River Valley of Ghana by the elimination of diagnostically 
redundant assays. This strategy is used to monitor the temporal as well as spatial 
distribution and spread of the M. ulcerans haplotypes in that region. Results of this 
ongoing study are expected to provide insights into the circulation of M. ulcerans 
variants in a BU endemic area. 
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MATERIALS AND METHODS 
 
Ethics statement 
M. ulcerans isolates analyzed in this study were cultivated for BU diagnosis. Ethical 
approval to use the isolates for immunological and microbiological research was 
obtained from the institutional review board of the Noguchi Memorial Institute for 
Medical Research, University of Ghana, Legon, Ghana (Federal-wide Assurance 
number FWA00001824). Written informed consent was provided by all patients 
involved in this study. 
 
Mycobacterial strains and genomic DNA extraction 
We analyzed a total of 33 M. ulcerans isolates cultivated from wound specimen of BU 
patients living in the BU endemic Densu River Valley of Ghana. Ten of these isolates, 
used for the setup of SNP typing assays, had been typed previously by real-time 
PCR as SNP haplotypes 1-10 (Agy99 (HT1), NM98/03 (HT2), NM83/03 (HT3), 
NM100/03 (HT4), NM27/02 (HT5), NM18/02 (HT6), NM74/03 (HT7), NM32/02 (HT8), 
NM28/02 (HT9), and NM78/03 (HT10)) [13]. Genomic M. ulcerans DNA was isolated 
by cell wall disruption and phenol-chloroform extraction as described earlier [14]. 
DNA was quantified by using Qubit Fluorometer (dsDNA HS Assay Kit, Invitrogen).  
 
Selection of single nucleotide polymorphism loci and TSP assay design 
In our previous work we have detected ten M. ulcerans haplotypes (HT1-10) in a 
relatively small BU endemic region within the Densu River Valley of Ghana by 
amplification refractory mutation system (ARMS) real-time PCR assays [13]. Here we 
constructed a phylogenetic tree of the ten identified haplotypes based on 
concatenated sequences of the 89 SNP loci (Figure 1A). For the TSP assay 
development, we selected ten representative SNP loci (TSP1, 3, 4, 6, 8, 9, 15, 16, 17 
and 18), providing a discrimination of all described M. ulcerans variants in the Densu 
River Valley by haplotype-specific allele combinations (Figure 1B). TSP assay 
primers were designed on the basis of the strategy described by Hayden and Tabone 
[15,16]. For each SNP marker, locus specific (LS) primers amplifying the region 
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surrounding the SNP of interest as well as a nested allele-specific (NAS) primer fully 
complementary to the sequence of reference strain Agy99, but mismatched at the 
3`end nucleotide for M. ulcerans strains harboring the SNP at this locus, were 
designed using Primer 3 Software [17] (Figure 2, Table S1). LS primers were 
designed to have an optimum melting temperature (Tm) of 63°C (range of 62-64°C) 
and to amplify a PCR product greater than 400 bp. The NAS primer was designed to 
have a core region with an optimum Tm of 46°C (range of 43-48°C) and a non-
complementary 5`tail region that increased the overall optimum primer Tm to 53°C 
(range of 52-55°C). The forward (TSP assays 1, 3, 4, 6, 8, 9, 15, 16) or reverse (TSP 
assays 17, 18) NAS primer was positioned in at least 60 bp distance from the 
corresponding forward/reverse LS primer to ensure a clear distinction between the 
larger LS and the smaller NAS PCR product. Primer sequences and PCR product 
sizes are provided in Table S1.  
 
Differentiation of alleles by TSP and analysis of PCR product size 
The TSP method described by Hayden and Tabone [15,16] served as basis for the 
development of a TSP assay protocol for M. ulcerans. A number of technical details 
were modified, including standard PCR reagents, the addition of diluted DNA instead 
of DNA desiccation and the usage of a three-primer system with optimized primer 
concentrations. PCR assays were performed using 0.5 U FIREPol DNA Polymerase 
(Solis BioDyne), Buffer BD, 3 mM MgCl2, 0.25 mM dNTPs (Sigma), 0.1 µM each of 
forward and reverse LS primer, 1 µM (0.25 µM, 0.5 µM, 0.75 µM) of forward/reverse 
NAS primer and 1-50 ng genomic DNA in a total reaction volume of 5 µl. In order to 
avoid evaporation of the relatively small reaction volume, PCRs were carried out in 
0.2 ml eppendorf PCR tube strips, which could individually be closed after addition of 
the reagents. PCRs were performed in a T-Professional thermocycler (Biometra).  
Thermal conditions for PCR amplification of M. ulcerans genomic DNA after an initial 
denaturation step (95°C for 5 min) were as follows: 15 cycles of 95°C for 30 s, 58°C 
for 30 s, 72°C for 1 min in order to enrich the LS product at a relatively high 
annealing temperature (Figure 2A); 5 cycles of 95°C for 10 s and 45°C for 30 s to 
enable a possible incorporation of the NAS primer into the enriched LS PCR product 
at a low annealing temperature (Figure 2B); 15 cycles of 95°C for 10 s, 53°C for 30 s 
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and 72°C for 5 s to facilitate a competitive amplification of LS and NAS PCR products 
(Figure 2C); final extension step of 72°C for 10 min. 1 µl of the PCR products were 
analyzed on 2% agarose gels and stained for 1-2 hours in an ethidium bromide bath 
(1 µg/ml in 0.5xTBE). Whether the tested M. ulcerans strains harbored reference or 
SNP allele at the analyzed loci could then be determined by the presence of either 
the smaller or the larger PCR product, respectively. 
 
TSP validation by real-time PCR SNP typing 
All TSP SNP typing results were validated by the recently described amplification 
refractory mutation system real-time PCR SNP typing technique [13]. 
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RESULTS 
 
Optimization of TSP assays  
TSP parameters described by Tabone et al. included the desiccation of genomic 
DNA by evaporation prior to PCR amplification [16]. In order to reduce the risk of 
contamination of the laboratory with DNA template, we eliminated this step. The 
addition of M. ulcerans DNA dissolved in water necessitated a new setup for all 
assay parameters.  
While standard PCR reagents were used according to the manufacturer’s (Solis 
Biodyne) recommendations, the most critical step for a specific detection of either the 
smaller NAS or the larger LS PCR product was to identify the optimal application of 
NAS and LS primers used for the PCR assays. Since initial PCR reactions using a 
four-primer system including both forward and reverse NAS and LS primers led to the 
amplification of additional non-specific PCR products (Figure 3A), we applied a three-
primer system with only one NAS primer. In order to ensure an accurate 
differentiation of reference and SNP alleles we determined optimal primer 
concentrations by performing TSP assays for the ten haplotype representatives at 
NAS:LS primer ratios of 2.5:1, 5:1, 7.5:1 and 10:1. Results of all TSP assays 
provided a correct differentiation of reference and SNP alleles for the four NAS 
primer concentrations (Figure 3B-E). However, a clear-cut visualization of only the 
allele-specific PCR product was obtained by deploying a tenfold concentration of the 
NAS primer compared to the LS primers (Figure 3E).  
The illustration of allele-specific PCR products could be further improved by loading 
only one-fifth of the PCR reaction on a 2% agarose gel. Gels initially overloaded by 
the whole PCR reaction volume showed traces of the non allele-specific PCR 
products.  
The optimal amount of DNA for the TSP assay reactions was assessed by 
performing TSP assays for the ten haplotype representatives with a NAS:LS-primer 
ratio of 10:1 and different genomic DNA concentrations ranging from 1-50 ng. TSP 
assays provided accurate results for all DNA concentrations tested. However, 
subsequent standardized TSP strain typing was performed using 5 ng DNA for each 
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reaction. The performance of TSP assays was dependent on the purity of the 
extracted DNA. While samples with a high ratio of OD 260/280 (>1.7) facilitated a 
clear visualization of allele-specific PCR products on the agarose gels, traces of non-
allele-specific PCR products were detected when using DNA extracts with poorer 
quality. TSP assays were evaluated on ten haplotype representatives in order to 
confirm accurate performance of all assays for both reference and SNP alleles 
(Figure S1). 
 
TSP typing of clinical M. ulcerans isolates 
We typed a total of 23 M. ulcerans strains isolated between 2009 and 2011 from BU 
patients living in the Densu River Valley of Ghana by the ten developed TSP assays 
using the optimized single standard condition (Figure S2). One additional strain 
served as a control for either the NAS or the LS PCR product amplification. Based on 
the resulting allele combinations at tested SNP loci, isolates could be differentiated 
into seven of the ten described M. ulcerans haplotypes (HT1 (1 strain), HT2 (7 
strains), HT3 (1 strain), HT5 (3 strains), HT6 (5 strains), HT7 (1 strain) and HT9 (5 
strains). ARMS real-time PCR SNP typing of the 23 isolates at the ten SNP loci 
confirmed the accuracy of TSP SNP typing results. In addition to clinical M. ulcerans 
strain typing, TSP assays were performed using DNAs directly extracted from BU 
lesion specimens. We selected four samples out of a panel of DNA extracts with the 
highest M. ulcerans DNA concentrations detected by IS2404 real-time PCR. However, 
all attempts to SNP-type these samples by TSP failed, since additional, unspecific 
PCR products were amplified. 
 
Establishment of TSP assays in a BU endemic country 
Robustness of the assay protocol and suitability of the technique for technology 
transfer to laboratories in BU endemic countries was verified by analyzing TSP 
assays in a laboratory of the Noguchi Memorial Institute in Accra, Ghana. For this 
purpose we tested the ten haplotype representatives again using the same PCR 
materials and optimized assay parameters. Each assay provided the expected TSP 
genotyping products and endpoint detection by 2% agarose gels and ethidium 
bromide staining was comparable to the TSP setup results (Figure 4). 
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DISCUSSION 
 
A global overview of genetic diversity in M. ulcerans could be established by 
comparative genomic hybridization analysis detecting insertional-deletional variation 
in 35 clinical M. ulcerans isolates of world-wide origin [18,19]. However, efforts made 
to resolve the population structure of M. ulcerans strains from the same BU endemic 
countries were limited by the extensive genetic monomorphism of closely related 
isolates [12,20–25]. Genome sequencing of several clinical M. ulcerans isolates from 
a BU endemic region in the Densu River Valley of Ghana has facilitated for the first 
time the development of a SNP-based genotyping strategy with sufficient resolution 
for micro-epidemiological studies. This real-time PCR-based approach provided first 
insights into the actual diversity of such closely related M. ulcerans isolates as well as 
the distribution of M. ulcerans variants in the BU endemic area. Among 75 M. 
ulcerans strains isolated between 1999 and 2007 ten haplotypes showing different 
patterns of geographical distribution could be detected. The identification of 
geographically clustered emerging haplotypes provides a valuable opportunity to 
monitor the spatio-temporal spread of haplotypes in this region.  
Cost is an important issue for all genetic fingerprinting analyses, and this particularly 
applies to neglected pathogens like M. ulcerans. While the established real-time PCR 
technique required relatively expensive equipment, the TSP-based assays described 
here, provide a simple and cheap alternative system, thus increasing the access of 
genetic typing assays for M. ulcerans to laboratories in tropical BU endemic areas. 
Low cost for the PCR assays, direct endpoint detection through PCR product staining 
on agarose gels and simple implementation of the method provided a practical 
means for rapid and cost-effective SNP typing.  
The critical step for TSP assay development was to design primers with optimal 
melting temperatures for the envisaged reaction phase participations. Efficient primer 
design enabled the performance of all TSP assays under a single optimized standard 
condition. Genotyping accuracy and robustness of the TSP strategy was 
demonstrated by the successful application of the designed assays in two different 
research laboratories, yielding identical results. 
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SNPs represent highly stable phylogenetic markers in genetically homogenous 
pathogens as they occur at very low rates and convergent or reverse mutations are 
highly unlikely [26]. Numerous genotyping studies of monomorphic pathogens have 
demonstrated that a limited set of SNPs can be used to define phylogenetic 
relationships [11,27–30]. The idea of a canonical SNP, a SNP that can be used to 
define species [31], major genetic lineages of a species [27,28] or even specific 
strains [32,33] has recently been described in a review article focussing on the 
molecular epidemiology of Bacillus anthracis [26]. Here we present an extreme 
example of the canSNP concept where a small number of SNPs is used to 
distinguish between strains from a relatively small endemic region. For that purpose 
we replaced the 89 real-time PCR-based SNP typing assays by ten strategically 
placed canSNPs that enabled a differentiation of the ten described M. ulcerans 
haplotypes in our panel of strains.  
The detected canSNPs provide useful genetic markers for the geographical and 
temporal analysis of M. ulcerans variants in the Densu River Valley of Ghana and the 
established TSP assays are now routinely used in the laboratories of the Noguchi 
Memorial Institute for M. ulcerans haplotype identification. However, a 
comprehensive overview of the M. ulcerans population structure in Africa can only be 
achieved by genome sequencing of M. ulcerans strains from other African BU 
endemic regions and subsequent identification of local sets of informative SNPs for 
further phylogenetic analyses. 
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TABLES 
 
Table 1. Summary of M. ulcerans genotyping in Ghana 
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FIGURES 
 
 
Figure 1. Selection of TSP SNP typing assays. A Linearized phylogenetic tree of 
the ten M. ulcerans haplotypes (HT1-10) detected in the Densu River Valley of 
Ghana (MEGA software version 4.1 (beta), scale: number of differences at the 89 
SNP loci tested). B Schematic overview of reference (0) and SNP (1) alleles present 
in the sequence of the ten M. ulcerans haplotypes, which can be identified by TSP 
assays 1, 3, 4, 6, 8, 9, 15, 16, 17 and 18. 
Chapter 4. TSP-Based SNP Typing of M. ulcerans 
Inauguraldissertation 
109 
 
Figure 2. Schematic illustration of TSP assay performance. NAS and LS primer 
locations relative to the M. ulcerans DNA sequence surrounding a SNP locus are 
shown for the different PCR reaction phases. A Initial PCR conditions enable an 
amplification of the larger LS PCR product by applying an annealing temperature (Ta) 
of 58°C. B Reduction of Ta to 45°C facilitates a possible incorporation of the NAS 
primer into the enriched LS PCR product. C Competitive amplification of the larger LS 
and the smaller NAS PCR products are ensured by an increase of Ta to 53°C. 
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Figure 3. Optimization of TSP SNP typing assays. TSP endpoint detection by 
analysis of PCR product sizes on ethidium bromide-stained agarose gels for 
haplotypes 1-10 (lanes 1-10) at TSP assay locus 6. TSPs were performed using: A a 
four-primer system including both NAS and LS forward and reverse primers as well 
as a three-primer system with only one NAS primer and different NAS:LS primer 
ratios of B 2.5:1, C 5:1, D 7.5:1 and E 10:1. 
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Figure 4. Application of TSP assay 16 in two different research laboratories. 
Comparison of TSP endpoint detection by analysis of PCR product sizes on ethidium 
bromide-stained agarose gels in two different laboratories in Basel, Switzerland and 
Accra, Ghana. PCR products are shown for haplotypes 1-10 (lanes 1-10). 
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SUPPORTING INFORMATION 
 
 
Figure S1. Setup of TSP SNP typing assays. TSP endpoint detection by analysis 
of PCR product sizes on ethidium bromide-stained agarose gels for all ten TSP SNP 
typing assays. PCR products are shown for haplotypes 1-10 (lanes 1-10). 
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Figure S2. TSP typing of clinical M. ulcerans isolates 
TSP endpoint detection by analysis of PCR product sizes on ethidium bromide-
stained agarose gels for all ten TSP SNP typing assays. PCR products are shown for 
NM167, NM187, NM209, NM219, NM229, NM230, NM232, NM236, NM237, 
NM238(4), NM285, NM310, NM311, NM312, NM340, NM377, NM421C, NM465, 
NM491C, NM555, NM561, NM579, NM585, NAS or LS amplification control (lanes 1-
24). 
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ABSTRACT 
 
Mycobacterium ulcerans (M. ulcerans) causes a devastating infection of the skin and 
underlying tissue commonly known as Buruli ulcer (BU). Genetic analyses indicate 
that M. ulcerans has a common ancestor with Mycobacterium marinum (M. marinum) 
and has diverged from this fish and human pathogen perhaps around a million years 
ago. M. ulcerans is characterized by minimal genetic diversity and since it has a 
highly clonal population structure, genetic differences between individual isolates 
reflect changes that have occurred sequentially from their respective progenitors. 
This feature, which is shared by other bacterial pathogens with low sequence 
diversity, such as Yersinia pestis and Bordetella pertussis renders M. ulcerans a 
promising model to reveal evolutionary mechanisms. Until today transmission 
pathways and environmental reservoirs of M. ulcerans are not entirely explored. 
However, comparative genome analysis of closely related M. ulcerans isolates is 
anticipated to give deeper insights into the population structure of this enigmatic 
mycobacterium. 
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1. INTRODUCTION 
The genus Mycobacterium comprises more than 120 species, many of which are 
important pathogens of animals and humans (Tortoli, 2006; Zakham et al., 2011). 
One species within this genus, Mycobacterium ulcerans (M. ulcerans), is the 
causative agent of Buruli ulcer (BU), a chronic, necrotizing infection of subcutaneous 
tissue. BU is reported from more than 30 countries worldwide, but predominantly 
affects impoverished populations living in remote areas of West Africa (Johnson et al., 
2005). One hallmark of the evolution of M. ulcerans is the acquisition of a 174 kb 
virulence plasmid, referred to as pMUM001. This plasmid harbours genes required 
for the synthesis of the macrocyclic polyketide toxin mycolactone (George et al., 
1999), which plays a key role in the pathogenesis of BU. While polyketides are 
produced by various bacteria, mycolactones are the first identified polyketide 
virulence determinants of a human bacterial pathogen (Hong et al., 2005a; Rohr, 
2000). The cytotoxic and immunosuppressive activities of mycolactone are 
responsible for the formation of chronic ulcerative skin lesions with only limited 
inflammatory response in the centre of the lesions (Hong et al., 2008). Mycolactone 
production was initially assumed to be restricted to M. ulcerans, but recent studies 
revealed the existence of other closely related mycolactone-producing mycobacteria 
(MPM) (Ranger et al., 2006; Rhodes et al., 2005; Stragier et al., 2008; Trott et al., 
2004). M. ulcerans and other MPM strains from around the world are characterized 
by limited genetic diversity, which is typically found in bacterial populations that have 
recently gone through an evolutionary bottleneck (Achtman, 2008). This feature may 
be related to the acquisition of the mycolactone plasmid and adaptation to a new 
lifestyle. Also other genomic signatures, like proliferation of the insertion sequence 
elements (ISEs) IS2404 and IS2606, extensive gene loss through pseudogene 
formation and DNA deletion are suggestive of a bacterial population that has been 
transformed by DNA acquisition and is adapting to a new, perhaps protected 
environment, where genes once needed for survival under diverse conditions are no 
longer required (Stinear et al., 2007).  
Although BU is commonly associated with proximity to aquatic habitats, an 
environmental reservoir of M. ulcerans is yet to be identified and so it is not clear to 
what conditions M. ulcerans is adapting. Consequently, the mode of BU transmission 
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remains an enigma. A recent study in South-Eastern Australia, which is the only non-
tropical setting reporting significant numbers of BU cases, has implicated tree-
dwelling native possums as a possible animal reservoir (Fyfe et al., 2010) and 
mosquitoes as potential vectors of M. ulcerans (Johnson, 2009; Lavender et al., 2011; 
Merritt et al., 2010). In African BU endemic areas numerous studies focusing on 
surveys of aquatic environments have suggested the potential of aquatic invertebrate 
and vertebrate species as well as aquatic vegetation as reservoirs and/or vectors of 
M. ulcerans but definitive evidence is lacking (Kotlowski et al., 2004; Marsollier et al., 
2002, 2007; Merritt et al., 2005; Portaels et al., 1999, 2008; Williamson et al., 2008). 
Since routine methods for the cultivation of the extremely slow growing M. ulcerans 
from environmental sources are not available, these studies are largely based on the 
detection of M. ulcerans genomic DNA sequences by PCR. However, this approach 
is complicated by the presence of the target DNA sequences used in other MPM. 
Furthermore, only one M. ulcerans strain has ever been isolated from a non-
vertebrate source (Portaels et al., 2008). Hence, the relevance of PCR positive 
environmental samples for the transmission of M. ulcerans to humans is not clear.  
Prior to the application of high-throughput genome sequencing, high-resolution 
genetic fingerprinting methods for M. ulcerans suitable for micro-epidemiological 
studies in BU endemic areas could not be developed due to the distinctive genetic 
monomorphism of M. ulcerans strains within a BU endemic region. Comparative 
genome sequencing has now enabled a genome-wide search for single nucleotide 
polymorphisms (SNPs). High-resolution SNP typing allows for a differentiation of M. 
ulcerans disease isolates from BU endemic areas into sets of haplotypes. A first 
retrospective study using this approach has revealed a focal transmission pattern of 
certain haplotypes (Röltgen et al., 2010), and future longitudinal micro-
epidemiological studies involving SNP typing are anticipated to provide deeper 
insight into M. ulcerans transmission pathways and relevant reservoirs.  
 
2. EMERGENCE OF M. ULCERANS FROM M. MARINUM  
Comparison of partial DNA sequences, commonly used for the identification and 
differentiation of mycobacteria, has revealed a close genetic relationship between M. 
ulcerans and M. marinum long before whole-genome sequences became available. 
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In the highly conserved 16S ribosomal RNA (rRNA) gene M. ulcerans and M. 
marinum isolates differ only at one dimorphic position (Portaels et al., 1996; Tønjum 
et al., 1998) and no difference was found in the 16S-23S rDNA internal transcribed 
spacer region (Roth et al., 1998). Analysis of eight housekeeping and structural 
genes revealed average nucleotide sequence identities of >98% between M. 
ulcerans and M. marinum (Stinear et al., 2000b). Genomic subtraction analyses have 
shown, that the major genetic acquisition by M. ulcerans was the polyketide synthase 
locus (Jenkin et al., 2003) harbored in the virulence plasmid pMUM001 (Stinear et al., 
2004). Comparative analyses in geographically diverse strains of M. ulcerans have 
demonstrated a common evolutionary origin of their pMUM plasmids (Stinear et al., 
2005a). Multi-locus sequence typing (MLST) of a panel of M. ulcerans, other MPM 
and M. marinum isolates has indicated that all MPM are genetically closely related. In 
the same study DNA-DNA hybridization analysis between MPM and M. ulcerans 
strains from Africa, Australia and China unveiled overall mean relative binding ratios 
of 98%, while mean ratios between MPM and non-MPM strains were only 40% (Yip 
et al., 2007). These data suggest that MPM have evolved from a common M. 
marinum ancestor (Yip et al., 2007) and comply with proposed criteria for species 
delineation (Vandamme et al., 1996). Therefore, it is currently debated whether this 
genetically coherent group of strains should be reclassified as M. ulcerans (Pidot et 
al., 2010a). MLST has shown that the ongoing process of evolution among MPM has 
generated at least two lineages, which occupy different ecological niches. One 
lineage includes strains, which typically cause disease in ectotherms such as frogs 
and fish, while strains of the other lineage cause BU in humans and can infect other 
endotherms such as possums (Yip et al., 2007). M. ulcerans isolates from BU 
patients can be distinguished from other MPM by the analysis of large sequence 
polymorphisms (LSPs) (Käser et al., 2009a) and by variable number of tandem 
repeat (VNTR) typing (Stragier et al., 2007).  
Detailed analyses of LSPs between M. ulcerans isolates from BU patients of a world-
wide origin revealed an intra-species evolutionary scenario with two distinct 
phylogenetic lineages (Käser et al., 2007; Rondini et al., 2007). M. ulcerans 
haplotypes from Asia, South America and Mexico belong to the ancestral lineage, 
whereas the classical lineage includes haplotypes from Africa, Australia and South 
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East Asia (Käser et al., 2007). While BU disease caused by strains belonging to the 
ancestral lineage is only sporadically reported (Faber et al., 2000; Guerra et al., 2008; 
Nakanaga et al., 2011), focal prevalence of BU in areas of Africa and Australia 
endemic for disease caused by the classical lineage is much higher. This may 
indicate that the ancestral lineage, which is genetically closer to M. marinum (Käser 
et al., 2007), is less virulent, but not necessarily less pathogenic, than the classical 
lineage (Käser et al., 2007; Käser and Pluschke, 2008; Mve-Obiang et al., 2003).  
In order to estimate the divergence time of the two M. ulcerans lineages, a 
systematic analysis of synonymous SNPs between African classical lineage isolates 
and a Japanese isolate belonging to the ancestral lineage has been carried out. 
Based on a universal clock rate (Ochman et al., 1999), it was estimated that the 
classical lineage diverged about 400,000 years ago from the ancestral lineage (Qi et 
al., 2009). Data furthermore suggested that the African strains and M. marinum strain 
M diverged from a common ancestor about 1.1 to 1.5 million years ago (Figure 1). 
However there are many uncertainties associated with such estimates and the major 
underlying assumption here - that all strains have been evolving at equal rates – 
needs to be verified. 
 
3. GENOME CHARACTERISTICS AND REDUCTIVE EVOLUTION 
The first complete genome sequence of M. ulcerans was from a clinical isolate, called 
Agy99, isolated in Ghana in 1999 from a BU lesion. The M. ulcerans Agy99 genome 
is composed of a 5,631,606-bp chromosome with the 174,155-bp virulence plasmid 
pMUM001 (Stinear et al., 2007). The chromosome of M. ulcerans Agy99 was shown 
to harbor 4160 protein-coding genes as well as 771 pseudogenes (Stinear et al., 
2007). It is rich in insertion sequences (IS), particularly IS2404 (209 copies) and 
IS2606 (83 copies) and contains two prophages, phiMU01 (18 kb, 18CDS) and 
phiMU02 (24 kb, 17CDS) (Stinear et al., 2007). The chromosome has a G+C content 
of about 65%, which is comparable to the G+C contents of M. tuberculosis, M. bovis 
and other mycobacteria (Marri et al., 2006). The virulence plasmid pMUM001 has a 
slightly lower G+C content of 62.5% and harbors 81 protein-coding DNA sequences 
(Stinear et al., 2007) including four copies of IS2404 and eight copies of IS2606 
(Figure 2) (Stinear et al., 2004). By comparison of the M. ulcerans genome to 21 
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other available mycobacterial genomes, forty-seven chromosomally-encoded open 
reading frames (ORF) potentially unique to M. ulcerans have been identified (Pidot et 
al., 2010b). While these ORFs seem to have been acquired by horizontal gene 
transfer, comparative genomics of M. ulcerans and M. marinum strain M, which has 
5426 protein-coding sequences and only 65 pseudogenes (Stinear et al., 2008), has 
shown that extensive genome downsizing and pseudogene formation is the 
dominating feature of genome adaptation of M. ulcerans (Stinear et al., 2007). 
Accumulation of pseudogenes has been reported from obligate intracellular 
organisms such as M. leprae (Cole et al., 2001), which harbours 1116 pseudogenes, 
and has been related to adaptation to a highly specialized ecological niche. Losses of 
genes, which are not essential for the survival in the new host, are tolerated due to a 
reduced pressure to maintain these genes (Moran and Plague, 2004). However, 
there are significant differences to M. leprae. While the majority of M. ulcerans 
bacteria have an extracellular location in advanced BU lesions, an intracellular stage 
may play a role only in an early stage of the infection (Schütte et al., 2009; Silva et al., 
2009; Torrado et al., 2007). The unique cytotoxic and immunosuppressive toxin 
mycolactone is of crucial importance for both the pathogenesis of BU and for the 
chronic nature of the M. ulcerans infection. However, reductive genome evolution 
may be contributing further to immune evasion. Comparative genomic analyses of 
classical and ancestral M. ulcerans strains have indicated that the genes esxA, esxB 
and hspX encoding the highly immunogenic proteins ESAT-6, CFP-10 and HspX are 
hot-spots for genomic variation in the development of M. ulcerans and its adaptation 
to a new environment (Huber et al., 2008). While the genome of M. marinum M 
contains two copies of the esxB-esxA gene cassette, members of the M. ulcerans 
ancestral lineage have retained only one copy of this gene cluster. Both copies are 
deleted from the genome of M. ulcerans strains belonging to the classical lineage. 
Loss of these strong B- and T-cell immunogens may help M. ulcerans to evade host 
immune responses and may confer a survival advantage in host environments that 
are screened by immunological defense mechanisms.  
In this vein, members of the PE and PPE multigene families are over-represented 
among the pseudogenes of M. ulcerans and M. leprae. While M. marinum has about 
170 PE and 105 PPE genes, M. ulcerans has retained only 70 intact PE and 46 PPE 
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genes (Stinear et al., 2007). Members of these protein families, which contain highly 
conserved Proline-Glutamate (PE) or Proline-Proline-Glutamate (PPE) residues, are 
surface-associated cell wall proteins believed to provide a diverse antigenic profile 
and thus may play an additional role in immune evasion (Sampson, 2011; Voskuil et 
al., 2004). Considering that M. leprae has lost almost all genes belonging to this 
family, the decreased number of PE/PPE proteins further indicates an intermediate 
stage of reductive evolution and niche adaptation of M. ulcerans (Marri et al., 2006; 
Stinear et al., 2007).  
Some of the genetic differences between M. ulcerans and M. marinum are reflected 
in their corresponding phenotype. While M. marinum grows relatively rapidly with a 
generation time of 4-6 hours at its optimal growth temperature (Stinear et al., 2008), 
M. ulcerans has a very long generation time of about 72 hours, which might be partly 
explained by a switch of essential protein coding sequences from the leading to the 
lagging strand and the associated deceleration of their transcription (Stinear et al., 
2007). In contrast to M. marinum, which is capable of producing pigments in order to 
protect itself from light, M. ulcerans contains an inactive copy of the responsible crtB 
locus (Stinear et al., 2007), further suggestive of the adaptation of M. ulcerans to a 
new, possibly dark environment. 
 
4. INSERTION SEQUENCE ELEMENTS (ISEs) AS DRIVERS OF GENOME 
REDUCTION 
ISEs are mobile genetic entities encoding transposases that catalyze DNA copying or 
movement. ISEs can promote genome plasticity in the form of deletions, inversions 
and replicon fusions (Mahillon and Chandler, 1998; Mahillon et al., 1999). It has 
previously been shown that genetic diversity of mycobacteria is in part driven by ISEs 
such as IS6110 of M. tuberculosis (Bifani et al., 1996; Sreevatsan et al., 1997), 
IS1245 of M. avium (Motiwala et al., 2006; van Soolingen et al., 2001) and IS900 of 
M. paratuberculosis  (Green et al., 1989; Motiwala et al., 2006). M. ulcerans contains 
ten putative ISEs (Stinear et al., 2007) in addition to the well-characterized high-
copy-number elements IS2404 and IS2606 (Stinear et al., 1999). IS2404 is 1368 bp 
long, containing 41 bp perfect inverted repeats and producing 10 bp target-site 
duplications. IS2606 is 1438 bp long, with 31 bp imperfect inverted repeats and 
Chapter 5. Invited Review 
Inauguraldissertation 
125 
producing target-site duplications of 7 bp (Stinear et al., 2005b). The origin of IS2404 
and IS2606 is not clear, but it has been shown, that both sequences are related to 
sequence elements found in the genus Streptomyces (Stinear et al., 2000b). 
Comparative genome analyses of M. ulcerans and M. marinum have shown that 
IS2404 and IS2606 are associated with many of the LSPs observed (Käser et al., 
2007; Stinear et al., 2007). Furthermore, 111 of the predicted pseudogenes of M. 
ulcerans were created by insertion of one of the ISEs (Stinear et al., 2007). 
 
5. PLASMID ASSOCIATED MYCOLACTONE PRODUCTION 
While horizontal gene transfer among pathogenic mycobacteria is generally rare, M. 
ulcerans has not only acquired several ISEs, but also the 174 kb virulence plasmid 
pMUM001. Plasmid pMUM001 encodes a type I polyketide synthase locus, which 
occupies about 120 kb (Tobias et al., 2009). Bacterial type I polyketide synthases are 
characterized by a multi-modular structure comprising different enzymatic domains 
responsible for the stepwise biosynthesis of polyketides (Jenke-Kodama et al., 2005). 
The polyketide synthases of M. ulcerans are among the largest known cellular 
enzymes. These giant proteins referred to as MLSA1 (1.8 MDa), MLSA2 (0.26 MDa) 
and MLSB (1.2 MDa) are encoded by three large genes, mlsA1 (51 kb), mlsA2 (7 kb) 
and mlsB (42 kb), respectively. MLSA1 and MLSA2 synthesize the 12-membered 
conserved core structure and the upper side chain of mycolactone, while the highly 
unsaturated acyl side chain is generated by MLSB (Stinear et al., 2004). Both 
nucleotide and amino acid identities between domains with the same general 
function are remarkably high (>98%) (Tobias et al., 2009), indicative for the recent 
acquisition of a core gene set and subsequent gene duplication and recombination 
events (Stinear et al., 2004). In contrast to the assumption that high sequence 
identity among the domains would lead to genomic instability through homologous 
recombination (Stinear et al., 2004; Townsend, 2004), only five variants of 
mycolactone (mycolactones A/B, C, D, E and F) have been found so far (Figure 3), 
when analyzing a worldwide collection of M. ulcerans strains and other MPM (Mve-
Obiang et al., 2003). Strong purifying selection is thought to ensure the maintenance 
of a mycolactone-producing form of the pMUM plasmid. In the absence of selection 
in vitro, deletion of plasmid sequences and a corresponding loss of mycolactone 
Chapter 5. Invited Review 
Inauguraldissertation 
126 
production can readily arise (Stinear et al., 2005a). In addition to the mls genes, the 
polyketide synthase locus of pMUM001 harbors three putative accessory genes, 
mup038, mup045 and mup053 coding for polyketide-modifying enzymes. While the 
type II thioesterase encoded by mup038 is thought to degrade abnormal polyketide 
extension products, the formation of an ester bond between acyl side chain and core 
structure of mycolactone is assumed to be catalyzed by the beta-ketoacyl synthase 
encoded by mup045 (Stinear et al., 2004). The level of mup053-encoded cytochrome 
P450 hydroxylase activity seems to determine the oxidation state of the side chain 
C12` (Hong et al., 2003; Mve-Obiang et al., 2003). African M. ulcerans strains 
predominantly produce a mixture of cis/trans isomers of a mycolactone with oxidized 
C12`, designated mycolactone A/B. Australian M. ulcerans strains deficient in 
mup053 produce a lower-mass metabolite with less of the hydroxylated C12` version, 
referred to as mycolactone C (Stinear et al., 2005a). A clinical isolate from China 
synthesized mycolactone D, which differs from mycolactone A/B by a methyl group at 
C2` of the side chain (Figure 3). The genetic basis for the production of mycolactone 
D was a recombination event within mlsB resulting in a different substrate specificity 
of one of its acyltransferase domains (Hong et al., 2005a).  
Recent studies have identified additional structural variants of mycolactone produced 
by mycobacterial fish and frog pathogens closely related to M. ulcerans. Mycolactone 
E (Hong et al., 2005b; Mve-Obiang et al., 2005) was found in mycobacterial isolates 
causing a mycobacteriosis outbreak in a laboratory colony of Xenopus tropicalis 
(Trott et al., 2004). The designation M. liflandii has been proposed for these bacteria 
but this name has no standing in nomenclature (Mve-Obiang et al., 2005). Their 
close genetic relation to M. ulcerans is suggested by the presence of high copy 
numbers of IS2404 in their genome (Trott et al., 2004). Furthermore, an unusual 
group of M. marinum strains from fish in the Red and Mediterranean Seas as well as 
an M. ulcerans-like Mycobacterium recovered from diseased striped bass and 
referred to as M. pseudoshottsii (Rhodes et al., 2005), also contain IS2404 and 
produce another structural toxin variant, mycolactone F (Figure 3) (Ranger et al., 
2006). These altered mycolactones are due to minor modifications in the acyl-side 
chains of mycolactones E and F caused by rearrangements between homologous 
modules within mlsB (Pidot et al., 2008). 
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6. DIVERSIFICATION OF LOCAL CLONAL COMPLEXES OF M. ULCERANS  
M. ulcerans strains isolated in different West African countries are genetically 
homogeneous, indicative of the relatively recent dispersal of this clone throughout 
West Africa. Comparative genomic hybridization analyses have identified extensive 
insertional-deletional sequence differences between M. ulcerans isolates belonging 
to the ancestral and the classical lineage (Käser et al., 2007; Rondini et al., 2007). In 
contrast, no insertional-deletional genomic variation was detected within a panel of 
African disease isolates (Käser et al., 2009b). Furthermore, whole genome SNP 
analysis with a set of Ghanaian strains revealed no evidence for the formation of 
further pseudogenes (Qi et al., 2009). The genetic monomorphism of M. ulcerans has 
hampered development of a genetic fine-typing method for micro-epidemiological 
studies. Conventional methods, such as restriction fragment length polymorphism 
(RFLP) analysis (Jackson et al., 1995), 16S rDNA sequencing (Portaels et al., 1996), 
analysis of the regions between adjacent copies of IS2404 and IS2606 (2426 PCR) 
(Stinear et al., 2000a), RFLP analysis of IS2404 (Chemlal et al., 2001a; Chemlal et 
al., 2001b), analysis of genomic regions between IS2404 and a repeated GC-rich 
sequence (IS2404-Mtb2 PCR) (Ablordey et al., 2005) and mycobacterial interspersed 
repetitive units (MIRU) typing (Stragier et al., 2005) enabled only discrimination of 
continental lineages, but could not detect genotypic variation between strains coming 
from the same BU endemic region. Only variable number of tandem repeat (VNTR) 
typing based on newly identified polymorphic loci showed some limited potential to 
reveal genetic diversity within isolates from Africa (Ablordey et al., 2007; Hilty et al., 
2006; Stragier et al., 2006). In one study VNTR typing with the VNTR loci ST1 and 
MIRU1 allowed for the differentiation of 57 strains from Ghana into three ST1/MIRU1 
allele combinations. However, all 47 recent isolates from one BU endemic region in 
the Densu River valley of Ghana displayed the same ST1/ MIRU 1 haplotype (Hilty et 
al., 2006).  
In a recent review, Achtman predicted that phylogenetic analyses of genetically 
monomorphic pathogens will focus on whole genome SNP analysis (Achtman, 2008). 
Phylogenetic analyses of monomorphic organisms like M. tuberculosis (Baker et al., 
2004; Sreevatsan et al., 1997), Bacillus anthracis (Pearson et al., 2004; Van Ert et al., 
2007), Salmonella enterica Typhi (Roumagnac et al., 2006) and Yersinia pestis 
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(Achtman et al., 2004) are now in fact based on high-resolution SNP typing. The first 
SNP typing study of M. ulcerans was based on a few SNPs identified in LSP-
haplotye specific ISEs and led to the identification of seven SNP types in Africa 
(Käser et al., 2009c). In 2010 our research group reported the first SNP typing 
method for M. ulcerans with sufficient resolution for micro-epidemiological analyses 
within one BU endemic area, namely the BU endemic Densu river valley of Ghana 
(Röltgen et al., 2010). In this study SNPs were detected by whole-genome 
comparison of three Ghanaian M. ulcerans strains with different VNTR type (Hilty et 
al., 2006; Qi et al., 2009; Röltgen et al., 2010; Yip et al., 2007;). Developed SNP 
typing assays enabled the differentiation of six haplotypes. Subsequent genome re-
sequencing of four haplotype representatives from the Densu River Valley of Ghana 
increased the resolution and allowed distinction of altogether ten local haplotypes 
(Röltgen et al., 2010). Analysis of the distribution of these haplotyes within the Densu 
River basin has shown that some haplotypes constitute focal transmission clusters. 
These haplotypes have probably emerged only recently. In contrast, the presumed 
founder haplotype was distributed over the entire BU endemic area. One possible 
explanation for these findings is the spread of M. ulcerans from ulcerated BU lesions 
to a currently unknown environmental reservoir and subsequent infection of 
individuals living in the same surrounding (Röltgen et al., 2010). Preliminary results 
obtained with isolates from other West African BU endemic areas speak for 
diversification of local M. ulcerans populations by acquisition of point mutations. High 
resolution SNP typing methods for individual BU endemic regions therefore have to 
be developed by whole genome sequencing of sets of local isolates. With the rapid 
development of next generation sequencing technology, micro-epidemiological 
studies may be performed in future by sequencing the genomes of all available 
isolates.  
Minimal genetic diversity of bacterial populations is often accompanied by a clonal 
population structure with low levels of recombination and horizontal genetic 
exchange. Hence, genetic typing of such genetically monomorphic microbes holds a 
great potential to explore their evolutionary histories by monitoring sequentially 
accumulated genetic differences of isolates from their respective progenitors 
(Suerbaum and Achtman, 2001). Genome sequencing of large numbers of M. 
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ulcerans strains of diverse origin will thus provide deep insight into the evolutionary 
history of this emerging pathogen.  
 
7. IMPACT OF ANTIBIOTIC USE ON M. ULCERANS GENOMIC DIVERSITY 
Since 2004 the World Health Organization has recommended combined antibiotic 
treatment of BU with rifampicin and streptomycin for eight weeks (WHO, 2011), which 
has routinely been implemented in the BU endemic African countries. Given the 
history of antibiotic resistance in M. tuberculosis (Borrell and Gagneux, 2011), there 
have been concerns that inappropriate rifampicin and streptomycin use may drive 
similar patterns of resistance in M. ulcerans. However, no cases of rifampicin or 
streptomycin resistant clinical M. ulcerans strains have been reported, although the 
development of phenotypic and genotypic resistance of M. ulcerans under rifampicin 
monotherapy was observed in experimentally infected mice (Marsollier et al., 2003). 
Sequencing of rpoB and rpsL genes (associated with rifampicin and streptomycin 
resistance respectively) of clinical M. ulcerans strains from Ghana isolated between 
2004 and 2007 led to the identification of one isolate with a point mutation in the rpoB 
gene (Beissner et al., 2010). Systematic surveillance for drug resistance among M. 
ulcerans is thus crucial, particularly as there is no alternative drug to replace 
rifampicin in the current BU treatment regimen. Drug resistance might also become 
more than a single-patient issue if the bacteria present in chronic BU wounds 
represent an active reservoir of M. ulcerans, required for transmission. Here, 
genomics will be a powerful tool as we study the movement and evolution of M. 
ulcerans within humans and the wider environment. 
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FIGURES 
 
 
 
Figure. 1. Minimum evolution tree of M. marinum (strain M) and M. ulcerans 
strains of the ancestral and classical lineages. Top scale: divergence time frame 
per thousand years. Bottom scale: number of synonymous substitutions per 
nucleotide site. Rate used for the time calibration: 5.8 × 10−9 substitutions per site per 
year. 
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Figure 2. Circular representation of the M. ulcerans Agy99 chromosome and 
plasmid. The outer black circle shows the scale in bases. The next two inner circles 
illustrate the forward and reverse strand CDS in blue and red, respectively. IS 
element regions are displayed in the next inner circle in black. The innermost circles 
show GC plot and GC skew. The graph was designed using DNAPlotter Release 1.4 
(Carver et al., 2009). 
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Figure 3. Simplified family tree of M. marinum, M. ulcerans and other MPM 
strains. Variants of mycolactone are shown with the corresponding color codes: 
mycolactone A/B produced by African M. ulcerans strains (blue); mycolactone C 
formed by M. ulcerans strains from Australia (green); mycolactone D produced by an 
M. ulcerans strain from China; mycolactones E and F formed by other MPM strains. 
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ABSTRACT 
 
Background: Previous analyses of sera from a limited number of Ghanaian Buruli 
ulcer (BU) patients, their household contacts, individuals living in BU non-endemic 
regions as well as European controls have indicated that antibody responses to the 
M. ulcerans 18 kDa small heat shock protein (shsp) reflect exposure to this pathogen. 
Here, we have investigated to what extent inhabitants of regions in Ghana regarded 
as non-endemic for BU develop anti-18 kDa shsp antibody titers. 
Methodology/Principal Findings: For this purpose we determined anti-18 kDa shsp 
IgG titers in sera collected from healthy inhabitants of the BU endemic Densu River 
Valley and the Volta Region, which was so far regarded as BU non-endemic. 
Significantly more sera from the Densu River Valley contained anti-18 kDa shsp IgG 
(32% versus 12%, respectively). However, some sera from the Volta Region also 
showed high titers. When interviewing these sero-responders, it was revealed that 
the person with the highest titer had a chronic wound, which was clinically diagnosed 
and laboratory reconfirmed as active BU. After identification of this BU index case, 
further BU cases were clinically diagnosed by the Volta Region local health 
authorities and laboratory reconfirmed. Interestingly, there was neither a difference in 
sero-prevalence nor in IS2404 PCR positivity of environmental samples between BU 
endemic and non-endemic communities located in the Densu River Valley. 
Conclusions: These data indicate that the intensity of exposure to M. ulcerans in 
endemic and non-endemic communities along the Densu River is comparable and 
that currently unknown host and/or pathogen factors may determine how frequently 
exposure is leading to clinical disease. While even high serum titers of anti-18 kDa 
shsp IgG do not indicate active disease, sero-epidemiological studies can be used to 
identify new BU endemic areas. 
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AUTHOR SUMMARY 
 
Sero-epidemiological analyses revealed that a higher proportion of sera from 
individuals living in the Buruli ulcer (BU) endemic Densu River Valley of Ghana 
contain Mycobacterium ulcerans 18 kDa small heat shock protein (shsp)-specific IgG 
than sera from inhabitants of the Volta Region, which was regarded so far as BU 
non-endemic. However, follow-up studies in the Volta Region showed that the 
individual with the highest anti-18 kDa shsp-specific serum IgG titer of all participants 
from the Volta Region had a BU lesion. Identification of more BU patients in the Volta 
Region by subsequent active case search demonstrated that sero-epidemiology can 
help identify low endemicity areas. Endemic and non-endemic communities along the 
Densu River Valley differed neither in sero-prevalence nor in positivity of 
environmental samples in PCR targeting M. ulcerans genomic and plasmid DNA 
sequences. A lower risk of developing M. ulcerans disease in the non-endemic 
communities may either be related to host factors or a lower virulence of local M. 
ulcerans strains. 
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INTRODUCTION 
 
Buruli ulcer (BU), a severe necrotizing skin disease, is caused by the environmental 
pathogen Mycobacterium ulcerans (M. ulcerans). Globally, it is the third most 
prevalent mycobacterial disease that affects immunocompetent individuals after 
tuberculosis and leprosy [1]. Currently more than 30 countries, mainly in the Tropics 
and sub-Tropics, are known to report BU cases [2]. The main countries that are 
severely affected lie along the Gulf of Guinea and include Ivory-Coast, Ghana, Togo, 
Benin and Cameroon. In the highly endemic countries BU is second after 
tuberculosis as the most prevalent mycobacterial disease [2], [3]. However, the 
global burden of BU is not clear, because efficient and comprehensive reporting 
systems are lacking in many of the BU endemic countries. One characteristic of BU is 
its focal distribution within highly endemic countries. Most cases occur in remote 
villages with limited access to the formal health sector, prompting affected people to 
seek health at traditional healers [4]. Even today, not all affected communities may 
be known to the National BU Control Programs. Therefore reliable tools to detect and 
monitor the presence of BU in communities are urgently needed. 
The disease presentation, which varies between individuals, starts either as a papule, 
nodule, plaque or edema and if these non-ulcerative early forms are not treated, 
extensive tissue destruction leads to the formation of large ulcerative lesions with 
characteristic undermined borders. Extensive tissue destruction frequently causes 
disfigurement and long lasting deformities such as loss of limbs and essential organs, 
like the eye [5], [6]. Many features of BU such as the mode of M. ulcerans 
transmission and risk factors for an infection with the pathogen are not clearly 
understood. However, BU is known to occur mainly in children less than 15 years of 
age and affects people in wetlands and disturbed environments [3], [7]. The 
pathology of BU is primarily associated with the secretion of the cytocidal and 
immunosuppressive polyketide toxin mycolactone [8]. 
Current methods for a laboratory confirmation of clinical BU diagnosis include 
microscopic detection of acid fast bacilli (AFB), culture of M. ulcerans, histopathology 
and detection of M. ulcerans DNA by PCR. Currently, PCR detection of the M. 
ulcerans specific insertion sequence IS2404 is the gold standard for BU diagnosis [9]. 
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Yet, PCR requires elaborate infrastructure and expertise and therefore make it out of 
reach for primary health care facilities in BU endemic low resource countries. 
Serology represents a more attractive approach for the development of a simple test 
format that can be applied to facilities treating BU in low resourced countries. 
Unfortunately, various studies have shown that serological tests targeting M. 
ulcerans antigens are not suitable to differentiate between patients and exposed but 
healthy individuals as both groups may exhibit serum IgG titers against these 
antigens [10], [11]. However, serology may be a useful tool for monitoring exposure 
of populations to M. ulcerans, although great antigenic cross reactivity between M. 
ulcerans, M. tuberculosis, BCG and other environmental mycobacteria complicates 
this approach. We previously profiled an immunodominant 18 kDa small heat shock 
protein (shsp) absent from M. tuberculosis and M. bovis as a suitable target antigen 
for sero-epidemiological studies. In spite of the presence of sequence homologues in 
M. leprae and M. avium, Western blot analyses, using a limited number of sera 
indicated that this protein can be used to distinguish between M. ulcerans exposed 
and non-exposed populations [10]. Here we have extended these studies with larger 
sets of sera. These sero-epidemiological studies identified a BU index case in a 
region of Ghana that was regarded, so far, as BU non-endemic. 
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MATERIALS AND METHODS 
 
Ethics statement 
Ethical clearance for the study was obtained from the institutional review board of the 
Noguchi Memorial Institute for Medical Research (Federal-wide Assurance number 
FWA00001824). Written informed consent was obtained from all individuals involved 
in the study. Parents or guardians provided written consent on behalf of all child 
participants. 
 
Study area 
One part of this study was conducted in five districts of the Eastern Region including 
East-Akim (EA), New-Juaben (NJ), Suhum-Kraboa-Coaltar (SHC), Akwapim South 
(AS) and Akwapim North (AN) as well as two districts of the Greater-Accra Region 
comprising Ga-West (GW) and Ga-South (GS). While EA and NJ report no BU cases 
and AN only occasionally, the remaining four districts have communities that report 
BU regularly to the NBUCP. GW reports the highest number of cases with an annual 
average number of 100 new cases, followed by AS, GS and the SKC. This study 
focused on selected communities within these districts, which are all located along 
the Densu River. 
The other part of this study was carried out in three communities of the Volta Region, 
namely Torgorme, Gblornu and Kasa. These communities are situated along the 
banks of River Volta in the North Tongu district of the Volta Region, which was so far 
regarded as BU non-endemic. Torgorme, Gblornu and Kasa have an estimated 
population of about a 1700, 350 and 160, respectively. 
 
Confirmation of BU endemicity in communities along the Densu river 
Initial community entry was done by first meeting community opinion leaders, which 
included the disease control officer responsible for the area, the assembly man and 
chiefs in order to explain the importance of the activity and to solicit their cooperation. 
A rough sketch and count of houses along the length and breadth of the community 
was carried out by walking through the community in order to estimate an 
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approximate number of houses to be surveyed. The area was then divided into two 
blocks, with one research team being responsible for one block. Each habitable 
structure within a block was then numbered serially. A house to house survey was 
carried out and interviews involving the head of a house were done. A data collection 
chart was used to collect information on the number of people in the house, healed 
and active BU cases and if active cases were found, samples were collected for 
confirmation of BU. Collected data of the BU patients included age and sex, when the 
disease was contracted and GPS coordinates of their houses. 
 
Participants and sampling for serological analysis 
Two milliliters of blood were collected into vacutainer tubes (BD) from participants of 
ten different villages within a 5 km radius along the Densu River; six and four of the 
communities were confirmed as BU endemic and non-endemic, respectively, using 
active search and mapping activities as described above. The endemic communities 
were: Kojo-Ashong and Otuaplem in the GW, Kwame Anum and Ayitey Kortor in the 
GS, Sakyikrom and Tetteh Kofi in the AS district, respectively. The non-endemic 
communities were Obuotumpan and Abotanso in the NJ and Abesim Yeboah and 
Ntabea in the EA district. The study participants aged between 5 and 90 years 
recruited from these communities were individuals with no history of BU. 188 
participants were from the non-endemic villages (94 each females and males); age 
range 5–84 years, arithmetic mean of 28.6 years, median 19 years and mode of 15. 
294 participants were from endemic villages (139 and 155 were male and females, 
respectively); age range 5–90 years, mean age of 26.8 years, median 20 and mode 
12 years. 
In addition, whole blood samples were also collected from 99 community members in 
three villages along the Volta River in the Volta Region which has so far been 
considered one of the non-endemic regions in Ghana. The three communities 
Torgorme, Gblornu and Kasa were selected as having never reported leprosy in the 
past five years according to data of the North Tongu District Directorate of Health 
Services. 
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Blood samples were transported immediately at ambient temperature to the 
laboratory for separation of serum by centrifugation at 2,000 g for 10 mins to remove 
the clot. Sera were stored at −80°C until analysis. 
 
Western blot analysis 
25 µg of recombinant M. ulcerans 18 kDa shsp protein was separated on NuPAGE® 
Novex 4–12% Bis-Tris ZOOM™ Gels, 1.0 mm IPG well (Invitrogen) using NuPAGE ® 
MES SDS Running Buffer (Invitrogen) under reducing conditions and transferred to 
nitrocellulose membranes. Membranes were blocked with 5% skim milk in 
phosphate-buffered saline (PBS), 0.1%Tween 20 (PBS-T) and cut into strips. Protein 
strips were incubated with serum samples at a 1:500 dilution in PBS-T for 1.5 hrs. 
Strips were washed with 0.3 M PBS, 1% Tween 20 and incubated with alkaline 
phosphatase-conjugated AffiniPure F(ab′)2 fragment goat anti-human 
immunoglobulin G (IgG, Milian). Nitro blue tetrazolium (NBT) and 5-bromo-4-chloro-
3-indolyl phosphate (BCIP) (BioRad) were used for color development. 
 
ELISA 
96-well Nunc-Immuno Maxisorp plates (Thermo Scientific) were coated with 0.5 µg 
recombinant 18 kDa shsp per well in 100 µl PBS. Plates were incubated at 4°C 
overnight. Plates were washed with dH2O, 2.5% Tween 20 (dH2O-T) and blocked for 
1 h with 200 µl blocking buffer (5% skim milk in PBS) at 37°C. Serial 2-fold dilutions 
of serum from 1:100 to 1:12800 in 50 µl blocking buffer per well were incubated for 
1.5 hrs at 37°C. The wells were washed with dH2O-T. 50 µl of 1:6000 diluted goat 
anti-human IgG (γ-chain specific) coupled to horseradish Peroxidase (HRP, 
SouthernBiotech) was added to each well and incubated for 1 h at room temperature. 
After the last washing step with dH2O-T, 100 µl TMB Microwell Peroxidase Substrate 
(KPL) was added. The reaction was stopped after 5 min. The absorbance was 
measured using an ELISA plate reader (Sunrise, Tecan) at 450 nm. 
Each ELISA plate contained two-fold dilutions of a negative control comprising a pool 
of 5 negative sera from people living in BU non-endemic communities in Ghana and 
a positive control consisting of 5 medium positive sera from people living in BU 
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endemic areas. The cut-off value for positivity was considered to be the mean optical 
density (OD) of negative and positive control at a 1:100 serum pool dilution. 
Statistically, data were analyzed using GraphPad Prism version 5.0 (GraphPad 
Software, San Diego California USA). The nonparametric Kruskal-Wallis test with 
Dunn's post-test was used to compare OD values for the different groups. 
 
PCR analysis of environmental samples 
Sampling was done from aquatic environments and from communities. Water, insects, 
fish, snails, dominant vegetation (both dead and living) and soil were collected 
randomly from the ground and edges of rivers at various locations in both endemic 
and non-endemic communities. Soil, vegetation and animal droppings were collected 
from various locations within both endemic and non-endemic communities. All 
collected samples were transported on the same day to the laboratory, stored at 4°C 
and analyzed within a week of collection. 
DNA was extracted from about 200 mg portions of all the environmental samples 
using the FastDNA Spin kit for soil (MP Biomedical) according to the manufacturer's 
instruction. For insect samples additionally glass beads were added to the lysing 
matrix and the breaking step with the Fast Prep instrument was substituted by 
heating specimens at 95°C for twenty minutes followed by vortexing full speed for 
two minutes. The extracted DNA was stored at −20°C until analysis by real-time PCR. 
TaqMan real-time PCR was performed using primers and procedures as previously 
described with some modifications in reaction conditions [12]. The primers and 
TaqMan MGB probes detecting IS2404, IS2606 and the ketoreductase (KR) domain 
were obtained from Applied Biosystems (Foster City, CA, USA). IS2404 real-time 
PCR mixtures contained 1X Qiagen master mix (containing HotstarTaq plus DNA 
polymerase, dNTP mix and PCR buffer) 1 µl of extracted template DNA, 0.5 µM 
concentrations of each primer and 0.2 µM probe, 1× TaqMan exogenous internal 
positive control (IPC) and probe reagents (Applied Biosystems), in a total volume of 
20 µl. Amplification and detection were performed with the Rotor-Gene Q (Qiagen) 
using the following program: 1 cycle of 95°C for 5 min, 40 cycles of 95°C for 15 s and 
60°C for 15 s. Each PCR run contained 2 non-template controls and an IS2404 
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positive control. Analysis for IS2606 and KR was in a multiplex PCR using KR and 
IS2606 probes with FAM and VIC fluorescence labels respectively and reaction 
conditions as above. 
 
Data analysis 
Initial BU survey results were entered in Microsoft Access and exported for 
integration using Quantum Geographic Information System (GIS) for analyses. 
Google Earth aerial images of communities were obtained, geo-referenced and 
linked to ground contours, features and other characteristics. The prevalence of BU 
was calculated by counting all individuals in the community with a classical BU scar, 
together with those with laboratory confirmed active disease, divided by the total 
number of persons examined within a community. The rate was expressed as a 
percentage. 
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RESULTS 
 
M. ulcerans 18 kDa shsp specific serum IgG responses in individuals living in 
the Volta region of Ghana and identification of a BU index case in the region  
We determined M. ulcerans 18 kDa shsp-specific serum IgG titers in 482 sera from 
people living in the BU endemic Densu River Valley in the Gar and Eastern Region, 
99 sera from people living in the BU non-endemic Volta Region and 20 sera from 
European controls without travel history to Africa (figure 1A). Based on the defined 
ELISA OD cut-off values, a sero-positivity rate of 32% was observed for the sera from 
the Densu River Valley. The sero-positivity rate of people living in the Volta Region 
(12%), as well as the mean ELISA readouts obtained with their sera were 
significantly lower (p<0.001). None of the sera from European controls exhibited a 
significant titer (figure 1A). Sero-positive individuals from the Volta region were re-
visited and interviewed. It was determined that all of them have lived entirely or at 
least for most of their life in their home communities in the Volta Region. One of the 
sero-positive participants from the village Torgorme reported at the interview to have 
a non-healing chronic wound on the leg (figure 1B). The wound was clinically 
diagnosed by an experienced physician as BU and clinical diagnosis was laboratory 
reconfirmed by positive IS2404 PCR of swab specimens. The serum of this 
reconfirmed BU patient had the highest anti-18 kDa shsp-specific serum IgG titer of 
all participants from the Volta Region tested (figure 1A). 
Following the identification of this index case, the health directorate of the Volta 
Region sent us specimens from eleven other individuals with suspected BU lesions. 
Six of these, were reconfirmed as IS2404 PCR-positive BU by our laboratory at the 
Noguchi Memorial Institute for Medical Research, which is one of the BU reference 
laboratories in Ghana. While sera of two laboratory confirmed BU patients contained 
anti-18 kDa shsp IgG, four patients were sero-negative. 
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Comparison of anti-18 kDa shsp IgG sero-positivity in BU endemic and non-
endemic communities along the Densu River 
Active case search surveys were performed to determine the prevalence of BU along 
the Densu River (figure 2). The average prevalence of BU in endemic communities 
with 3 km buffer was 3.4%. While in some communities upstream no BU cases were 
found, the disease burden increases as the River runs downstream (figure 2A). Of 
the ten communities included in the sero-epidemiological study, four (Ntabea, 
Abesim-Yeboah, Obotanso and Obuotupan) were confirmed as non-endemic, as 
both the passive surveillance by the National BU control program and our active case 
search identified neither healed nor active cases. The total prevalence rate, including 
both healed and active cases, of the six endemic communities ranged from 1% to 
19% with Tetteh Kofi, Otuaplem and Sode having the highest rates (4.8%, 14.9% and 
19.1%, respectively). The prevalence of active cases ranged from <1% to 2.4%, with 
Sode also having the highest active case prevalence rate. 
When 18 kDa shsp-specific serum IgG titers of 295 sera from BU endemic and of 187 
sera from non-endemic communities were analyzed by ELISA (figure 1A), 
comparable sero-positivity rates (33% versus 31%, respectively) were found. ELISA 
results were reconfirmed by Western blot analysis with a randomly chosen subset of 
sera. There was good agreement between Western blot band intensities and ELISA 
titers with a few discrepancies related to a higher sensitivity of the ELISA method 
(data not shown). Sero-responders were found in all age groups (>5 years) tested, 
but sero-negative individuals dominated throughout (figure 3). 
 
PCR analysis of environmental samples 
211 environmental samples were collected randomly from both aquatic and dry land 
environs. The sampled BU endemic communities included Kojo-Ashong (KA), Sode 
(SD), Amasaman and surrounding hamlets (AS), and Kudeha and surrounding 
hamlets (KD) located in the GW and GS districts. Samples from non-endemic 
communities were collected in Abesim-Yeboah (AY), Obuotumpan (OB) and Ntabea 
(NB) located in the EA and NJ districts further up-stream of the Densu River (figure 
2A). 
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M. ulcerans DNA in an environmental sample was confirmed by the presence of all 
three tested loci (IS2404, IS2606 and KR) as revealed by positive results with all 
three PCR tests performed. In all, 19/211 (9.0%) of the samples tested were positive, 
including 5/19 aquatic snails, 5/28 sand samples collected from the communities, 
4/30 samples from river water and river bed sand, 2/30 samples from aquatic 
vegetation, 1/6 sand samples collected from farms, 1/12 aquatic insects and 1/1 
millipedes. As shown in Table 1 the average positivity rates for samples from 
endemic communities were 13.4% (7.7%, 13.3%, 14.3% and 18.5% in KA, AS, SD 
and KD, respectively) and 6.2% for samples from non-endemic communities (26.0%, 
2% and 1.8% for NB, OB and AY, respectively). 
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DISCUSSION 
 
Broad antigenic cross-reactivity between mycobacterial species represents a major 
challenge for the development of a serological test that is specific and sensitive 
enough to monitor immune responses against M. ulcerans in populations where 
exposure to M. tuberculosis and BCG vaccination is common. In our earlier work, we 
have identified the M. ulcerans 18 kDa shsp as an immunodominant antigen, which 
has no homologues in M. tuberculosis and M. bovis [10]. However, interspecies 
cross-reactivity of this protein with an 18 kDa protein of M. leprae as well as a 20 kDa 
protein of M. chelonae was detected. In the same study we evaluated the use of 
measuring anti-18 kDa shsp IgG titers for assessing the exposure of a population to 
M. ulcerans on the basis of a limited number of BU patients, household contacts and 
people living in areas where BU is not endemic [10]. Since sera from inhabitants of 
BU non-endemic regions showed largely no reactivity with the 18 kDa protein of M. 
ulcerans, immune responses against environmental mycobacteria, such as M. 
chelonae, do not seem to compromise the developed serological test for M. ulcerans 
exposure. Here we have extended our previous analysis by comparing sera from 
areas of Ghana, which rarely report leprosy cases, but differ in their reported BU 
endemicity. 
In Ghana, a national case search performed in 1999 yielded a crude national BU 
prevalence rate of 20.7/100,000 and hence demonstrated that BU is the second most 
common mycobacteriosis in the country after tuberculosis [13]. In this study diagnosis 
of both active and healed lesions was based solely on clinical grounds without any 
microbiological confirmation. Since the creation of the national control program, 32 of 
the 166 nation-wide districts continuously report BU. Through this passive 
surveillance system, over 11,000 cases have been reported between 1993 and 2006 
(http://www.who.int/mediacentre/factsheets/fs199/en/) from mainly six of the ten 
regions of Ghana. No BU cases have been reported from the Volta, Northern, Upper 
East and West regions, giving the impression that those four regions do not harbor 
BU cases and therefore are non-endemic. However, in our analysis of sera from the 
Volta Region, a relatively small, but significant number of serum samples contained 
anti-18 kDa shsp IgG. Follow-up visits and interviews revealed that one of the sero-
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positive individuals had a chronic wound which was subsequently laboratory 
confirmed as BU [14]. After identification of this index case, additional laboratory 
confirmed BU cases were found by active case search in the Volta Region. In our 
previous analyses [10], only part of the sera from laboratory reconfirmed BU patients 
were tested postitive for anti-18 kDa shsp IgG. In accordance with these findings, not 
all of the BU patient sera from the Volta region were sero-positive. These data clearly 
show that anti-18 kDa shsp IgG titers are no indication for active disease. A large 
epidemiological survey is now required to determine the prevalence of BU over the 
entire Volta Region. Until today no serological test allows for a distinction of BU 
patients and healthy individuals, which are exposed to M. ulcerans. However, our 
results demonstrate that sero-epidemiological studies can be used to complement 
active case search in regions, where data about the BU prevalence are lacking. 
Future longitudinal sero-epidemiological studies are planned in order to monitor the 
exposure of certain populations to M. ulcerans over a longer period of time. At this 
stage we cannot conclude how timing and frequency of exposure influences antibody 
titers against the pathogen. 
The prevalence of 18 kDa shsp sero-positive individuals within populations along the 
Densu River was >30%. This confirms our earlier conclusion that a large proportion 
of healthy individuals living in endemic communities who have responded 
immunologically to M. ulcerans exposure do not develop overt disease. While the 
percentage of 18 kDa shsp sero-positive individuals was higher compared to that 
found using a Burulin skin test in healthy controls, it is comparable to that obtained 
for the serologic response to M. ulcerans culture filtrate [15],[16]. Diverse outcome of 
infection with the causative agents of the main mycobacterial diseases such as 
tuberculosis seems to be a common feature of their natural history. Not all exposed 
individuals show immunological evidence of infection and of those who get infected 
by M. tuberculosis estimations indicate that only 10% will ever develop overt disease 
[17], [18]. Manifestation of the disease ranges from self-limited pulmonary infection to 
localized extra-pulmonary infection and disseminated disease [19]. Factors 
accounting for the diversity in outcomes are not entirely known, but may relate to 
both host and pathogen factors. Even though clinical M. ulcerans isolates from Africa 
are clonally related and genetically largely monomorphic [20]–[27], differences in 
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virulence among African M. ulcerans strains cannot be ruled out completely. Hence, 
the percentage of M. ulcerans infected individuals who proceed to develop BU 
remains to be established. BU is known to develop in all age groups with a nearly 
equal gender distribution but most cases occur in children 15 years of age or younger 
[28]. In our study we found anti-18 kDa shsp sero-responders in all age groups (>5 
years) analyzed. A future cohort study with infants could provide important insight, at 
which age these immune responses start to emerge. 
Both in endemic and non-endemic villages of the Densu River Valley we found M. 
ulcerans PCR positive environmental samples. This is indicative for the presence of 
M. ulcerans or of closely related environmental bacteria all along the Densu River. 
Our findings are consistent with earlier findings of Williamson et al. [29] in the same 
region. Since the mode of M. ulcerans transmission and risk factors for the exposure 
to the pathogen are still not entirely elucidated, it is not clear, whether the types of 
environmental samples that were PCR positive have direct relevance for infection 
with M. ulcerans. Hence methods for the routine isolation and characterization of M. 
ulcerans from the environment need to be developed. 
Hypotheses on risk factors and the mode of infection with M. ulcerans include 
contamination of wounds from an environmental reservoir, inhalation of vaporized 
contaminated water and inoculation by insects [30]–[32]. Our molecular 
epidemiological studies have recently demonstrated a focal transmission pattern for 
M. ulcerans [27]. This may help to explain one of the mysteries of BU transmission, 
the close proximity of endemic and non-endemic villages. As indicated in figure 2, 
while M. ulcerans is endemic in some villages within the Suhum-Kraboa-Coaltar 
district, through active case search we did not find any case (both healed and active) 
in neighboring districts located at the upper part of the river, such as East-Akim and 
the New-Juaben. In contrast, communities of the four districts, which are situated 
downstream (Akwapim South, Akwapim North, Ga-West and Ga-South) regularly 
report BU cases. BU endemic and non-endemic communities along the Densu river 
differ in terms of their vegetation. Upstream, within the wet semi-equatorial zone, the 
vegetation is predominantly moist semi-deciduous rain forest, which gradually 
changes downstream into a short stretch of Guinea Savannah around Nsawam and 
ends with coastal scrub and savannah grassland in the Ga districts. In addition, there 
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is a variation in the features of the Densu River, which takes its source from the 
Atewa Forest Range near Kibi and flows for 116 km into the Weija Water Reservoir 
before entering the Gulf of Guinea through the Densu Delta Ramsar site. While 
upstream the river flows fast, has clear water and the river bed consists of rocky 
stones, downstream the river flows sluggishly, has a muddy river bed, and the water 
is turbid. We did not find significant differences in anti-18 kDa shsp IgG seropositivity 
rate or titers between people living in communities in the Densu River Valley that 
were classified based on active case search as BU endemic or non-endemic. These 
findings could imply at least one of the following: 1) people in the non-endemic 
communities in the upper Densu River Valley may be exposed to M. ulcerans 
lineages with low virulence; 2) currently unknown host genetic, behavioral or socio-
economic factors trigger the development of subclinical M. ulcerans infection to 
clinical disease; 3) in the non-endemic communities 18 kDa shsp binding antibodies 
are triggered by subclinical infections with environmental mycobacteria harboring 
antigens that are cross-reactive with the 18 kDa shsp [10]. 
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TABLES 
 
Table 1. IS2404, IS2606, KR PCR positivity of environmental samples collected 
in communities along the Densu River. 
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FIGURES 
 
 
Figure 1. Anti-M. ulcerans 18 kDa shsp IgG titers. A OD values of sera from 
individuals living in BU endemic (E) and non-endemic (NE) communities along the 
Densu River (Gar/Eastern) or in the Volta Region (Volta) of Ghana obtained in an 18 
kDa shsp ELISA for a 1∶100 serum dilution are shown for individual sera. Sera from 
Europeans without travel history to Africa served as controls. Statistical differences 
between groups were calculated by the Kruskal-Wallis test with Dunn's post test (*** 
= p<0.001). B Laboratory confirmed BU lesion of a sero-positive participant from the 
Volta region. 
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Figure 2. Prevalence of BU and sample 
collection procedure. A Map showing the 
prevalence of BU in selected communities along 
the Densu River. The prevalence rate was 
calculated by adding the number of individuals 
both with active or healed BU lesions divided by 
the total population number of the community. 
Exemplarily, the housing and population census is 
illustrated for the village Otuaplem. B Photographs 
illustrating environmental sampling (a), 
reconnaissance visit in the communities (b), an 
active BU lesion found in a community during 
active search (c) as well as a healed BU lesion 
also identified in a community (d). 
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Figure 3. Age distribution of anti-18 kDa shsp IgG titers. OD values of sera from 
individuals living in BU endemic (E) and non-endemic (NE) communities along the 
Densu River obtained in an 18 kDa shsp ELISA for a 1∶100 dilution are shown for 
individual sera. 
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An Alamar Blue-based growth inhibition assay has been adapted for the 
thermosensitive and slow growing pathogen Mycobacterium ulcerans (M. 
ulcerans). The standardized test procedure enables medium-throughput 
screening of pre-selected compound libraries. Testing of a set of 48 azoles with 
known antifungal activity led to the identification of an imidazole antifungal 
displaying an inhibitory dose (ID) of 9 µM for M. ulcerans. 
 
M. ulcerans is the causative agent of Buruli ulcer, a disfiguring disease characterized 
by the formation of chronic, necrotizing skin ulcers. Buruli ulcer is a major public 
health problem primarily in West Africa, where it typically affects impoverished 
inhabitants of remote rural areas (25). Surgical excision of lesions was the only 
therapeutic option until the World Health Organization released provisional guidelines 
in 2004 advising an eight-week combination chemotherapy of oral rifampicin and 
intramuscular streptomycin (26). Implementation of this regimen has significantly 
reduced recurrence rates. However, there are some drawbacks associated with the 
administration of these antibiotics. Streptomycin requires daily injections and is 
potentially nephrotoxic and ototoxic (5). Monotherapy with rifampicin is not a solution 
because resistance can develop rapidly (14). While studies on fully oral regimens 
replacing streptomycin by clarithromycin yielded promising results (2, 6), identification 
of new drugs that could replace rifampicin would be most desirable.  
Since lead compounds identified by target-based approaches are frequently inactive 
against the pathogen grown in culture (4, 13, 19), whole cell assays are highly 
valuable in the search for new antibiotics. The extremely slow growth rate of M. 
ulcerans complicates the identification of potentially effective new scaffolds. In this 
study, we describe the development of an Alamar Blue microplate assay, which 
enables screening of compounds for their activity against M. ulcerans within ten days. 
Here we report results of a pilot study with this medium-throughput screening 
procedure. Testing of a pre-selected group of azoles led to the detection of 
compounds with potency against M. ulcerans.  
Alamar Blue-based assays have been shown to be powerful and sensitive tools for 
the identification of growth inhibitory compounds irrespective of the underlying mode 
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of action and chemical classification. They are widely used for screens both with 
mammalian cells and microorganisms, including mycobacterial species (4, 7, 9, 10, 
13, 19). In order to develop a suitable test format for M. ulcerans, the specific growth 
features, a long generation time of about 72 hours and a low optimal growth 
temperature of 28-32°C, had to be taken into account. To reduce the problem that M. 
ulcerans tends to aggregate when grown in liquid medium, the inoculum was 
prepared in BacT/ALERT® culture bottles supplemented with enrichment medium 
according to the manufacturer’s protocol (Biomerieux). NM20/02, a M. ulcerans strain 
isolated in 2002 from the Buruli ulcer lesion of a Ghanaian patient (22, 27) as well as 
additional strains from Togo (ITM 970680), Côte d'Ivoire (ITM 940511) and Australia 
(JS5147) were grown for 6-8 weeks at 30°C until exponential phase. The test 
inoculum was prepared by diluting the culture with BacT/ALERT® medium to a final 
OD600 of about 0.02.  
The Alamar Blue growth inhibition assay was performed in clear, flat-bottomed 96-
well plates (BD Falcon). Stock solutions of the tested compounds were prepared in 
high-grade DMSO (Sigma) at a concentration of 10 mg/ml and diluted for the assay 
with DMSO to a concentration of 0.2 mg/ml. Then two-fold dilution series in medium 
starting from 0.0125 mg/ml to 0.0001953 mg/ml were prepared in a volume of 100 µl 
and set up in triplicates. As controls, streptomycin (Sigma) at a concentration of 
0.0125 mg/ml to 0.0001953 mg/ml was used. In addition, medium and DMSO 
controls were included. To each well of a 96-well plate, 100 µl of the diluted M. 
ulcerans suspension was added. Plates were incubated for 8-10 days at 30°C, then 
20 µl alamarBlue® (Invitrogen) was added and the plates were further incubated and 
monitored at 37°C as recommended for the reduction of the alamarBlue® component 
resazurin. During the short incubation period of 24 hours M. ulcerans viability was not 
affected by this elevated temperature (8). Since M. ulcerans is considered a biosafety 
level 3 pathogen in Switzerland, bacterial suspensions were afterwards inactivated 
for measurement of the fluorescence intensity outside of the BSL3 laboratory. 100 µl 
portions of each well were transferred to corresponding wells of a new 96-well plate 
containing 100 µl neutral buffered formalin solution (Sigma, final concentration 5% 
v/v). The plates were sealed with optical adhesive film (Applied Biosystems) and the 
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fluorescence intensity was measured using a SPECTRAmax Gemini XS device with 
Softmax Pro 5.2 software (λ = 540/588 nm). Procentual signal reduction was 
assessed by comparison with M. ulcerans control cultures containing compound-free 
DMSO and inhibitory dose (ID) values corresponding to 90% and 50% inhibition were 
determined.  
For registered drugs, a complete toxicological profile is commonly available, but also 
registered agrochemicals have been broadly examined for their toxicological potential 
and for other features that have to be characterized prior to clinical phase I testing. 
Hence, compounds from both sources represent preferred candidates for medium-
throughput testing for new indications. Here we have focused on azole-type 
fungicides, commercialized as drugs or agrochemicals. These compounds are 
cytochrome P450 inhibitors with partial specificity for the lanosterol 14-alpha-
demethylase, cytochrome P450 51 (CYP51). The genomes of Mycobacterium 
tuberculosis (M. tuberculosis) and M. ulcerans (http://genodb.pasteur.fr/cgi-
bin/WebObjects/GenoList.woa/wa) encode at least 20 CYP enzymes. CYP inhibitors 
have been shown to inhibit M. tuberculosis growth (15) and among them, CYP51 
seems to be highly relevant (21). Therefore, azole-type fungicides might have 
potential as drug candidates against mycobacterial infections. We have retrieved 48 
commercialized azoles from the BASF compound repository (Table S1) and tested 
them in the Alamar Blue-based screening assay for M. ulcerans growth inhibitory 
activity. Of these 48 azoles, only the antifungal drug Croconazole, 1-[1-[2-[(3-
chlorophenyl)methoxy]phenyl]ethenyl]-1H-imidazole (18), showed significant activity 
with an ID-90 of 2.9 µg/ml, equivalent to 9 µM, and an ID-50 of 0.8 µg/ml, equivalent 
to 2.6 µM (Figure 1A). In addition to the Ghanaian reference strain, we tested the 
activity of Croconazole on M. ulcerans isolates originating from Côte d'Ivoire, Togo 
and Australia and obtained similar ID-50 values of 0.7 µg/ml, 1.1 µg/ml and 0.6 µg/ml, 
respectively.   
The characteristic feature of Croconazole, discriminating it from all other tested 
azoles, is a methylen-substitution at the imidazole-binding carbon. To further 
evaluate the structure-activity relationship of this compound class, eight additional 
analogues possessing this structural motif have been tested. Of these, only the 4-Cl-
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isomer of Croconazole displayed a similar activity with an ID-90 of 2.8 µg/ml, 
equivalent to 8 µM, and an ID-50 of 0.95 µg/ml, equivalent to 2.7 µM (Figure 1B, 
Figure 2). While cytochrome binding via the imidazole is the essential interaction with 
the P450-enzyme, these data indicate that also the lipophilic side chain interaction is 
of critical importance, since already moderate side chain modifications lead to loss of 
activity. However, also metabolic deactivation cannot be ruled out. As all the other 
tested commercial azole drugs and agrochemicals, which show a very broad 
spectrum of substitution patterns and intrinsically high activity on a variety of CYPs, 
were inactive against M. ulcerans, the unique activity of Croconazole and its 4-Cl-
analogue is rather surprising. 
Croconazole is a potent imidazole antifungal that acts extracellularly on the cell 
membrane of fungi. It has been shown to inhibit predominantly CYP51, and thus 
interferes with the synthesis of ergosterol, the precursor of vitamine D2 (11).  The 
active sites of CYP51 are conserved in many mycobacterial species and virtually 
identical in M. tuberculosis and M. ulcerans while there are many differences to 
human CYP51 (21). It remains to be elucidated whether Croconazole exerts its 
inhibitory activity on M. ulcerans via inhibition of CYP51 or via another target. 
Interestingly, apart from being employed as a broad spectrum fungicide (17, 24) 
developed by Shionogi Research Laboratories (Osaka, Japan), Croconazole is 
commercially also available as an active ingredient of a cream called Pilzcin® (Merz 
+ Co., Frankfurt/Main, Germany (16)), indicated for topical treatment of 
dermatomycoses and candidiasis. Pilzcin® is in particular recommended for 
treatment of tinea pedis, an infection of the skin caused by fungi of the genus 
Trichophyton (3). Severe side-effects upon treatment with Croconazole containing 
drugs have not been described; however, a few cases of contact sensitization have 
been reported (23). Since Buruli ulcer primarily affects the skin and underlying tissue, 
topical treatment regimens have been considered and evaluated (1, 20). In active 
lesions clusters of toxin producing M. ulcerans are primarily found in deep layers of 
the subcutaneous fat tissue. Topical treatments thus may only be effective if the 
antimycobacterial agent is able to act in these deeper layers of the skin. 
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Since the development of new drugs is a very costly and time-consuming process, 
re-evaluation of already existing therapeutics for their potential effects against other 
diseases is a straightforward approach. A recent study focusing on the detection of 
new anti-tuberculosis drugs by re-evaluating a library of known human therapeutics 
led to the identification of promising new scaffolds (12). In a similar approach we 
identified Croconazole as a potent compound active against M. ulcerans by revisiting 
a panel of 48 well-characterized azole drugs and agrochemicals. In conclusion, 
screening of such pre-selected sets of compounds increases the chance to detect 
scaffolds on which future drug development efforts can be focused. 
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FIGURES 
 
 
 
Figure 1. Inhibition of M. ulcerans growth upon treatment with the azole compound 
Croconazole (A) and its 4-Cl-analogue (B).  
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Figure 2. Overview of the Croconazole derivatives with corresponding CAS numbers 
and MIC values. 
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CHAPTER 8 
  
“The war against infectious diseases has been won”, was proclaimed by U.S. 
Surgeon General William H. Stewart in the late 1960s, contemplating the benefits of 
antibiotics and vaccines [1]. However, the history of infectious diseases from that 
time until now has witnessed quite the opposite, namely the appearance and 
dissemination of Legionnaires` disease, Hantavirus pulmonary syndrome (HPS), 
Lyme disease and the acquired immune deficiency syndrome (AIDS), to mention but 
a few. Although the occurrence of these diseases often may seem mysterious, 
factors contributing to their emergence can be determined in virtually all cases 
studied [2–6]. While the continual evolution and adaptation of potentially pathogenic 
organisms provides an inexhaustible source for the emergence and re-emergence of 
infectious diseases, other determinants including ecological, environmental or 
demographic factors interact to precipitate disease emergence [2]. The recurring 
theme throughout all of these factors are human-induced changes [7], leading to an 
increased contact of individuals/populations to the pathogen, its vector or 
environmental reservoirs [2], which can be illustrated on the basis of the above and 
below mentioned disease examples. Outbreaks of Legionnaires` disease caused by 
Legionella pneumophila are largely associated with human-made aquatic 
environments containing water at elevated temperatures. Multiplication of the 
bacteria and subsequent inhalation of contaminated droplets through artificial water 
supply systems can lead to infection [6,8]. Human behavioral factors including 
farming, land development, deforestation and camping favor epidemics of HPS, 
which occur with increased exposure of people to faeces of specific rodent species, 
the natural reservoir of Hantaviruses [5,8]. The emergence of Lyme disease in the 
United States caused by Borrelia burgdorferi was probably the consequence of 
reforestation around settlements, which increased the population of deer and 
simultaneously the occurrence of the deer tick vector [3]. The unprecedented spread 
of HIV/AIDS was fostered by changes in human demographics and behavior 
including increased travel, movement of rural populations to large cities, urban 
poverty and a weakening of family structures promoting sexual practices that 
facilitate HIV transmission [8].  
The resurgence of historically important diseases such as cholera, diphtheria and 
plague has been accelerated by wars or natural disasters such as earthquakes and 
  
floods [8]. Recurrence or geographical dissemination of diseases transmitted by 
mosquitoes and other arthropod vectors have been mostly attributed to ecological 
changes resulting in the creation of standing water [9]. To give one example, dam-
building and irrigation projects appear to favor the spread of schistosomiasis to new 
geographical areas, since they provide ideal habitats for both the schistosomes and 
their freshwater snail intermediate hosts [10].  
Buruli ulcer, caused by infection with Mycobacterium ulcerans, is classified by the 
World Health Organization as one of currently 17 neglected tropical diseases [11]. 
Though not officially categorized by the former National Center for Infectious 
Diseases (CDC, currently reorganized into multiple national centers), as emerging or 
re-emerging, strong increases of BU case numbers in West Africa as well as the 
detection of new infection foci in the last decades [12–17], render BU an emerging 
infectious disease. While vast underreporting of BU cases in rural African regions 
results in an underestimation of the actual disease burden, it is believed that the 
incidence of BU in highly affected areas may exceed that of leprosy and in some 
regions even that of tuberculosis. Until today the emergence of BU can not entirely 
be explained and environmental reservoirs as well as transmission pathways remain 
to be established. However, several aspects mentioned above including evolution 
and niche adaptation of the pathogen M. ulcerans as well as ecological and 
environmental factors, which may contribute to the emergence of BU, will be 
discussed in the following sections and connected with the obtained results 
described in this PhD thesis. 
 
Buruli ulcer: emergence of a mysterious disease  
Morse suggested in 1991 that the emergence of infectious diseases can be thought 
of as a two-step process, in which the introduction of a pathogen into a new host 
population is followed by the establishment and further dissemination of the pathogen 
within the new host population [2,18]. But long before new host populations can be 
infected, a pathogen emerges itself by incessant evolution and adaptation processes. 
 
 
  
Evolution and genetic diversity of M. ulcerans 
The evolution of Mycobacterium ulcerans was coined by the acquisition of the 
virulence plasmid pMUM, probably enabling its divergence from the fish pathogen 
Mycobacterium marinum around a million years ago [19,20]. Although the genomes 
of these two species share more than 97% nucleotide identity, they cause different 
diseases in humans and exhibit widely different phenotypes [19,21,22]. The 
pathology of BU characterized by chronic and necrotic skin ulceration is largely 
mediated by the production of mycolactone, an immunosuppressive polyketide toxin 
encoded by pMUM and restricted to representatives of the species M. ulcerans, 
collectively referred to as mycolactone producing mycobacteria (MPM) [22,23]. M. 
marinum is a ubiquitous waterborne organism that usually infects fish and 
amphibians. Infection in humans occurs only occasionally and leads to the 
development of granulomatous skin lesions [24]. Thus, it seems likely that the ability 
to produce mycolactone was a first step in the emergence of a potentially infectious 
agent and that this evolutionary bottleneck has facilitated the development of a highly 
clonal species with increased virulence compared to that of its ancestor. A strong 
selective advantage is thought to preserve a mycolactone-proficient form of pMUM, 
since only seven structural variants of mycolactone (referred to as A/B, C, D, E, F, S1 
and S2) could be identified so far and strains isolated from different African countries 
over a 40 year period were shown to produce the same mycolactone A/B [25,26]. 
Mycolactone production probably provided the ability for an early M. ulcerans 
population to persist in a new environment, where its generalist M. marinum 
progenitor could not be extant [22]. It is currently debated whether amoebae may act 
as a host for M. ulcerans in the environment [27]. However, until today it is not clear 
how M. ulcerans might benefit from mycolactone production in biotic surroundings. In 
the human host it has long been assumed that a potential anti-microbial activity of 
mycolactone might prevent secondary infections of the BU lesions and thus confer an 
advantage by circumventing competition with other microbes. As opposed to this, a 
recent study analyzing the bacterial flora of BU lesions has shown that a broad 
spectrum of bacterial species is present within the lesions (Yeboah-Manu, submitted). 
Presently it is assumed that the combination of cytotoxic as well as 
immunosuppressive properties of mycolactone confers a fitness advantage for M. 
  
ulcerans by preventing a host immune system-mediated elimination of the bacteria. A 
second important event in the emergence of M. ulcerans was the acquisition and 
expansion of an insertion sequence (IS2404), which has resulted in the inactivation 
of genes and extensive loss of DNA [19]. While the genome of M. marinum strain M 
comprises a 6.6-Mb circular chromosome with 5424 coding sequences (CDS) and 
only 65 inactivated genes [21], the genome of M. ulcerans strain Agy99 consists of 
two circular replicons with a size of 5.8-Mb, 4241 CDS and 771 pseudogenes [19]. 
The described genomic signatures of M. ulcerans such as acquisition of foreign DNA, 
proliferation of IS elements, extensive gene loss through pseudogene formation and 
genome downsizing indicate that M. ulcerans is adapting to a new, apparently 
protected niche environment, where genes once needed for survival under diverse 
conditions are no longer required [19,22,28]. The current conception of a possible 
niche after analyses of the genome content of M. ulcerans strain Agy99 suggests that 
in contrast to the generalist M. marinum, M. ulcerans has become a specialist 
bacterium adapted to a dark, extracellular environment, where special characteristics 
such as the extremely slow growth rate, the reported depletion of highly 
immunogenic proteins [29] and the production of an immunosuppressive toxin 
provide a selective advantage [19,22]. Recent comparative genome sequencing data 
including mycolactone producing mycobacteria isolated from human, possum, fish, 
frog or insect sources of different geographical areas suggests a distinction of at 
least three M. ulcerans sublineages, which should be considered as M. ulcerans 
ecovars, in view of their adaptation to related, but distinct niche environments. The 
occupation of different ecological niches seems to be connected with the contact of 
MPM variants to different hosts, since one of these ecovars is responsible for BU 
cases in West Africa and Australia (sublineage 3), while representatives of the other 
two lineages are only occasionally reported to cause disease in humans (sublineage 
2) or are exclusively associated with disease in ectotherms. M. ulcerans sublineage 3 
is highly clonal and exhibits genome signatures indicating that this lineage has 
undergone another evolutionary bottleneck and further adaptation to its niche 
environment [22]. Comparative genome analysis of closely related lineage 3 isolates 
is expected to provide insights into possible sources and transmission routes of M. 
ulcerans. 
  
In the past, the clonality and extremely limited genetic diversity of M. ulcerans lineage 
3, most notably M. ulcerans strains from West Africa, combined with the lack of a 
typing method with sufficient resolution for micro-epidemiological studies have 
hampered attempts to identify evolutionary relationships between these closely 
related strains [30–33]. As a consequence, only fragmentary information is available 
regarding the routes of M. ulcerans dispersal both throughout West Africa and within 
BU endemic countries or even geographically confined M. ulcerans infection foci. 
Recent advances in genetic typing technologies and whole genome sequencing have 
provided the basis for investigations on the population structure of clonal bacterial 
populations characterized by limited genetic diversity such as Yersinia pestis, 
Bacillus anthracis or Mycobacterium leprae, leading to important insights into their 
spread, transmission routes and/or reservoirs [34–37]. To mention one example, a 
recent study investigated the phylogeography and molecular epidemiology of 
Yersinia pestis in Madagascar, one of the most plague-affected regions in the world. 
By typing 262 Malagasy isolates from 25 districts isolated between 1939 and 2005 on 
the basis of 56 single nucleotide polymorphisms (SNPs) and a 43-marker multiple 
locus variable number of tandem repeat (MLVA) system, island-wide geographic-
genetic patterns and potential transmission routes could be identified. The results of 
this study, namely that significant geographic separation exists among the identified 
Y. pestis subclades, are consistent with the population genetics and ecology of the 
black rat, which is the main reservoir of Y. pestis in rural Madagascar and 
characterized by limited geographic ranges. The two primary flea vectors of Y. pestis 
may also play a role in maintaining genetically distinct subpopulations [37]. As highly 
stable phylogenetic markers that are unlikely to mutate again [38], SNPs represent 
ideal entities for detailed phylogenetic analyses of clonal pathogens with limited 
genetic diversity [39]. Once SNPs have been identified by comparative genome 
sequencing, various technologies are available for SNP typing analyses [40].  
Our comparative genome sequencing of clinical M. ulcerans strains from Ghana has 
facilitated a genome-wide search for SNPs (chapter 2), enabling micro-
epidemiological analyses within BU endemic areas of Ghana. In order to capture as 
much as possible of the genetic information present in the Ghanaian M. ulcerans 
population, one representative isolate of each of the three previously identified 
  
variable number of tandem repeat (VNTR) types [31] was selected for genome 
comparison and SNP detection. Subsequent development of a real-time PCR 
method based on the identified SNPs facilitated for the first time a differentiation of 
75 M. ulcerans strains isolated from BU patients of one geographically confined M. 
ulcerans infection focus in the Densu River Basin of Ghana between 1999 and 2007 
into six haplotypes. Re-sequencing of four haplotype representatives led to the 
identification of additional SNPs enabling the establishment of even more SNP typing 
assays and consequently the differentiation of ten M. ulcerans haplotypes in the 
Densu River Basin of Ghana. Interestingly, several of the ten haplotypes showed a 
geographically clustered distribution within the small BU endemic region. Since the 
most prevalent haplotype was distributed over the entire area, it was hypothesized 
that this M. ulcerans variant was probably the founder haplotype in this area, from 
which the other haplotypes derived (chapter 3). However, whole genome sequencing 
of additional strains from the Densu River Valley is required to support this 
hypothesis. Typing results of clinical M. ulcerans isolates from another BU endemic 
region in the Amansie-West district of Ghana indicate the presence of two different 
clonal M. ulcerans complexes in the two geographically separate regions (chapter 3). 
The geographic separation of M. ulcerans haplotypes both between and within BU 
endemic areas is reminiscent of the distribution of Y. pestis subclades in Madagascar. 
While geographic-genetic patterns of Y. pestis could already be explained by the 
natural cycle between primary host, the black rat, and the flea vectors [37], 
reservoir(s) and vector(s) for M. ulcerans in West Africa have yet to be explored. 
Similar to Y. pestis, a transmission model has been established for M. ulcerans in 
Australian BU endemic settings pointing to mammals, most notably tree-dwelling 
native possums as possible reservoir [41] and mosquitoes as potential vectors for M. 
ulcerans [42]. In this concept, infection of humans is thought to take place via biting 
mosquitoes that fed on infected possums or had contact to vegetation contaminated 
by diseased possums [41]. However, this model is not easily translatable to African M. 
ulcerans infection foci. Firstly, because no M. ulcerans infections have been 
described in African mammals so far and, secondly, because higher BU case 
numbers would be expected, if mosquitoes were vectors of M. ulcerans in West 
African countries, where people are frequently bitten by mosquitoes. While BU has 
  
consistently been linked to stagnant or slow-flowing water bodies in African BU 
endemic areas, it is controversially discussed whether the detection of M. ulcerans 
DNA in many biotic components of aquatic ecosystems, such as plants, snail, fish, 
insects or amoeboid protozoa is indicative for potential reservoirs or vectors of M. 
ulcerans or merely points towards the ubiquitous presence of M. ulcerans in these 
ecosystems [43–52,27].  
The existence of different clonal M. ulcerans complexes in the two Ghanaian BU 
endemic areas under study indicates that M. ulcerans is maintained in geographically 
separate subpopulations. The observed focal clustering of certain M. ulcerans 
haplotypes in the Densu River Basin of Ghana shows that geographic separation of 
haplotypes even occurs within a relatively small BU endemic region. Based on these 
results we anticipate that if a reservoir in the aquatic ecosystem is involved in 
transmission, the spread of M. ulcerans from chronic BU lesions to such a currently 
unknown environmental reservoir and subsequent infection of individuals, in contact 
with the same reservoir, should be considered. Transmission could take place 
through trauma of the skin or vectors that still have to be identified (chapter 3). 
While the evolution and adaptation of M. ulcerans to its new niche environment 
provided the basis for the emergence of a pathogenic organism for humans, 
ecological factors could be identified that probably have contributed to the 
emergence of BU in focal areas. Interestingly, literally all epidemiological 
investigations have associated BU outbreaks with close proximity to human-disturbed 
aquatic environments. 
 
Introduction of M. ulcerans to the human host population 
The emergence of infectious diseases is surprisingly often caused by human actions, 
with ecological changes being among the most frequently identified factors [2].  
Emerging M. ulcerans infection foci have been related to various ecological and 
environmental disturbances, which can be considered as the introduction of M. 
ulcerans to the human host. Thus, increased BU incidence has been reported after 
alterations of water systems such as irrigation or damming of streams or rivers 
connected with the creation of wetlands and impoundments or severe flooding of 
  
lakes and rivers exposing people to swampy terrain. Moreover, infection foci were 
associated with agricultural activities leading to flooding or the creation of irrigation 
systems as well as land development accompanied by resettlement near water 
bodies [53–55,13,56–59].  
One of the major mysteries around BU is why residence near certain water bodies is 
associated with BU, whereas the disease seems to be absent along other aquatic 
environments of the same countries and why even along the same water body 
tremendous differences in case numbers can be recorded. To give one example, BU 
is highly associated with residence along the Densu River in Ghana, whereas only a 
few cases have so far been reported along the Volta River, which is the largest water 
system in Ghana. Furthermore, BU cases are found in the lower part of the Densu 
River, but not further upstream (chapter 6).  
The Densu River system, one of the coastal drainage basins in Ghana, has been 
dramatically altered by a number of human activities such as farming, salt mining, 
sand winning, animal grazing and dam construction. These activities have significant 
implications on the fluvial processes of the river such as erosion, braiding and 
flooding [60]. An impoundment created downstream, at the southern part of the river 
(Weija Dam) led to the formation of the Weija Lake and wetlands surrounding this 
area [58]. Active BU case search surveys in 24 communities located in close 
proximity to and along the Densu River revealed prevalence rates of BU ranging from 
0% to 20%. While in four communities upstream no BU cases were detected, 
increasing prevalence rates could be recorded as the river runs downstream 
approximating the Weija Lake (chapter 6). It is tempting to speculate that the creation 
of the Weija Dam and the associated environmental changes have contributed to the 
emergence of BU in the Densu River basin by increasing the contact of people to 
water bodies and consequently to M. ulcerans. However, so far, only a few BU cases 
have been reported from the Volta region [15], where the creation of the Akosombo 
dam and subsequent formation of the Lake Volta [61,62] resembles the situation in 
the Densu River basin and has led to the dissemination of other water borne 
diseases such as Schistosomiasis [61]. Moreover, our results of the largest sero-
epidemiology study ever conducted for BU showed, that inhabitants of both six BU 
endemic communities mid- and downstream and four communities upstream the 
  
Densu River seem to be equally exposed to M. ulcerans, since a considerable 
proportion (about 32%) developed specific humoral responses against the M. 
ulcerans 18KDa shsp antigen. In addition, environmental samples collected in BU 
endemic and non-endemic communities showed no significant difference in PCR 
positivity targeting M. ulcerans sequences (chapter 6). This indicates that not only 
increased contact to possible reservoirs of M. ulcerans, but also currently unknown 
host, pathogen or other environmental factors must contribute to the establishment 
and further dissemination of BU in certain focalized areas.  
 
Establishment and further dissemination of BU in the human host population 
The observation that more than 30% of healthy individuals living in BU endemic and 
non-endemic communities in the Densu River basin of Ghana develop a specific 
humoral immune response against an M. ulcerans antigen indicates that infection 
with M. ulcerans may lead only in a proportion of exposed individuals to active 
disease (chapter 6). Diverse outcome of infection with other mycobacteria such as M. 
tuberculosis or M. leprae has already been well described and associated with host 
genetic factors amongst others [63,64]. To date it is not clear, whether the 
development of BU may equally be determined by host genetic factors. Only one 
study reports that susceptibility to BU may be associated with a polymorphism in the 
natural resistance-associated macrophage protein gene, which had already been 
associated with tuberculosis and leprosy [65]. Various host behavioral factors that 
may lead to increased probability of acquiring BU have been reported for African and 
Australian BU endemic settings. In a recent review article summarizing results from 
currently available risk factor studies conducted in Australia and different African 
countries poor wound care, failure to wear protective clothing, and living or working 
near water bodies were identified as the most common risk factors [66]. A case-
control study from south-eastern Australia reported reduced odds of having BU for 
those who frequently used insect repellent and protected their bodies from 
environmental exposure and increased odds for those who were bitten by 
mosquitoes on the lower extremities implicating mosquitoes in the transmission of M. 
ulcerans in this region [67]. 
  
In view of the limited genetic diversity of M. ulcerans strains from the same country, it 
is rather unlikely that pathogen factors such as differences in virulence account for 
the establishment of focalized transmission clusters within these countries. However, 
it cannot be ruled out that host-specific pathogen adaptation occurs as recently 
described for M. tuberculosis [68], considering that M. ulcerans is adapting to 
different niche environments and that one of these M. ulcerans ecovars (lineage 3) 
seems to be more virulent for humans than the others [22,69,70].  
One of the most important environmental factors associated with the described 
creation of stagnant water bodies contributing to the establishment of BU, may be the 
promotion of optimal breeding sites for potential M. ulcerans vectors or 
animal/environmental reservoirs. However, since only certain water bodies seem to 
be connected with increased BU case numbers, the emergence of this disease 
cannot only be based on an interaction between M. ulcerans and the environment. 
Recently, it has been reported that the detection of M. ulcerans DNA in several 
environmental samples from the same villages appears to be a strong predictor of 
high BU case burden [71]. In this sense, the observed clustering of BU cases in 
certain endemic villages combined with the reported focalized M. ulcerans haplotype 
distribution in the Densu River basin encourages the assumption that humans and 
especially BU patients with ulcerative lesions may play an active role in the 
dissemination of M. ulcerans in the environment (chapters 3 and 6).  
 
Outlook 
Our ongoing research is focused on further genome comparison of closely related 
isolates from the Densu River Basin as well as different BU endemic areas in Ghana 
in order to trace transmission pathways and potential sources of M. ulcerans in this 
country. While spatial analysis of the M. ulcerans haplotype distribution in the Densu 
River Basin has already provided important insights into geographic-genetic patterns 
of this pathogen in a relatively small BU endemic area (chapter 3), future longitudinal 
analysis of the haplotype circulation is expected to give deeper insights into 
reservoirs and transmission routes of M. ulcerans in this area. First typing results of 
M. ulcerans strains isolated between 2009 and 2011 in the Densu River Basin at ten 
canonical SNP markers indicate that the geographic separation of M. ulcerans 
  
haplotypes persists over several years (Chapter 4). Genome sequence comparison 
of additional isolates will show whether new M. ulcerans variants have emerged over 
time and how they are distributed within the BU endemic area. Genome comparison 
of M. ulcerans strains isolated from patients living in different BU endemic areas of 
Ghana as well as strains from other African countries is anticipated to help identifying 
sources and routes of dispersal of M. ulcerans on country and continental scale. In 
view of the ongoing enormous advances in next generation sequencing technologies 
facilitating whole-genome sequencing at ever-lower cost, future analyses might 
rather be performed by sequencing the genomes of all available isolates. Cultivation 
of M. ulcerans from potential reservoirs or vectors would prove that PCR positivity 
reflects at least in part presence of viable bacteria. Comparative genome analysis of 
strains obtained from potential reservoirs or vectors with human disease isolates 
could confirm or reject hypotheses on their involvement in transmission.  
Understanding of transmission pathways and reservoirs of M. ulcerans may lead to 
the identification of preventable risks for infection. This could lead to the design of 
improved surveillance and control schemes for BU. Since no vaccine is currently 
available, the present control strategy of BU relies on early case detection and rapid 
treatment. 
 
Treatment of Buruli ulcer 
Until 2004 surgical excision of infected skin and underlying soft tissue, often 
accompanied by transplantation of healthy skin tissue, was the standard treatment 
for BU, since drug therapy has long been considered ineffective [72]. However, major 
drawbacks including the limited accessibility of surgery in remote areas, 
complications due to patients presenting at advanced disease stages as well as high 
recurrence rates [73,74], have rendered the identification of an effective drug 
treatment one of the major research priorities for BU. Following a pilot study 
demonstrating the efficacy of oral rifampicin and intramuscular streptomycin in a 
limited number of BU patients with early lesions [75], WHO released and promoted a 
new treatment protocol advising the daily administration of these antibiotics for eight 
weeks [76]. Routine implementation of this strategy in endemic countries such as 
Ghana and Benin has greatly improved healing and dramatically reduced 
  
recurrences [77,78]. Even though effective, the daily injection of streptomycin 
represents one of the major obstacles to decentralize health care to facilities in 
remote areas in Africa where most of the patients live [79]. Furthermore streptomycin 
has several side effects including potential nephrotoxicity and ototoxicity [80]. 
Whether all-oral antibiotic treatment will be equally effective is currently under 
investigation. There is evidence that in combination with rifampicin, streptomycin 
administered for only four weeks followed and replaced by oral clarithromycin for 
another four weeks may be as effective as the standard protocol [81]. In a pilot study 
in Benin evaluating the efficacy of an all-oral regimen composed of rifampicin and 
clarithromycin for eight weeks all 30 BU patients were successfully healed [79]. In 
Australia, where surgery is widely accessible and the main treatment modality for BU, 
rifampicin is routinely combined with oral clarithromycin or moxifloxacin [82]. Taken 
together, rifampicin is currently the only key drug for the treatment of BU and has to 
be combined with other drugs to avoid the development of resistances. Hence the 
pipeline for drug combinations effective against BU is thin. Given the history of 
antibiotic resistance in other bacterial diseases such as tuberculosis [83,84], where 
resistance to most drugs has appeared soon after the introduction of the drug, the 
identification of alternative drugs or novel therapeutic approaches for the treatment of 
BU is of high importance.  
While incubation times for drug candidate screening and susceptibility testing relying 
on the development of colonies or turbidity are exceedingly long for slow-growing 
bacterial species, Alamar Blue-based assays provide rapid and inexpensive tools 
and have widely been applied to analyze mycobacterial pathogens such as M. 
tuberculosis, M. leprae or M. avium [85–88]. The adaptation of a compound 
screening platform for M. ulcerans using Alamar Blue allows for the medium-
throughput analysis of compounds with potential activity against this extremely slow-
growing pathogen. In a pilot study analyzing a pre-selected set of azole compounds, 
one imidazole antifungal, referred to as Croconazole, could be identified as a potent 
compound active against M. ulcerans (chapter 7). Croconazole is commonly 
indicated for the treatment of dermatomycoses as topical application in the form of a 
cream termed Pilzin® [89]. Even though increased healing rates of BU lesions upon 
topical treatment with nitrogen oxide-releasing acidified nitrite creams have been 
  
previously reported from a pilot randomized trial [90], their application has not been 
widely adopted. Since Pilzin® is commercially available and hence directly applicable, 
topical treatment of BU lesions with Pilzin® in combination with chemotherapy should 
be further investigated. The developed Alamar Blue-based screening procedure is 
currently used to identify further compounds inhibiting the growth of M. ulcerans. 
Another alternative approach for the local treatment of BU lesions is the application 
of heat. Since M. ulcerans has a restricted, relatively low optimal growth temperature 
of 28-32°C, the maintenance of temperatures around 40°C in the ulcerated areas is 
expected to inhibit the growth of M. ulcerans. While successful treatment of individual 
patients or small case series by heat application has already been reported since 
1950 [91–94], the recent employment of cheap and reusable phase change material 
(PCM) packs provided a major breakthrough for heat treatment of BU [94]. In a proof-
of-principle trial six BU patients with ulcerative lesions could be successfully treated 
by the application of PCM devices. A larger trial evaluating the efficacy and 
applicability of treatment by PCM packs is currently ongoing. 
 
Future research priorities and required tools for the control and prevention of 
Buruli ulcer 
In remote African BU endemic regions diagnosis and hence treatment of BU are still 
primarily based on clinical findings, since available diagnostic tools require expensive 
equipment and experienced personnel or are not sensitive enough. However, 
differential diagnosis includes other important diseases, which are prevalent in BU 
endemic areas and involve different treatment regimens. Thus, one of the major 
research priorities for BU is to develop a fast, low-tech, sensitive and specific point of 
care diagnostic test, which could directly be used at peripheral health centers. We 
are currently evaluating the use of an antigen capture assay based on ELISA and 
lateral flow techniques that will now be optimized to increase sensitivity. 
Alternative treatment regimens for BU suitable for application at peripheral health 
centers are of urgent need. While trials replacing streptomycin by specific orally 
administered antibiotics provided promising results, no alternate drug is presently 
available to replace rifampicin. By using our Alamar Blue-based drug screening 
  
approach, we have not only identified Croconazole, but also another compound with 
high activity against M. ulcerans. The potential application of this promising drug 
candidate will now be further evaluated with respect to its efficacy in animal models, 
safety and bioavailability. However, the development of a drug is an expensive and 
time-consuming endeavor. Hence, the pharmaceutical industry has no interest in the 
development of drugs for low-return neglected diseases. Therefore we are currently 
testing the potency of our drug candidate against M. tuberculosis, representing a 
potentially more profitable target. 
While in recent years considerable progress has been made in the management of 
BU, the disease still imposes an enormous social and economic burden on endemic 
developing countries. The most desired solution to control BU in focal, highly BU 
endemic areas would be the vaccination of affected populations. Since no advanced 
vaccine candidate is presently available, research is focused on the development of 
new vaccine candidates including mycolactone-directed vaccines, attenuated live 
vaccines and subunit protein vaccines. 
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